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Group II introns are both catalytic RNAs and retrotransposable elements. Group II 
intron-encoded proteins (IEPs) have maturase activity, which promotes intron RNA 
splicing, and reverse transcriptase activity, which functions in intron mobility. Previous 
studies of the Lactococcus lactis Ll.LtrB intron suggested a model in which its IEP binds 
first to a high-affinity binding site in intron subdomain DIVa and then makes additional 
contacts with the conserved catalytic core to stabilize the active RNA structure. In the 
absence of DIVa, the IEP promotes residual splicing by binding directly to the catalytic 
core. I developed E. coli genetic assays to detect in vivo splicing of the Ll.LtrB intron and 
identify regions in the IEP essential for interacting with different parts of the intron RNA. 
Mutational and biochemical analysis combined with three-dimensional structural 
modeling support the hypothesis that the extended N-terminal finger region of LtrA is 
involved in high-affinity binding of DIVa, possibly forming a binding pocket in 
combination with parts of the thumb domain (domain X), while other regions of the RT 
and X domains are potentially involved in binding the catalytic core.  
 vii
The Ll.LtrB intron works very efficiently for gene targeting in bacteria, and it is 
desirable to target mammalian genomes, for which efficient means of manipulation are 
lacking. I developed an expression system to produce Ll.LtrB intron RNA and IEP in 
cultured human cells and found that the expressed intron splices in vivo. I also explored 
different methods for introducing RNPs into cells, including electroporation and 
injection, and was able to detect a chromosomal targeting event with RNP 
electroporation. With improvements in targeting efficiency, group II introns would be 
generally useful for functional genomics and gene therapy. 
 
 viii
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Chapter 1: Introduction 
Group II introns are ribozymes that catalyze their own splicing. Mechanistically, 
group II introns splice like eukaryotic spliceosomal introns and have been hypothesized 
to be ancestors of spliceosomes (see section 1.4.3). First identified in 1982 (Davies et al., 
1982; Michel et al., 1982; Schmelzer et al., 1982) and widely distributed in bacterial and 
organellar genomes, some group II introns encode a multifunctional protein and are 
retrotransposable elements (Lambowitz & Zimmerly, 2004). The intron-encoded protein 
(IEP) assists the intron RNA in various reactions in vivo and in vitro, including intron 
splicing, recognition and insertion of the intron RNA into DNA targets, and reverse 
transcription of the inserted intron into DNA. The reverse transcriptases (RTs) encoded 
by mobile group II introns are related to those encoded by non-long terminal repeat (non-
LTR) retrotransposons and telomerase. Group II introns provide a model for 
understanding how proteins interact with catalytic RNAs (see section 1.4.3). In addition, 
mobile group II introns have potential applications in functional genomics and gene 
therapy. 
1.1 STRUCTURAL CHARACTERISTICS OF GROUP II INTRON RNAS 
Group II introns lack significant primary sequence conservation but have 
characteristic secondary and tertiary structures (Michel & Ferat, 1995). Subtle variations 
in secondary and tertiary features were used as criteria to categorize group II introns into 
subgroups IIA and IIB, each of which can be further divided into two subclasses: A1 and 
A2; B1 and B2 (Toor et al., 2001). Both IIA and IIB introns include protein-coding 
introns that are retroelements. More recently, certain bacterial introns were classified as 
IIC introns. All known IIC introns encode an open reading frame 
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(http://www.fp.ucalgary.ca/group 2introns/). The signature secondary structure consists 
of six stem-loop domains denoted DI to DVI (Figure 1.1).  
Domains I and V are essential for the catalytic activity. Domain I contains exon-
binding sequences (EBS) and other sequence motifs involved in intra- and inter-domain 
tertiary interactions (Figure1.1) and acts as a scaffold for the folding of the intron RNA 
(Qin & Pyle, 1998). Domain V is the most phylogenetically conserved portion of the 
intron and docks onto domain I to form the minimal catalytic core (Michel et al., 1989; 
Qin & Pyle, 1998). 
DII and DIII are not required for catalysis but contribute to optimal splicing. At 
least in the yeast intron aI5γ, DIII is a catalytic effector during the formation of the 
catalytic core. DII mediates conformational changes during splicing, including 
positioning of 5’ splice site and recruitment of domain III to the catalytic core (Fedorova 
et al., 2003). DIV is the least conserved domain and not essential for RNA catalysis, but 
always encodes the IEP ORF in protein-coding introns. DVI is not conserved in primary 
sequence but contains structural determinants for branch-site recognition, including the 
most common feature, a bulged adenosine (Chu et al., 2001). 
Remarkably, most group II domains, when transcribed in vitro as separate 
molecules, can fold independently and maintain discrete functions in intron catalysis (Qin 
& Pyle, 1998). In vivo, two group II introns in the green alga Chlamydomonas reinhardtii 
chloroplast are transcribed in pieces and splice in trans with the help of proteins (Perron 
et al., 1999). The ability of group II intron domains to function in trans demonstrates that 
inter-domain tertiary interactions correctly determine how these substructures associate 
with each other and that group II intron domains could be prototypes for snRNAs in the 
spliceosome. 
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1.2 CHARACTERISTICS OF GROUP II INTRON IEPS 
Group II intron IEPs are intron-specific protein factors for splicing and/or 
mobility. Generally, four distinct domains are defined in group II IEPs. A reverse 
transcriptase (RT) domain is located at the N-terminus, followed by domain X and the C-
terminal DNA-binding (D) and endonuclease (En) domains (Figure 1.2). Four enzymatic 
activities are associated with group II IEPs. The maturase activity refers to the ability of 
an IEP to bind and induce conformational changes in an intron RNA during splicing 
(Saldanha et al., 1999; Wank et al., 1999; Matsuura et al., 2001; Noah & Lambowitz, 
2003). Reverse transcriptase, DNA binding and DNA endonuclease activities play key 
roles in mobility. The N-terminal RT domain is related to the RTs of non-LTR 
retrotransposons, such as the Bombyx mori R2Bm element and the human LINE elements 
(Eickbush, 1994), and carries out the essential step of reverse transcription in intron 
mobility. The D domain recognizes target DNA, and the En domain cleaves bottom 
strand of the target site. The En domain contains conserved sequence motifs 
characteristic of the H-N-H family of DNA endonucleases, interspersed with two pairs of 
conserved cysteine residues, which are required to maintain the active structure of the 
domain (San Filippo & Lambowitz, 2002). Some group II IEPs contain all four domains, 
whereas others only have RT and X domains (http://www.fp.ucalgary.ca/group 
2introns/). 
There are two major hypotheses about the origin of ORF-encoding group II 
introns. One is that IEP ORFs were recruited by preexisting self-splicing RNA structures 
(Kennell et al., 1993; Wank, et al., 1999). The other model speculates that group II intron 
RNA structure evolved from a retroelement RNA (Curcio & Belfort, 1996). Over 50 
group II introns have been identified across the prokaryotic spectrum, including Gram-
negative, Gram-positive, proteobacteria, cyanobacteria, and archaea (Dai et al., 2003). 
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Virtually, all bacterial group II introns identified so far encode IEPs. Without identifying 
the ultimate origin, analyses of bacterial group II introns supported a new model for 
group II intron evolution, termed the retroelement ancestor hypothesis (Toor, et al., 
2001).  This hypothesis suggests that modern mobile group II introns may have come 
from bacterial ORF-containing group II introns, which horizontally spread to 
mitochondria and chloroplasts. The intron RNAs and IEPs then co-evolved in both 
bacteria and organelles. Toor et al. (2001) also presented evidence that most ORF-less 
introns are derivatives of ORF-containing introns. In higher organisms, organellar group 
II introns lost or have mutated ORFs and rely on cellular factors for splicing (Toor et al., 
2001). 
1.3 OVERVIEW OF STUDIES ON GROUP II INTRON SPLICING 
Group II intron RNAs are ribozymes, some of which are capable of splicing in 
vitro in the absence of protein (Michel et al., 1989). However, self-splicing requuires 
extreme conditions including high salt and magnesium concentrations. The presence of 
the maturase protein lowers the required concentrations for both salt and magnesium, and 
protein-dependent splicing is more rapid than self-splicing (Saldanha et al., 1999). The 
protein helps the intron RNA to fold and maintains active structures that are not optimally 
formed with high salt and magnesium (Saldanha et al., 1999). 
1.3.1 Splicing mechanism 
Group II intron splicing occurs via two transesterification reactions. First, the 
bulged A residue in DVI attacks the first nucleotide of the intron at the 5’ splice site to 
form a 2’, 5’-phospodiester bond and to release the 5’ exon. The 3’ hydroxyl of the 5’ 
exon then attacks the phosphodiester bond at the 3’ splice site, resulting in ligated exons 
and an intron lariat (Figure 1.3a). The first step of splicing is reversible and rate limiting. 
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This reversibility may provide a proofreading mechanism for the 5’ splice site cleavage 
(Chin & Pyle, 1995). After protein-dependent splicing, the IEP stays bound to the excised 
lariat RNA, forming ribonucleoprotein (RNP) particles, which are functional entities in 
mobility.  
The first step of splicing can also occur through hydrolysis, in which a water 
molecule attacks the phosphodiester bond at the 5’ splice site (Figure 1.3b). After an 
essentially identical second step, a linear intron, instead of a lariat intron, is released. The 
hydrolysis pathway is slow but irreversible and is favored by potassium chloride in the 
reaction in vitro (Chin & Pyle, 1995). In vivo, this pathway is observed in yeast 
mitochondrial intron aI5γ with the bulged A residue mutated (Podar et al., 1998) and in a 
barley chloroplast intron lacking a bulged A in domain VI (Vogel & Borner, 2002). 
1.3.2 The Lactococcus lactis group II intron Ll.LtrB  
The Lactococcus lactis group II intron Ll.LtrB belongs to the IIA1 subgroup and 
is by far the best biochemically studied RT/maturase-coding group II intron, mainly 
because it expresses and splices efficiently in E. coli (Matsuura et al., 1997). The Ll.LtrB 
IEP, LtrA, has RT, maturase, and DNA endonuclease activities (Matsuura et al., 1997). 
Biochemical analysis showed that LtrA is an intron-specific splicing factor that binds the 
intron RNA with high affinity (kinetically measured apparent Kd ≤ 0.12 pM) and is by 
itself sufficient for maturase activity (Saldanha et al., 1999). A series of deletions of the 
intron RNA were analyzed and showed that a high-affinity binding site for LtrA is 
located in DIVa (Wank et al., 1999). The high-affinity binding site was further localized 
by in vitro selection and mutagenesis to the distal end of the DIVa, including the 
ribosome-binding site (RBS) and ATG codon for LtrA translation. The binding of LtrA to 
the RBS was also shown to down-regulate its own translation (Singh et al., 2002). 
Matsuura et al. (2001) identified potential low-affinity protein-binding sites in the 
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conserved catalytic core and demonstrated that binding of LtrA induced the intron RNA 
to form critical tertiary interactions for splicing. UV-cross linking experiments showed 
that LtrA also stabilizes specific tertiary interactions. Magnesium, on the other hand, 
stabilizes all tertiary interactions including non-native ones, and may slow down the 
splicing reaction because the misfolded RNAs need time to refold into active structures 
(Noah & Lambowitz, 2003). 
Modifying the intron RNA has been a major approach for studying the 
RNA/protein interactions in the Ll.LtrB intron splicing. It is also important to address the 
question of how the protein interacts with the RNA, which was one main goal of my 
dissertation research. 
1.3.3 Other splicing factors 
In addition to maturases, a number of other proteins have been found to be 
involved in group II intron splicing. These splicing factors are summarized here in two 
categories: maturase-related and maturase-unrelated. 
The maturase-related category includes MatK proteins and nMat proteins. MatK 
proteins are encoded in a group II intron in the tRNAlys genes of higher plant chloroplasts 
or by freestanding ORFs in the residual plastid genomes of non-photosynthetic plants 
(Mohr et al., 1993; Vogel et al., 1997; Young & dePamphilis, 2000).). MatK ORFs 
contain an X domain and a degenerate RT domain, but lack the DNA-binding and DNA-
endonuclease domains. They may function in splicing multiple chloroplast group II 
introns, many of which do not encode ORFs themselves (Mohr et al., 1993; Vogel et al., 
1997; Young & dePamphilis, 2000). 
nMat proteins were identified in higher plant nuclear genomes by sequence 
comparisons and contain two families, each with two members: nMat-1a, nMat-1b, nMat-
2a, and nMat-2b. Both protein families have characteristic group II intron IEP RT and X 
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domains. The nMat2 proteins also have D and En domains, and the nMat1 proteins have 
a novel C-terminal domain. All four proteins have a conserved X domain but mutated RT 
(nMat2) or D/En domains (nMat1), implying that they may retain the ability to function 
in group II intron splicing but are unable to fully support intron mobility. All nMat 
proteins are encoded by nuclear genes with no association with group II intron structures. 
The proteins have mt localization sequences and may be imported into that organelle to 
facilitate the splicing of ORF-less group II introns (Mohr & Lambowitz, 2003).   
Besides maturase-related proteins, several other group II intron splicing factors 
have been identified. Two of these proteins were identified in yeast mitochondria. The 
Mrs2p protein seemed to be the only splicing factor essential for splicing of all group II 
introns in the yeast mitochondria. However, Mrs2p is a magnesium transporter, and 
facilitates splicing indirectly by increasing the Mg2+ concentration (Gregan et al., 2001). 
Mss116p is an RNA helicase encoded by a nuclear gene and is transported to the 
mitochondrion. Mss116p is required for the efficient splicing of all group I and II introns 
and acts as an RNA chaperone likely to disrupt misfolded RNA structures (Huang et al., 
2004). In addition to participating in the intron splicing in the yeast mitochondrion, 
Mss116p also functions in translation (Seraphin et al., 1989). 
The CRS1 and CRS2 proteins from maize were identified as splicing factors via a 
genetic screening. CRS1 helps splice a subgroup IIA intron, atpF, whereas CRS2 
functions in splicing of multiple subgroup IIB introns (Till et al., 2001). Both proteins 
function in the context of large RNPs containing intron RNAs (Jenkins & Barkan, 2001; 
Till et al., 2001). In addition to helping intron splicing, CRS1 may play a role in the 
chloroplast translation, and CRS2 is a homolog of peptidyl-tRNA hydrolase enzymes 
(Till et al., 2001). Additionally, two more splicing factors were shown to interact with 
CRS2 through a yeast two hybrid screen: CRS2-associated factors 1 and 2 (CAF1 and 
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CAF2). Each is present in RNPs containing CRS2 and a distinct set of intron RNAs. In 
rare cases, some introns require both CAF proteins for splicing. Like CRS1, CAF1 and 
CAF2 contain an RNA-binding domain of a novel family named the Chloroplast RNA 
splicing and ribosome maturation (CRM) domains (Ostheimer et al., 2003). 
Three Raa proteins were found to function in trans splicing of different group II 
introns in algae chloroplasts (Perron et al., 1999; Rivier et al., 2001; Perron et al., 2004). 
Like the CRS proteins, Raa proteins are also associated with large intron-containing 
RNPs (Perron et al., 2004). The Raa2 protein is related to pseudouridine synthases, but 
the pseudouridine synthetase activity is not required for the trans-splicing reaction 
(Perron et al., 1999). 
Most recently, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has been 
found to help splice yeast bI1 intron in vitro. However, since GAPDH does not enter 
mitochondria, it is unlikely that the same interaction happens in vivo (Bock-Taferner & 
Wank, 2004).   
1.3.4 Evolutionary aspects 
Two classes of spliceosomal introns, denoted U2-dependent and U12-dependent, 
have been identified in eukaryotes. Each class is spliced by a different spliceosome 
assembled from five small nuclear RNAs and numerous proteins (Zhu & Brendel, 2003). 
Group II introns are hypothesized to be ancestors of spliceosomes (Michel & Ferat, 
1995). The following evidence supports the hypothesis. First, group II introns and 
spliceosomes use two essentially identical transesterification reactions for splicing 
(Guthrie, 1991; Steiz & Steiz, 1993; Sontheimer et al., 1999; Gordon et al., 2000). 
Spliceosomal introns could participate in alternative splicing by selecting different 
splicing sites. Interestingly, a bacterial group II intron was also found to have a primitive 
form of alternative splicing (Robart et al., 2004). Second, as in group II intron splicing, 
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RNA is believed to be the catalytic unit in spliceosomes (Will & Luhrmann, 2001; Villa 
et al., 2002; Valadkhan & Manley, 2003). Third, structural similarities were identified 
between group II intron domains and snRNAs (Yu et al., 1995; Sashital et al., 2004). 
Segments of a group II intron and certain snRNAs can replace each other for function. 
For examples, a group II intron DV can function in the U12-dependent spliceosome in 
vivo in place of the U6atac snRNA stem loop (Shukla & Padgett, 2002), and the U5 
snRNA trans-activates group II intron splicing by replacing its ID3 structure (Hetzer et 
al., 1997). If group II introns are in fact ancestors of spliceosomes, the much simpler 
group II intron system provides a unique platform for studying the splicing reactions. 
1.4 OVERVIEW OF STUDIES ON GROUP II INTRON MOBILITY 
Retroelements propagate via RNA intermediates and reverse transcription. This 
broad category includes, but is not limited to, LTR and non-LTR retrotransposons, 
retrovirus, telomerase, and mobile group II introns (Kazazian, 2004). Group II introns 
and non-LTR retrotransposons use the similar mechanism to integrate into DNA targets, 
and RTs encoded by these two groups are phylogenetically related (Eickbush, 1994). 
1.4.1 General mobility mechanism—target DNA-primed reverse transcription  
Non-LTR retrotransposons use a pathway termed target DNA-primed reverse 
transcription (TPRT) during integration, where the 3’ end of a nicked genomic DNA 
strand is used as a primer for reverse transcription of the element’s RNA sequences 
(Figure 1.4, Eickbush, 1992). Many non-LTR retrotransposons insert nonspecifically at 
random nicks, whereas some generate specific cleavages. For example, the R2Bm 
element from the silkworm, Bombyx mori, inserts into a specific site in the 28S rRNA 
gene (Luan et al., 1993). However, TPRT only accomplishes the 3’ end insertion of 
R2Bm, and the host homologous recombination is required for 5’-end insertion (Fujimoto 
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et al., 2004). Human LINE 1 elements appear to integrate nonspecifically into the 
genome likely through TRPT (Moran et al., 1996; Feng et al., 1996; Morrish et al., 2002). 
In addition to non-LTR retrotransposons, telomerase also uses TPRT to synthesize the 
highly specific telomere repeat sequences at most eukaryotic chromosomal termini 
(Lingner et al., 1997). 
1.4.2 Overview of the work on yeast intron mobility 
Mobile group II introns are site-specific retroelements and insert at high 
frequencies into intronless alleles, a process termed retrohoming, and at low frequencies, 
to ectopic sites that resemble the natural homing site, a process termed retrotransposition 
(Lambowitz & Zimmerly, 2004). Pioneering work on group II intron mobility was done 
mainly with yeast introns aI1 and aI2, which are the first and second introns of the COX1 
gene encoding subunit 1 of cytochrome oxidase. Zimmerly et al. (1995a, b) showed that 
TPRT was the mechanism for aI1 and aI2 homing, and that the intron RNA cleaves the 
top strand. Homing is mediated by RNP particles, complexes assembled from the intron 
lariat and the maturase protein. The intron RNA in an RNP particle inserts into the sense 
strand of the target DNA, and the maturase protein cleaves the bottom strand after the 
10th nucleotide downstream of the insertion site, and uses the liberated 3’-OH to prime 
cDNA synthesis. In the major retrohoming pathway, the intron cDNA invades an 
intronless allele to initiate reverse splicing and reverse transcription stimulate 
repair/recombination event that leads to intron insertion with subsequent coconversion of 
upstream exon sequences. Retrohoming can also be completed by complete reverse 
splicing, synthesis of a full-length of cDNA, and repairing the gap in the top strand, 
independent of homologous recombination. Finally, retrohoming can occur independent 
of RT activity after target-site cleavage, likely through double strand break repair 
recombination and characterized by bidirectional coconversion of flanking exon 
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squences. The DNA target site, intron, and the environment that retrohoming takes place 
are contributing factors to which pathway is chosen (Eskes et al., 2000). 
During target recognition, EBS and δ sequences in the intron RNA base pair with 
IBS and δ’ sequences in the DNA target site. Modifying these base-pairing interactions 
changes the targeting specificity (Eskes et al., 1997; Guo et al., 1997), raising the 
possibility of targeting group II introns to desired sites. Unfortunately, neither aI1 nor 
aI2-encoded proteins have been expressed and correctly processed other than in the yeast 
mitochondria. This largely limits the usefulness of these introns in targeting elsewhere. 
1.4.3 Studies on the Lactococcus lactis LtrB intron 
The ability to express the Ll.LtrB intron in E. coli made it possible to study the 
Ll.LtrB intron mobility in great detail. Mechanistically, the intron was shown to use 
TPRT for mobility via complete reverse splicing and reverse transcription, and modifying 
EBS and δ sequences of the intron changes the target site specificity for reverse splicing 
(Matsuura et al., 1997). Unlike the situation for yeast introns, the Ll.LtrB intron cannot 
use an RT-independent pathway, in which after reverse transcription, the intron cDNA 
integrates by a DNA repair step, dependent on homologous recombination (Cousineau et 
al., 1998). During mobility, the RNPs bind DNA non-specifically and search for target 
sites (Aizawa et al., 2003). At a target site, the IEP first recognizes a few bases in the 
distal 5’ exon region via major groove and phosphate-backbone interactions, which 
triggers the unwinding of the double-strand target DNA, enabling base pairing 
interactions between the intron RNA and target DNA for reverse splicing of the intron in 
the top strand (Singh & Lambowitz, 2001). Bottom-strand cleavage then occurs with 
additional interactions between the IEP and the 3’ exon (San Filippo & Lambowitz, 
2002). However, top-strand insertion is not required for bottom-strand cleavage (Aizawa 
et al., 2003). After reverse transcription, the host RNase H activity probably digests the 
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intron RNA inserted in the top strand, and the host repair machinery synthesizes the 
second strand. Interestingly, when the RT is defective in cleaving the bottom strand, 
reverse transcription proceeds using a nascent strand at a DNA replication fork as the 
primer, and mobility still can be completed at a lower frequency (Zhong & Lambowitz, 
2003). This could be one of the pathways for the mobility of introns encoding 
endonuclease-less IEPs (Munoz-Adelantado et al., 2003), as well as a mechanism for 
group II intron retrotransposition, which is independent of the D and En domains 
(Ichiyanagi et al., 2002). 
Using group II introns to target desired genes has always been one of the most 
favorable prospects of group II intron studies. Remarkable progress has been made in 
bacteria in using group II introns as tools for gene disruption. Target-site recognition 
rules were obtained (Mohr et al., 2000; Guo et al., 2000; Zhong et al., 2003) and used to 
develop an algorithm that designs introns to target a given gene with high efficiency 
(Perutka et al., 2004). Genomes of different bacteria were targeted by group II introns 
(Karberg et al., 2001; Zhong et al., 2002), and in L. lactis, conditional knockouts using 
group II introns were obtained (Frazier et al., 2003). 
1.4.4 Significance of intron mobility 
Using group II introns in higher organisms is of great interest because of the 
difficulties of manipulating their more complex genomes. Guo et al. (2000) presented 
initial evidence that group II RNPs were active in human cells. The second part of my 
dissertation focuses on using group II introns in mammalian targeting. 
 In addition to their practical potentials, group II introns may be ancestors of 
telomerase and non-LTR retroelements, such as the human LINE elements, which use a 
similar TPRT mechanism for mobility (Lambowitz & Zimmerly, 2004). Studies of group 
II intron mobility may also advance the understanding of these retroelements.  
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1.5 OVERVIEW OF THE CHAPTERS 
This dissertation research has two main themes: maturase/intron RNA interactions 
during group II intron splicing and utilizing group II introns to target mammalian 
genomes. Two chapters are devoted to each of these areas, followed by a chapter 
describing Materials and Methods. 
Chapter 2 focuses on the identification of LtrA domains that function in the 
Ll.LtrB intron splicing. I will describe a genetic system I developed to monitor in vivo 
splicing of the Ll.LtrB intron in E. coli. Based on this system, I constructed a random 
LtrA library and screened for splicing-competent mutants. Statistical analysis of the ratios 
of missense to silent mutations in different regions demonstrated that both RT and X 
domains are required for splicing. Biochemical analysis suggested that the N-terminus of 
the RT domain is involved in high-affinity binding of the intron RNA, while domain X 
participates in interaction with the intron catalytic core. Chapter 3 is a continuation of the 
studies of chapter 2, where I did another genetic screening in the absence of the high-
affinity protein-binding site of the intron. By comparing the two sets of data, several 
regions were identified as candidates for directly interacting with the DIVa sequence.  A 
series of site-directed mutations were tested to further pinpoint the interaction spots. The 
mutagenesis data were interpreted by using a newly developed LtrA structural model 
based on HIV-1 RT structures. This part of the research provides a detailed model of how 
LtrA binds DIVa. Differences between in vivo and in vitro data are discussed. Chapter 4 
describes work on expressing the Ll.LtrB intron RNA and the LtrA protein in human 
cells. Major findings of this part include that maturase-promoted splicing can take place 
in human cells with expressed components and that some protein-independent splicing 
can occur when high magnesium is present in the medium. The expressed LtrA protein 
had RT activity and was localized to the nucleus. In chapter 5, RNP particles purified 
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from E. coli were used to target human cells directly. A series of in vitro experiments was 
done to show that RNPs are capable of identifying target sites in the context of the human 
genome and in nuclear lysates. Electroporation could deliver RNPs into the cells without 
compromising RNP activity. A chromosomal rRNA gene in human cells was targeted 
with electroporated RNPs. Thus, using RNPs for targeting is feasible but the efficiencies 
need to be increased. Chapter 6 describes the methods used in this research. 
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Figure 1.1 Characteristic secondary structure and predicted tertiary interactions of group 
II introns.   
The six domains of a group IIA intron are labeled as I to VI surrounding the central 
wheel. IBS1 and 2 sequences in the 5’ exon and EBS1 and 2 sequences in the intron are 
labeled. Tertiary interactions are indicated as pairs in Greek letters. 
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Figure 1.2 Schematic of the Ll.LtrB intron-encoded protein, LtrA, showing general 
features of group II intron IEPs. 
Four domains are present.  The RT domain is at the N-terminus of the protein, with seven 
conservative motifs, RT1 to 7, found in the fingers and palm of retroviral RTs, and RT0, 
a motif characteristic of non-LTR RTs (Eickbush, 1994).  Domain X, believed to be 
involved in splicing and historically called the maturase domain (Mohr et al., 1993), 
follows the RT domain and functions in RNA splicing.  Further downstream are the 




Figure 1.3 Splicing mechanisms of group II introns. 
(a) The branching pathway.  In this pathway, the 2’ hydroxyl group of the bulged A in 
domain VI attacks the 5’ splice site and form a 2’, 5’ phospodiester bond, releasing the 5’ 
exon.  The 3’ hydroxyl group of the 5’ exon then attacks the 3’ splice site and generates 
splicing products: lariat intron and ligated exons.  The first transesterification step is 
reversible and rate limiting, and the second step is rapid and drives the reaction to 
completion (Qin & Pyle, 1998).  (b) The hydrolysis pathway. In this pathway, instead of 
the bulged A, a water molecule initiates the reaction by attacking the 5’ splice site to free 
the 5’ exon irreversibly.  After an essentially identical second step, ligated exons and 
linear intron are formed (Chin & Pyle, 1995).  
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Figure 1.4 Schematic of the TPRT mechanism used by group II introns to insert into 
DNA target sites. 
An RNP particle consisting of the lariat intron and the IEP recognizes the target 
sequence, and the intron RNA reverse splices into the sense strand of the insertion site.  
The IEP uses its endonuclease activity to cleave the antisense-strand and its RT activity 
to reverse transcribe the intron RNA using the 3’ end of the cleaved antisense DNA as the 
primer. The second strand is then synthesized and gaps repaired by host factors 




Chapter 2: An E. coli Genetic Assay for Maturase-promoted Group II 
Intron Splicing and Delineation of Regions of the IEP Required for 
Splicing 
The best characterized group II intron IEPs are encoded by the yeast 
mitochondrial introns aI1 and aI2 and the Lactococcus lactis intron Ll.LtrB. These 
proteins contain all four conserved domains (see section 1.2), RT, X, DNA-binding (D) 
and DNA endonuclease (En) domains. The N-terminal RT domain contains conserved 
amino acid sequence blocks 1-7 (RT-1 to -7) characteristic of the fingers and palm of 
retroviral RTs, preceded by an upstream region, RT-0 (previously denoted Z) found in 
the RTs of non-LTR-retrotransposons, such as human LINE elements and insect R2 
element (Xiong & Eickbush, 1990; Zimmerly et al., 2001).  The RT domain is followed 
by domain X, which was identified as a site of mutations affecting maturase activity 
(Mohr et al., 1993; Moran et al., 1994). Domain X is located in the position 
corresponding to the thumb and connection domains of retroviral RTs (Mohr et al., 
1993).  Finally, the C-terminal D and En domains function in intron mobility. The En 
domain contains conserved amino acid sequence motifs characteristic of the H-N-H 
family of DNA endonucleases, interspersed with two pairs of conserved cysteine 
residues, which are thought to help maintain the active structure of the domain (San 
Filippo & Lambowitz, 2002).  
In addition to being the site of mutations that affect RNA splicing, the association 
of domain X with maturase activity is supported by the pattern of conserved and 
nonconserved regions in degenerate group II IEPs, which have lost mobility functions but 
may retain RNA splicing activity (Mohr et al., 1993; Mohr & Lambowitz, 2003).  These 
include two classes of maturase-related splicing factors: higher plant chloroplast MatK 
proteins and higher plant mitochondrial nMat proteins (see section 1.3.1).  MatK proteins 
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lack the En domain and have degenerate RT domains in which only RT-5 to -7 are 
recognizable, but still retain a conserved domain X (Mohr et al., 2003; Vogel et al., 1997; 
Young & dePamphilis, 2000). All of the nMat proteins have a putative mitochondrial 
targeting sequence and contain RT and X domains, and nMat-2 proteins also contain 
cognates of the D and En domains. However, only domain X is conserved in all cases, 
while the RT and En domains generally have mutations, suggesting loss of mobility 
functions, similar to the situation for MatK proteins.  MatK and nMat proteins may 
function in the splicing of multiple chloroplast and mitochondrial group II introns, 
respectively, most of which do not themselves encode ORFs (Wolfe et al., 1991; Vogel et 
al., 1999; Mohr & Lambowitz, 2003). 
To study maturases biochemically, an E. coli expression system for the L. lactis 
Ll.LtrB intron was developed, which allows purification of large quantities of the IEP, 
denoted LtrA protein (Saldanha et al., 1999; Matsuura et al., 1997).  Studies using the 
purified protein showed that LtrA is an intron-specific splicing factor, which binds tightly 
and specifically to the Ll.LtrB intron but not other group II introns, and is by itself 
sufficient to promote the splicing of the Ll.LtrB intron in vitro at a low Mg2+ 
concentration (5 mM), where the intron cannot self-splice efficiently. LtrA binds the 
intron RNA as a dimer, the same active form as the HIV-1 RT (Saldanha et al., 1999).  
After splicing, the IEP remains bound to the excised intron lariat RNA and promotes 
intron mobility by target-DNA primed reverse transcription (TPRT; see section 1.5.1).  
Thus, the interaction of the maturase with the intron RNA is critical for both RNA 
splicing and intron mobility. 
Biochemical studies also identified DIVa, an idiosyncratic structure that contains 
the ribosome-binding site and initiation codon of the LtrA ORF, as the primary high-
affinity binding site of LtrA (Wank et al., 1999; Fig. 2.1).  The binding of LtrA to DIVa 
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is thought to occur first and occludes the ribosome-binding site, thereby down-regulating 
translation and preventing ribosome entry into the intron, which might otherwise impede 
splicing (Singh et al., 2002).  After binding to DIVa, the LtrA protein makes additional 
contacts with conserved catalytic core regions, including DI and possibly parts of DII and 
DVI, to stabilize RNA tertiary structure required for ribozyme activity (Matsuura et al., 
2001; Noah & Lambowitz, 2003). 
Notably, when DIVa is deleted, the LtrA protein can still promote residual 
splicing in vitro by binding directly to the catalytic core. However, the stability of the 
complex is decreased by ~105, and the residual splicing is slower even at saturating 
protein concentrations, suggesting that DIVa also facilitates one or more rate-limiting 
conformational changes to the active RNA structure (Wank et al., 1999; Matsuura et al., 
2001).  Recent UV-cross-linking experiments indicated that the catalytically active RNA 
structure might form at least transiently at low Mg2+ concentration, raising the possibility 
that after binding to DIVa, the maturase functions at least in part by tertiary structure 
capture (Noah et al., 2003). The finding that the IEP interacts with conserved as well as 
idiosyncratic regions implies that it contains multiple binding sites that interact with 
different regions of the intron RNA. It also suggests how maturases could have evolved 
from intron-specific into a general group II intron splicing factor, as may have occurred 
for the plant MatK and nMat proteins. 
Here, to further study RNA-protein interactions in group II intron splicing, I 
developed an E. coli genetic assay for maturase-dependent splicing by linking the 
splicing of the Ll.LtrB intron to the expression of GFP. I then used this assay to analyze 
the in vivo splicing of wild-type and mutant introns and to delineate regions of the 
maturase required for RNA splicing. My results indicate that the IEP functions in splicing 
by using the RT and X domains to bind different regions of the intron RNA and suggest 
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that the IEP may have adapted to function in splicing, at least in part, via interactions 
used to recognize the intron RNA as a template for reverse transcription. 
2.1 AN E. COLI GENETIC ASSAY FOR MATURASE-PROMOTED SPLICING OF THE 
LL.LTRB INTRON 
I developed an E. coli genetic assay for maturase activity by linking the splicing 
of the Ll.LtrB intron to the expression of green fluorescent protein (GFP). Insertion of the 
intron RNA into reporter genes is not trivial because group II intron splicing requires 
base pairing of intron sequences EBS1, EBS2 and δ located in DI to 5’- and 3’-exon 
sequences IBS1, IBS2, and δ’ (Figure 2.1; Michel & Ferat, 1995). EBS and IBS denoted 
exon- and intron-binding sites, respectively. I solved this problem by inserting the intron 
and minimum-sized flanking exon sequences from the ltrB gene at the N-terminus of the 
GFP ORF, with the 5' exon fused in-frame to a short φ10 leader sequence, and the 3’ 
exon fused to codon 2 of GFP (Figure 2.2). Splicing then leads to the synthesis of GFP 
with a short N-terminal extension (42 amino acid residues) corresponding to the φ10 
leader and ligated exons, whereas in the absence of splicing, translation is terminated by 
multiple stop codons within the intron (Figure 2.2(c)). The wild-type construct, pALG1-
WT, contains the full-length Ll.LtrB intron with the LtrA protein encoded in DIV (Figure 
2.2(a)), while pALG2-WT contains a 0.9-kb Ll.LtrB-∆ORF intron with the LtrA protein 
expressed from a position just downstream of the 3’-exon/GFP sequence (referred to as 
the downstream cis position; Figure 2.2(b)). 
To assay splicing, plasmids containing the ltrB/GFP fusion were transformed into 
E. coli HMS174(DE3), which contains an integrated T7 RNA polymerase gene under the 
control of the lacUV5 promoter. After induction with IPTG, single-cell fluorescence was 
measured with a fluorescence-activated cell sorter (FACS). As shown in Figure 2.3(a), 
cells transformed with pALG1-WT and induced with IPTG gave a peak of 820 
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fluorescence units, whereas a similar fluorescence increase was not seen without IPTG 
induction, nor for cells transformed with the vector pAT (Figure 2.3(b) and (c), 
respectively). Likewise, no fluorescence increase was seen after IPTG-induction for the 
splicing-defective mutants pALG1-∆DV, which is deleted for the catalytically essential 
intron DV, nor for pALG1-∆ORF, which has a large deletion in the LtrA ORF (Figures 
2.3(d) and (e), respectively). 
Notably, the splicing of the ∆ORF intron measured by GFP expression occurred 
at wild-type levels in pALG2-WT, in which the LtrA protein is expressed from the 
downstream cis position (peak of 843 units; Figure 2.3(f)), but at a much lower level 
when LtrA is expressed in trans from a separate plasmid (pALG1-∆ORF + LtrA; peak of 
48 units; Figure 2.3(g)). Immunoblots of total cellular protein showed that all three 
constructs produced similar amounts of LtrA (Figure 2.4(a)). Since the plasmid used to 
express LtrA in trans is of higher copy number than that used to express LtrA in cis, the 
similar levels of LtrA suggest that excess, unbound protein is degraded (see below). In 
addition, when expressed in trans, the proportion of soluble LtrA was usually decreased 
substantially, as shown in Figure 2.4(b) (compare lanes 2 and 5 with lane 6). The cis 
constructs pALG2-∆DIVa and pALG2-∆IVa/b, which lack the high-affinity binding site 
in DIVa, also generally gave a high proportion of insoluble LtrA (Figure 2.4, lanes 7 and 
8), while the construct pALG1-∆DV, which is missing a key region of the intron’s 
catalytic core, gave ~50% lower amounts of soluble LtrA in some experiments, but not 
others (Figure 2.4, lanes 5, and data not shown). These results are consistent with 
previous findings that the yield of LtrA was decreased threefold and the protein was 
largely insoluble when expressed at 37˚C in the absence of the intron RNA (Matsuura et 
al., 1997), and with in vitro experiments demonstrating that LtrA is prone to rapid and 
irreversible denaturation when incubated by itself in splicing reaction medium at 37˚C 
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(Saldanha et al., 1999). Together, these findings suggest that the decreased splicing 
efficiency when LtrA is expressed in trans reflects in part that the protein is unstable 
when it cannot bind rapidly and tightly to the intron RNA. 
2.2 RT-PCR AND POISONED PRIMER ASSAYS OF IN VIVO SPLICING 
The results of the FACS assay were confirmed by using both RT-PCR and 
poisoned primer extension assays. The RT-PCR assays were carried out with 5’- and 3’-
exon primers PHIII and PPI, yielding a 145-bp product for ligated exons and larger 
products for precursor RNAs (Figure 2.5). In agreement with the FACS assays, the wild-
type constructs pALG1-WT, containing the full-length intron, and pALG2-WT, 
containing the ∆ORF intron with LtrA expressed from the downstream cis position, gave 
similar amounts of ligated-exon product (lanes 4 and 7), while the construct in which 
LtrA is expressed in trans from a separate plasmid gave significantly less of this product 
and showed increased amounts of unspliced precursor RNA (lane 8). The mutants 
pALG1-∆ORF and pALG1-∆DV gave no detectable ligated exons (lanes 5 and 6, 
respectively), even when the PCR was extended to 40 cycles (not shown). I note that the 
larger RT-PCR product, corresponding to the unspliced precursor RNA, was at most 
barely detectable for constructs containing the full-length Ll.LtrB intron (pALG1-WT 
and pALG1-∆DV), but much stronger with constructs containing the shorter ∆ORF-
version of the intron. This situation likely reflects both decreased efficiency of RT-PCR 
with longer templates and greater susceptibility of the larger precursor RNA to 
nucleolytic degradation (Matsuura et al., 1997; Guo et al., 2000). 
In the poisoned primer extension assay (Figure 2.6), the 5’-labeled primer PRET, 
complementary to a sequence just downstream of the 3’-splice site, was extended with 
M-MLV RT in the presence of ddCTP to terminate cDNA synthesis at the first G-residue 
in the template. The resulting products for the ligated exons and unspliced precursor 
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RNA have lengths of 36 and 38 nts, respectively, with the E1-E2 product resolved as a 
doublet even when synthesized from an in vitro transcript control (lane 2). In agreement 
with the GFP and RT-PCR assays, the poisoned primer extension assay showed that wild-
type construct pALG1-WT and the cis-construct pALG2-WT spliced efficiently (lanes 4 
and 7; ratio of ligated exons:unspliced precursor = 1.2 ± 0.3 and 1.1 ± 0.07, respectively, 
where the values are the mean ± standard deviation for three determinations). By 
contrast, splicing was again undetectable for the Ll.LtrB-∆ORF or ∆DV mutants (ratios < 
0.01; lanes 5 and 6), confirming that both the LtrA protein and the ribozyme activity of 
the intron RNA are required for the Ll.LtrB intron to splice significantly in E. coli. When 
LtrA was expressed in trans, the assays showed decreased amounts of both ligated exons 
and unspliced precursor RNA (lane 8), suggesting that more rapid turnover of unbound 
precursor RNA also contributes to the decreased splicing efficiency in trans. 
2.3 SPLICING OF MUTANTS WITH DELETIONS IN DIFFERENT SEGMENTS OF THE 
INTRON RNA 
I next tested the in vivo splicing of intron deletion constructs, which had been 
assayed previously for protein-dependent splicing in vitro (Figure 2.1; Wank et al., 1999). 
The deletions were analyzed in the pALG2 background, in which LtrA is expressed from 
the downstream cis position, where modifications can be introduced into DIV without 
affecting the LtrA coding sequence. Data for the FACS, RT-PCR, and poisoned primer 
assays are shown in Figures 2.3, 2.5, and 2.6, respectively. In agreement with previous in 
vitro assays (Wank et al., 1999), constructs deleted for DI or III abolished maturase-
promoted splicing in vivo, as monitored by all three assays. Surprisingly, a construct 
deleted for DII showed very weak splicing in the RT-PCR assay with an increased 
number of cycles (Figure 2.5(b) and (c), lanes 10 and 17), and this splicing was 
confirmed by sequencing the RT-PCR product.   
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I also tested the effect of deleting different regions of DIV, which plays a key role 
in binding the LtrA protein. The deletion of DIVa, which contains the high-affinity LtrA-
binding site, alone or together with DIVb, inhibited splicing by ≥ 90%, but not 
completely (ratios of ligated exons to unspliced precursor RNA in poison primer assay 
were 0.067 ± 0.006 for ∆DIVa and 0.11 ± 0.04 for ∆DIVa/b, corresponding to 6 and 
10%, respectively, of that for the parent construct pALG2; 1.1 ± 0.07; see above). In a 
construct containing DIVa, deletion of the peripheral regions of DIVb (∆DIVb1/b2) 
inhibited splicing by ~30%, while the complete deletion of DIVb (∆DIVb) inhibited 
splicing by ~60% (ratio of ligated exons to unspliced precursor RNA 0.67 ± 0.16 and 
0.37 ± 0.06, respectively). We confirmed by sequencing that the residual splicing of the 
∆DIVa construct yields the correct ligated-exon product and that the residual splicing of 
all four constructs is LtrA-dependent (not shown). The deletion of all of DIV (pALG2-
∆DIV) reduced splicing to 2-4% of wild type. In pALG2-∆DIVstem, the DIVstem is 
deleted, whereas the rest of DIV is intact (Figure 2.1(b)).  This mutant spliced similarly to 
pALG2-∆DIV. However, pALG2-∆DIVTL, with the majority of DIV deleted except for 
the DIV stem and a few extra bases to form a loop, had about 10% wild type splicing, 
similar to those of pALG2-∆DIVa and ∆DIVa/b. I suspected that a stem-loop structure in 
DIV was important for splicing. pALG2-∆DIV+st was constructed by inserting a five-
base pair GC stem and a TTTT tetra loop in the position of DIV in pALG2-∆DIV (Fig 
2.1c) and spliced with an efficiency similar to that of pALG2-∆DIVTL (~ 10% wild type; 
not shown). 
pALG2-∆ORF/∆DIVa, pALG2-∆ORF/∆DIVa/b, and pALG2-∆ORF/∆DIVTL 
were deleted of the LtrA ORF to make pALG1-∆ORF/∆DIVa, pALG1-∆ORF/∆DIVa/b, 
and pALG1-∆ORF/∆DIVTL, all of which did not splice in vivo (not shown).   
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Together, these findings indicate that the high-affinity binding site in DIVa is 
required for efficient splicing in vivo, but in the absence of DIVa, residual maturase-
dependent splicing can still occur by direct binding of the protein to the catalytic core. 
DIVb also makes a significant contribution to splicing, either directly by contributing to 
the binding of the maturase, or indirectly by affecting the structure of the intron RNA. 
The DIV stem also contributes to splicing but can be replaced by a stem-loop structure 
with unrelated sequence. 
2.4 UNIGENIC EVOLUTION ANALYSIS OF LTRA 
To identify regions of LtrA required for splicing, I employed a method termed 
unigenic evolution in which a genetic assay is used to identify functional protein variants 
in a library containing random mutations (Deminoff et al., 1995). The mutations are then 
analyzed statistically to determine the ratio of missense to silent mutations compared to 
that expected based on codon degeneracy and the mutation frequency in the library. For 
unigenic evolution analysis of LtrA, I used error-prone PCR to create a library of mutant 
proteins in plasmid pELG2, a higher copy number version of pALG2, in which the LtrA 
protein is expressed from the downstream cis position. The higher copy number 
decreases plasmid loss during the assays. Sequencing of 36 randomly selected plasmids 
from the library showed that the mutation frequency was 0.78%, resulting in an average 
of ~10 amino acid substitutions per protein. 
To identify functional protein variants, I first attempted to use FACS to sort cells 
harboring splicing-competent mutants by high GFP fluorescence. However, I found that 
the sorted cells were generally inviable or had lost fluorescence after overnight culturing, 
likely due to depletion of nucleotide pools and plasmid loss resulting from the relatively 
long (2.5 h) IPTG-induction of T7 RNA polymerase required to give sufficient signal 
intensity. For that reason, we developed an alternate assay in which the plated colonies 
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were duplicated onto nitrocellulose filters. The filters were then induced with IPTG for 4 
h and scanned by using a FluorImager (Figure 2.7). Variants that exhibited high GFP 
fluorescence on the filters were isolated from the original plate, grown up in liquid 
culture, and assayed quantitatively by FACS to determine the level of splicing. This 
procedure enables the screening of 1000-1500 colonies per plate duplicated onto five to 
seven 35-mm diameter filters at ~200 colonies per filter, and it eliminates the need for 
culturing cells that have been induced. Variants that gave more than 50% of wild-type 
fluorescence in the FACS assay were classified as active and sequenced. 
 In total, I identified 111 LtrA variants that gave ≥ 50% wild-type fluorescence. 
These variants contained 622 mutations of which 369 were missense (Figure 2.8). To 
determine which regions of the LtrA protein are required for splicing, I calculated the 




where fOmis is the observed frequency of missense mutations and fEmis is the expected 
frequency based on the mutation frequency of the library and codon degeneracy 
(Deminoff et al., 1995). Figure 2.9 shows a plot of the mutability value versus the amino 
acid residue at the center of the sliding window. Negative values in the plot indicate 
hypomutability with a maximal value of -1 indicating no missense mutations, and 




so that all values lie between  -1 and +1. 
The mutability plot shows seven regions (A-G) spanning the RT and X domains 
that were hypomutable in functional LtrA variants, separated by regions that were less 
constrained. Although some of the latter regions appear to be hypermutable, χ2 
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calculations indicate that in each case the difference from the expected frequency of 
missense mutations is not statiscally signifant (p values > 0.1). By contrast, the seven 
hypomutable regions are highly significant with A, B, C, E, and F having p values  < 
0.001 and D and G having p values < 0.01. At the C-terminus of the protein, the DNA-
binding domain was less constrained, and the DNA endonuclease domain showed an 
essentially random ratio of silent to missense mutations. Additionally, several splicing-
competent mutants were found to have premature stop codons, the farthest upstream 
being at amino acid 522 in the DNA-binding domain. These findings indicate that the RT 
and X domains but not the DNA-binding or DNA endonuclease domains are required for 
efficient splicing. 
HIV-1 RT, whose structure has been determined by X-ray crystallography, is a 
heterodimer, with the active p66 subunit consisting of fingers, palm, thumb, connection, 
and RNase H domains (Kohlstaedt et al., 1992). The palm contains the RT active site, 
including the highly conserved YADD motif, which binds catalytically essential metal 
ions, while the fingers, thumb, and connection domain contribute to template and primer 
binding (Huang et al., 1998). Conserved RT motifs 2 and 4 in the fingers help position 
the template RNA at the active site and are part of the "template grip", while RT-7 in the 
palm interacts with primer terminus and is referred to as the "primer grip" (Jacobo-
Molina et al., 1993).  
In the LtrA protein, the hypomutable regions A to E correspond to the fingers and 
palm of HIV-1 RT, with the most conserved regions, B, C, and E, encompassing the 
template and primer grip regions (RT-2, -4, and -7; amino acid residues involved in 
template and primer binding denoted by "T" and "P", respectively, in Figure 2.8). The 
additional conserved regions A and upstream part of B at the N-terminus of the RT 
domain, include RT-0 and -1, and may be part of an extended fingers region proposed to 
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be involved in specific binding of the template RNA in non-LTR retroelement RTs (Chen 
& Lambowitz, 1997; Bibillo & Eickbush, 2002). By contrast, the catalytically essential 
YADD motif, which is part of RT-5 in the palm, was mutated in some variants, as were 
amino acid residues involved in dNTP binding in HIV-1 RT (denoted by "N" in the 
Figure). These findings extend previous results for the yeast aI2 intron, which showed 
that mutations in the conserved YADD motif abolish RT activity, but leave substantial 
splicing activity in vivo, indicating that RT activity per se is not required for splicing 
(Moran et al., 1995).  
Domain X, which corresponds in position to the thumb and connection domains 
of HIV-1 RT, contains two hypomutable regions F (amino acid residues 399-429) and G 
(amino acid residues 461-481), which appear to be separated by a short non-conserved 
region. All of the amino acid residues that are conserved in the X domains of other group 
II IEPs were either invariant or replaced only by amino acid residues found at the same 
position in other group II IEPs. The invariant amino acid residues include S462, which 
was mutated in a splicing-defective yeast aI2 maturase (Moran et al., 1994).  
The predicted secondary structure of domain X in LtrA and other group II intron 
maturases has three predicted α-helices in an arrangement similar to that found in the 
thumb of HIV-1 RT (PHD program; http://cubic.bioc.columbia.edu/PP; Jacobo-Molina et 
al., 1993; Blocker et al., 2005). The first two α-helices lie in hypomutable region F and 
the third lies in hypomutable region G. We also note that domain X is separated from the 
RT domain by a non-conserved region of 25 amino acid residues (positions 363-388) 
suggestive of an inter-domain linker. 
Considered together, the results of the unigenic evolution analysis show that 
regions of both the RT and X domains are required for RNA splicing activity, and the 
critical regions include those involved in template and primer binding in other RTs. In 
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general, missense mutations in these regions could inhibit RNA splicing directly, or 
indirectly by affecting the structure of another region or by leading to a decreased amount 
of active protein. 
2.5 BIOCHEMICAL ANALYSIS OF RT AND X DOMAIN MUTANTS 
Three other people contributed to this part of the work. Dr. Manabu Matsuura 
generated figures 2.10 to 2.12. Dr. Hongwen Ma and Ms. Qin Wang constructed a 
number of mutants and conducted some initial biochemical experiments.  
To investigate how the RT and X domains contribute to splicing, we constructed a 
series of LtrA mutants for biochemical analysis. Four of the mutants have different-sized 
N-terminal truncations, while the remainder have small numbers of alanine substitutions 
in critical regions identified in the unigenic evolution analysis. The mutant proteins were 
expressed in E. coli, purified, and assayed for RT activity and for their ability to splice 
and bind the Ll.LtrB intron (Figures 2.10-12). The RT assays were carried out both with 
the artificial template-primer substrate poly(rA)/oligo(dT)18 and with a previously 
described natural substrate mimic denoted Ll.LtrB/E2+10 (Wank et al., 1999; San Filippo 
& Lambowitz, 2002).  The latter consists of Ll.LtrB RNA (in vitro transcript containing 
the Ll.LtrB-∆ORF intron and flanking exons) with an annealed 20-mer DNA primer 
(E2+10), whose 3’ end corresponds to that of the cleaved bottom strand normally used as 
the primer for TPRT. The RNA splicing assays were carried out by incubating LtrA 
protein with Ll.LtrB RNA at 1:1 and 10:1 protein:RNA ratios to help distinguish effects 
due to decreased binding affinity of the LtrA protein. The binding of the LtrA protein to 
Ll.LtrB RNA was assayed by equilibrium binding, and supplemented by koff 
determinations for some mutants. 
The results for the wild-type LtrA protein are in close agreement with those 
obtained previously (Saldanha et al., 1999; Wank et al., 1999; Matsuura et al., 2001). The 
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wild-type protein has high RT activity with both the poly(rA)/oligo(dT)18 and 
Ll.LtrB/E2+10 substrates (Figure 2.10), promotes splicing of the Ll.LtrB intron in 
reaction medium containing 5 mM Mg2+, where the intron is not self-splicing (Figure 
2.11), and binds the Ll.LtrB RNA with high affinity (Figure 2.12). As reported 
previously, the apparent Kd (K1/2) measured by equilibrium binding (2.0 nM) is 
substantially higher than that measured kinetically as koff/kon (0.12 pM) (Saldanha et al., 
1999). This difference could reflect either a multi-step binding mechanism in which a 
stable intermediate forms prior to the final complex (Webb et al., 2001) or that the 
apparent Kd measured by equilibrium binding is limited by some other factor, such as the 
dissociation of LtrA dimers, instability of the protein at low concentrations, or long 
incubation times required for equilibrium at low concentrations of the interacting 
molecules (Saldanha et al., 1999). In either case, the koff value provides the best measure 
of the stability of the final active complex. 
First, analysis of N-terminal truncations showed that mutant proteins lacking the 
first 10 or 20 amino acid residues (∆N10 and ∆N20) retained some activities, while 
mutant proteins with larger truncations (∆N30 or ∆N40) were poorly expressed and 
lacked RT and RNA splicing activities (not shown). Strikingly, both the ∆N10 and ∆N20 
mutants had substantial RT activity with the artificial template-primer substrate 
poly(rA)/oligo(dT)18 (50-55% wild type), but completely lacked RT activity with the 
Ll.LtrB/E2+10 substrate (Figure 2.10). Further, both mutants had strongly decreased 
binding affinity for Ll.LtrB RNA (K1/2’s > 200 nM; Figure 2.12(a)), but retained 
surprisingly high levels of RNA splicing activity (Figure 2.11(a)). This biochemical 
phenotype is expected for mutant proteins that have impaired interaction with the high-
affinity binding site DIVa. Such mutants are expected to have strongly decreased binding 
affinity for the intron RNA, but may still promote splicing by binding directly to the 
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catalytic core (Wank et al., 1999; Matsuura et al., 2001). Further, since binding to DIVa 
positions the protein to initiate reverse transcription in the 3’ exon of the Ll.LtrB/E2+10 
substrate (Wank et al., 1999) impaired interaction with DIVa could also account for the 
differential inhibition of reverse transcription of that substrate relative to 
poly(rA)/oligo(dT)18. The data for these mutants demonstrate that very tight binding of 
LtrA to the intron RNA is not essential for RNA splicing, at least under in vitro 
conditions where the protein concentration is relatively high. 
The mutant DK has two amino acid substitutions (D107A, K108A) in the 
template grip (RT-2). This mutant had strongly decreased RT activity with both the 
poly(rA)/oligo(dT)18 and Ll.LtrB/E2+10 substrates (Figure 2.10). However, the mutant 
retained high RNA splicing activity (Figure 11(b); the somewhat decreased amplitude at 
1:1 protein:RNA likely reflects a decreased proportion of active protein) and high affinity 
for Ll.LtrB RNA (K1/2 = 3.2 nM compared to 2.0 nM for wild type; Figure 2.12(b); and 
koff = 3.1 x 10-4 min-1 compared to 3.6 x 10-4 min-1 for wild type; Figure 2.12(d)). Given 
the location of the mutations, a reasonable possibility is that they do not strongly affect 
the specific binding of Ll.LtrB RNA but rather the positioning of the RNA template at the 
active site. Other template and primer grip mutants tested (S218A, P219A in RT-4 and 
R355A, F356A, L357A, and G358A in RT-7) were poorly expressed, preventing 
biochemical analysis. 
The mutants YADD→YAAA, at the RT active site, and R98A and L100A, which 
correspond to amino acid residues involved in dNTP binding in HIV-1 RT, had strongly 
decreased RT activity with both the poly(rA)/oligo(dT)18 and Ll.LtrB/E2+10 substrates, 
as expected (Figure 2.10). However, all three mutants retained high RNA splicing 
activity (Figure 2.11(b)) and bound Ll.LtrB as well as the wild-type protein (K1/2's = 0.6 
to 2.3 nM; Figure 2.12(b); koff values = 2.2 to 3.1 x 10-4 min-1; Figure 2.12(d)). These 
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findings show that neither RT activity nor the integrity of the RT active site is required 
for RNA splicing activity. 
Finally, the domain X mutant EYSC (E460A, Y461A, S462A, C463A) had low 
RT activity with poly(rA)/oligo(dT)18 (15% wild type) and no detectable RT activity with 
Ll.LtrB/E2+10 (Figure 2.10). The mutant also had no detectable RNA splicing activity at 
either 1:1 or 10:1 protein:RNA ratio (Figure 2.11). However, in equilibrium binding 
assays, the EYSC protein bound Ll.LtrB as well as the wild-type protein (K1/2 = 0.91 nM; 
Figure 2.12(c)). Further, this binding was verified to be specific, as judged by failure of 
either the wild-type or EYSC protein to bind a group I intron RNA (Figure 2.12(c)). The 
koff for the EYSC protein was about 30-fold faster than that for the wild-type protein (1.1 
x 10-2 min-1 compared to 3.6 x 10-4 min-1; Figure 2.12(d)), but comparable to that for 
LtrA bound to a small RNA containing the DIVa high affinity binding site (1.2 to 1.3 x 
10-2 min-1 under the same temperature and ionic conditions; Wank et al., 1999). Together, 
these findings show that the EYSC mutant still binds Ll.LtrB specifically and with 
relatively high affinity, possibly via interactions with DIVa, but is likely defective in one 
or more critical weaker interactions with catalytic core regions required for splicing. 
Other domain X mutants tested (Y442A, Y443A, K470A, and K472A) were too poorly 
expressed for biochemical analysis. 
2.6 DISCUSSION 
Here, I developed an E. coli genetic assay for maturase-promoted group II intron 
splicing by linking the splicing of the L. lactis Ll.LtrB intron to the expression of GFP. 
To accommodate the requirement for specific 5’- and 3’-exon sequences that base pair 
with the intron RNA, the intron and short flanking exon sequences from the ltrB gene 
were inserted at the N-terminus of the reporter, so that splicing of the intron leads to the 
expression of GFP with a small N-terminal extension. The same approach should be 
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generally applicable to other selectable or screenable markers that tolerate N-terminal 
fusions. The E. coli genetic assay enabled us to investigate several key aspects of 
maturase-promoted group II intron splicing in vivo. 
First, I found that the maturase functions most efficiently when expressed in cis, 
either from its normal location within the intron or from a position just downstream of the 
3’-exon/GFP marker. The maturase also functions when expressed in trans from a 
separate plasmid, but the extent of splicing measured by GFP fluorescence was < 10% of 
that for either cis configuration. The decreased splicing efficiency when LtrA is 
expressed in trans appears to reflect both the instability of the free protein and more rapid 
turnover of unspliced precursor RNA when the formation of stable complex is delayed. In 
Ll.LtrB and other bacterial introns, the initial binding of the maturase may occur prior to 
the completion of transcription or translation, facilitated by the proximity of the newly 
synthesized N-terminus to its putative binding site in DIVa, which contains the initiation 
codon. The initial binding to DIVa could then nucleate other interactions with the 
catalytic core. Since LtrA binds the intron RNA as a dimer (Saldanha et al., 1999), the 
presumption is that stable binding requires at least two rounds of translation. Consistent 
with our results, Zhou et al. (2000), using an L. lactis assay in which splicing of the 
intron from the ltrB relaxase gene in one plasmid is required for conjugation of a second 
plasmid carrying a genetic marker, observed a 27-fold decrease in conjugation efficiency 
when the LtrA ORF was deleted from its normal location in DIV and expressed in trans 
from a third plasmid. However, they could not exclude that the decrease was due to the 
introduction of the third plasmid or variability in the assays. 
Experiments analyzing the effect of deleting different intron domains or the intron 
ORF showed that in vivo splicing of Ll.LtrB intron is dependent on both the integrity of 
the group II intron core, whose ribozyme activity catalyzes splicing, and on expression of 
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active maturase, which promotes RNA folding. The intron was not detectably self-
splicing in vivo. In agreement with previous in vitro assays (Wank et al., 1999), I found 
that the high-affinity maturase binding site in DIVa is required for efficient splicing of 
the Ll.LtrB intron in vivo, but in the absence of DIVa, 6-10% residual splicing can occur 
by direct binding of the maturase to the catalytic core. Thus, both the DIVa-dependent 
and DIVa-independent splicing mechanisms defined by previous in vitro assays with the 
Ll.LtrB intron are physiologically relevant. In an intron containing DIVa, the deletion of 
the peripheral regions DIVb1/b2 inhibited in vivo splicing by ~30%, while the complete 
deletion of DIVb inhibited splicing by ~60%, in reasonable agreement with in vitro 
results (Wank et al., 1999). Recent studies with the yeast aI2 intron showed that deletion 
of DIVb strongly inhibits maturase-promoted reverse splicing in an in vitro assay, but its 
effect was not assessed in vivo (Huang et al., 2003). In both the yeast intron and Ll.LtrB, 
DIVb could contribute to maturase-promoted reactions either by providing additional 
binding sites for the LtrA protein, or indirectly by affecting the conformation of DIVa or 
other regions of the intron RNA.  
For the yeast aI2 intron, DIVa is also required for stable binding of the maturase, 
but its deletion inhibited in vivo splicing by only ~30%, a smaller effect than found here 
for the Ll.LtrB intron (Hunag et al., 2003). This smaller effect could reflect different 
relative affinities of the maturase for different regions of the intron RNA, a smaller effect 
of DIVa deletion on the underlying ribozyme activity, or different assays used to detect in 
vivo splicing (e.g., a lower rate of turnover of spliced product would result in less 
apparent inhibition of RNA splicing). Notably, for both the lactococcal and yeast introns, 
the deletion of DIVa has a much larger effect on intron mobility than it does on RNA 
splicing (mobility decreased by >105 for Ll.LtrB and to undetectable levels using a less 
sensitive assay for the yeast aI2 intron) (Huang et al., 2003; D’Souza & Zhong).  These 
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findings suggest that binding to DIVa is more important for intron mobility than for RNA 
splicing and that somewhat different RNA-protein interactions may be used for the two 
processes. The larger effect deletion of DIVa on intron mobility may reflect that binding 
to DIVa is particularly critical for positioning the protein on the Ll.LtrB RNA for 
initiation of reverse transcription (Wank et al., 1999). 
Interestingly, the domain IV stem can be replaced by an unrelated stem-loop and 
splicing is restored to the level of ∆DIVa. It should be interesting to see whether adding 
back DIVa to the unrelated stem loop could further restore the activity. 
The unigenic evolution analysis identified seven regions (A-G) spanning the RT 
and X domains that are hypomutable in splicing-competent LtrA variants. Hypomutable 
regions A-E span regions corresponding to the fingers and palm of retroviral RTs, while 
hypomutable regions F and G are in domain X, which likely corresponds to the thumb of 
retroviral RTs. By contrast, the C-terminal DNA-binding and DNA endonuclease 
domains were not highly constrained in splicing-competent LtrA variants and were in fact 
truncated by nonsense mutations in some variants. These findings together with previous 
in vivo results for the yeast aI2 intron (Zimmerly et al., 1995b) show that the DNA-
binding and DNA endonuclease domains are not essential for RNA splicing. 
Within the RT domain, the hypomutable regions A and the upstream part of B 
encompass the N-terminus of the protein and include conserved sequence motifs RT-0 
and RT-1. The larger N-terminal region in non-LTR-element RTs has been postulated to 
be part of an extended fingers domain involved in specific binding of the template RNA 
for initiation of reverse transcription in non-LTR-element RTs (Chen & Lambowitz, 
1997; Bibillo & Eickbush, 2002). Biochemical assays support this hypothesis by showing 
that the N-terminal truncation mutants ∆N10 and ∆N20 have strongly decreased binding 
affinity for Ll.LtrB RNA and are unable to initiate reverse transcription on Ll.LtrB RNA 
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using a 3’-exon primer, but retain substantial RT activity with the artificial substrate 
poly(rA)/oligo(dT)18 (Figure 10). Further, both mutants retain high RNA splicing 
activity. These findings suggest that the N-terminal truncations specifically affect 
interactions with DIVa, which are required for high-affinity binding and positioning the 
RT to initiate reverse transcription in the 3’ exon of Ll.LtrB RNA, without impairing 
critical but weaker interactions with catalytic core regions required for RNA splicing.   
Within the RT domain, the hypomutable regions A and the upstream part of B 
encompass the N-terminus of the protein and include conserved sequence motifs RT-0 
and RT-1. The larger N-terminal region in non-LTR-element RTs has been postulated to 
be part of an extended fingers domain involved in specific binding of the template RNA 
for initiation of reverse transcription in non-LTR-element RTs (Chen & Lambowitz, 
1997; Bibillo & Eickbush, 2002). Biochemical assays support this hypothesis by showing 
that the N-terminal truncation mutants ∆N10 and ∆N20 have strongly decreased binding 
affinity for Ll.LtrB RNA and are unable to initiate reverse transcription on Ll.LtrB RNA 
using a 3’-exon primer, but retain substantial RT activity with the artificial substrate 
poly(rA)/oligo(dT)18 (Figure 10). Further, both mutants retain high RNA splicing 
activity. These findings suggest that the N-terminal truncations specifically affect 
interactions with DIVa, which are required for high-affinity binding and positioning the 
RT to initiate reverse transcription in the 3’ exon of Ll.LtrB RNA, without impairing 
critical but weaker interactions with catalytic core regions required for RNA splicing. 
Hypomutable regions B, C, and E in the unigenic evolution analysis encompass 
conserved sequence blocks RT-2 and -4, which are part of the template grip, and RT-7, 
which corresponds to the primer grip. Within these regions, there was strong conservation 
(immutability or conservative changes) of most amino acid residues corresponding to 
those involved in template and primer binding in HIV-1 RT (see Figures 2.8 and 2.9). In 
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biochemical assays, the double mutation D107A, K108A in RT-2, which is part of the 
template grip, strongly inhibited RT activity with both the poly(rA)/oligo(dT)18 and 
Ll.LtrB RNA/E2+10 substrates, while having little effect on intron RNA splicing or 
binding. Given the location of the mutations, this phenotype likely results from the 
disruption of one or more critical contacts required for positioning template RNA at the 
RT active site. Such contacts could also contribute to RNA splicing, but are expected to 
be weak and non-specific, since the template RNA must translocate through the active 
site. Thus, their disruption may have little effect on intron RNA binding, so long as other 
contacts, including those with the high-affinity binding site DIVa, are maintained. 
Although regions of the RT domain involved in template and primer binding are 
required for efficient RNA splicing, the integrity of the RT active site itself is not 
required. Thus, a number of mutations in the unigenic evolution analysis occurred in the 
highly conserved YADD motif at the RT active site and in amino acid residues 
corresponding to those involved in dNTP binding in retroviral RTs. The biochemical 
assays confirmed that the mutation YAAA at the RT active site, as well as the mutations 
R98A and L100A, which are expected to affect dNTP binding, strongly inhibited RT 
activity with both the poly(rA)/oligo(dT)18 and Ll.LtrB/E2+10 substrates, while leaving 
high RNA splicing activity in vitro. These results extend previous findings for the yeast 
aI2 protein, which showed that the YADD mutant lacks RT activity, but has substantial 
RNA splicing activity in vivo (Moran et al., 1995). 
Finally, domain X, which corresponds in position to the thumb and connection 
domains of retroviral RTs, contains two hypomutable regions, F and G. A secondary 
structure prediction program indicates that the two hypomutable regions contain three 
predicted α-helices, which correspond in size and position to α-helices in the thumb 
domain of HIV-1 RT (Jacobo-Molina et al., 1993; Blocker et al., 2005). In an X-ray 
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crystal structure of HIV-1 RT containing a bound DNA template:primer and dNTP, the 
thumb and connection domains interact with the phosphodiester backbone of the DNA 
template/primer duplex (Huang et al., 1998), but during initiation the same regions are 
thought to interact with the template RNA/tRNALys duplex, which may be more akin to 
the binding of a structured group II intron RNA (Isel et al., 1999). In the unigenic 
evolution analysis, all of the amino acid residues that are highly conserved in the X 
domains of other group II IEPs were either invariant or replaced only by amino acid 
residues found at the same position in other group II IEPs. Further, the invariant amino 
acid residues include the conserved S462, which is located in one of the predicted α-
helices and was mutated in a splicing-defective yeast aI2 maturase (Moran et al., 1994).  
Additionally, biochemical assays showed that the LtrA domain X mutant EYSC→A, 
which includes S462, has exactly the phenotype expected for impairment of a critical 
secondary contact with the catalytic core. This mutant still binds Ll.LtrB RNA 
specifically and with relatively high affinity, likely at least in part via interaction with 
DIVa, but is totally unable to promote splicing.   
Considered together, our results indicate that group II IEPs function in splicing by 
using the RT and X domains to bind different regions of the intron RNA. The 
biochemical analysis of LtrA mutants suggests further that regions at the N-terminus of 
the RT domain interact with the high-affinity binding site in DIVa, while domain X and 
possibly other regions of the RT domain make secondary contacts with conserved 
catalytic core regions. Remarkably, the biochemical data for the N-terminal truncation 
mutants ∆N10 and ∆N20 show that splicing activity does not require very tight binding of 
the maturase to the intron RNA. Conversely, the biochemical data for the domain X 
mutant EYSC→A show that a mutant protein can bind Ll.LtrB tightly and specifically 
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but be totally unable to promote splicing, presumably due to impairment of a weaker, but 
critical interaction with the catalytic core. 
The suggestion that the N-terminal part of the RT domain interacts with DIVa, 
while other parts of the RT and X domains interact with conserved catalytic core regions 
agrees well with findings for other introns. First, studies with the yeast aI1 and aI2 
introns, which are 50% identical, showed that genetically isolated hybrids consisting of 
the N-terminal region of the aI1 maturase (RT-0 to -2 or -5) fused to the C-terminal 
region of the aI2 maturase functioned as an aI1-specific splicing factor (Anziano & 
Butow, 1991). These results indicate that the N-terminal region of the protein, which we 
find is required for binding DIVa, is engaged in intron-specific interactions, while 
downstream regions of the aI2 protein function equally well with aI1 and must therefore 
interact with regions conserved between the two introns. DIVa binding has been shown 
directly to contribute to intron specificity for the yeast aI1 and aI2 maturases (Huang et 
al., 2003).  Second, cp MatK proteins, which are thought to function in splicing multiple 
group II introns, lack RT motifs 0-4, encompassing the region suggested to be involved in 
intron-specific interactions with DIVa, but retain recognizable RT motifs 5-7 along with 
domain X, which are suggested to interact with conserved regions of the group II intron 
catalytic core (Mohr et al., 1993). We note that MatK proteins still retain an N-terminal 
region upstream of RT 5-7, and phylogenetic analysis suggests that it has also been 
subject to evolutionary constraint (Young & dePamphilis, 2000). If MatK proteins do in 
fact function in splicing multiple group II introns, these findings imply that the N-
terminal region of MatK proteins also has some function, either contributing directly to 
RNA binding for one or more introns, or being required for proper folding of other 
protein regions that function directly in RNA binding. 
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Finally, with respect to evolution, it has been suggested that mobile group II 
introns evolved either by insertion of an RT from another retroelement into a pre-existing 
group II intron (Kennell et al., 1993) or from a non-LTR retrotransposons that acquired 
self-splicing activity (Curcio & Belfort, 1996). In either case, the RT must have 
functioned initially in intron mobility and then adapted secondarily to function in RNA 
splicing. Our findings support the hypothesis that the IEP adapted to function in splicing 
by using, at least in part, interactions that were used initially for the specific binding of 
the intron RNA for the initiation of reverse transcription. 
2.7 SUMMARY 
Mobile group II introns encode proteins with both reverse transcriptase activity, 
which functions in intron mobility, and maturase activity, which promotes RNA splicing 
by stabilizing the catalytically active structure of the intron RNA. Previous studies with 
the L. lactis Ll.LtrB intron suggested a model in which the intron-encoded protein binds 
first to a high-affinity binding site in intron subdomain DIVa, an idiosyncratic structure at 
the beginning of its own coding region, and then makes additional contacts with 
conserved catalytic core regions to stabilize the active RNA structure. Here, we 
developed an E. coli genetic assay that links the splicing of the Ll.LtrB intron to the 
expression of GFP and used it to study the in vivo splicing of wild-type and mutant 
introns and to delineate regions of the maturase required for splicing. Our results show 
that the maturase functions most efficiently when expressed in cis from the same 
transcript as the intron RNA. In agreement with previous in vitro assays, we find that the 
high-affinity binding site in DIVa is required for efficient splicing of the Ll.LtrB intron in 
vivo, but in the absence of DIVa, 6-10% residual splicing occurs by the direct binding of 
the maturase to the catalytic core. Critical regions of the maturase were identified by 
statistically analyzing ratios of missense to silent mutations in functional LtrA variants 
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isolated from a library generated by mutagenic PCR (“unigenic evolution”). This analysis 
shows that both the RT domain and domain X, which likely corresponds to the RT 
thumb, are required for RNA splicing, while the C-terminal D and En domains are not 
required. Within the RT domain, the most critical regions for maturase activity include 
parts of the fingers and palm that function in template and primer binding in HIV-1 RT, 
but the integrity of the RT active site is not required. Biochemical analysis of LtrA 
mutants indicates that the N-terminus of the RT domain is required for high-affinity 
binding of the intron RNA, possibly via direct interaction with DIVa, while parts of 
domain X interact with conserved regions of the catalytic core. Our results support the 
hypothesis that the intron-encoded protein adapted to function in splicing by using, at 





Figure 2.1 Predicted secondary structures of wild-type and mutant Ll.LtrB introns. 
(a) The predicted secondary structure of the wild-type Ll.LtrB intron, based on the 
generalized group IIA intron structure in Toor et al. (2001). Ll.LtrB positions are 
numbered according to Mills et al. (1994). Nucleotide residues involved in the EBS/IBS 
pairings and tertiary interactions (Greek letters) are marked. Tertiary structure elements 
ζ, η, and η' are demarcated by dashed lines to indicate previously discussed uncertainties 
in defining these elements (Matsuura et al., 2001). 5’- and 3’-exon sequences are boxed. 
(b) The predicted secondary structure of DIV, containing the Shine-Dalgarno (SD) 
sequence and initiation codon (boxed) of the LtrA ORF. The location of the 1596 nts 
deleted in the ∆ORF intron is indicated, and an MluI site introduced in constructing the 
deletion is boxed. The boundaries of intron deletion mutants (circled) are indicated by 















Figure 2.2 E. coli genetic assay of maturase-dependent splicing of the Ll.LtrB intron.  
(a) and (b) Plasmids pALG1-WT and pALG2-WT, respectively. Both plasmids contain 
ltrB/GFP fusions cloned downstream of a T7lac promoter (PT7lac; arrow) and φ10 Shine-
Dalgarno (SD) sequence. The ltrB/GFP fusion is comprised of the first eight codons of 
the φ10 gene linked to a segment of the L. lactis ltrB gene consisting of the Ll.LtrB intron 
(open rectangle) and flanking exon sequences (E1 and E1; black boxes), with E2 linked 
in-frame to codon 2 of the GFP (hatched). pALG1-WT contains the full-length Ll.LtrB 
intron with the LtrA ORF encoded in DIV, whereas pALG2-WT contains an Ll.LtrB-
∆ORF intron with the LtrA ORF cloned downstream of the GFP coding sequence. T1 and 
T2 are E. coli rrnB transcription terminators. (c) Schematic showing splicing of the 
Ll.LtrB intron linked to the expression of GFP. Splicing leads to the expression of GFP 
with 42-amino acid residue fusion corresponding to the φ10 sequence and ligated exons. 
In the absence of splicing, translation is terminated by stop codons within the intron. 
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Figure 2.3 FACS assay of in vivo splicing of the Ll.LtrB intron.  
Cells containing the indicated constructs with or without (-IPTG) induction were 
analyzed by flow cytometry to count the number of cells in a given window of 
fluorescence intensity. Peak positions are indicated by horizontal lines. In panel (g), the 
LtrA protein was expressed from plasmid pLI1P. Data are representative of at least two 
independent repeats for each construct. 
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Figure 2.4 Immunoblot analysis of LtrA protein expressed from different constructs.  
E. coli HMS174(DE3) containing the indicated constructs was induced with IPTG, and 
(a) total and (b) soluble proteins were resolved in an 8% polyacrylamide/1% SDS gel, 
blotted to a nitrocellulose membrane, and probed with an anti-LtrA polyclonal antibody 
preparation. Each gel lane was loaded with protein from 0.044 O.D.595 of cells, and equal 
loading was confirmed by AuroDye staining of the immunoblot (not shown). Lanes: (1) 
purified LtrA protein (0.03 µg); (2) pALG1-WT; (3) pALG1-∆ORF; (4) pALG1-∆DV; 
(5) pALG2-WT; (6) pALG1-∆ORF plus LtrA expressed in trans from pET-LtrA; (7) 
pALG2-∆DIVa; (8) pALG2-∆DIVa/b. The more rapidly migrating bands in the total 
protein samples are degraded LtrA. 
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Figure 2.5 RT-PCR assay of in vivo splicing of the Ll.LtrB intron.  
(a) to (c) RT-PCR assays. RNA from cells containing the indicated constructs was used 
for RT-PCR with primers PHIII and PPI, and the products were analyzed in a 1% agarose 
gel containing ethidium bromide (0.5 µg/ml) against 1-kb DNA size markers 
(Invitrogen). PCR was carried out for 16 cycles in panels (a) and (b) and 35 cycles in 
panel (c). (d) Schematic showing predicted RT-PCR products for unspliced precursor and 
ligated exon RNAs. 
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Figure 2.6 Poisoned primer extension assay of in vivo splicing of the Ll.LtrB intron.  
(a) and (b) Poisoned-primer assays. The same RNA preparations as in Figure 5 were used 
for primer extension with 5'-labeled primer PRET (complementary to the first 21 nts of 
E2) and M-MLV RT in the presence of ddCTP to terminate reverse transcription at the 
first G-residue of the template. The products were analyzed in a denaturing 10% 
polyacrylamide gel, which was dried and quantified with a PhosphorImager. Constructs 
are indicated at the top of the gel. (c) Schematic showing the predicted products for 







Figure 2.7 Colony-based fluorescence assay of maturase-promoted Ll.LtrB splicing 
linked to GFP expression.  
(a) Flow chart of assay. Colonies growing on plates containing LB plus ampicillin were 
duplicated onto five to seven 35-mm diameter nitrocellulose filters and incubated on an 
absorbent pad saturated with LB + ampicillin + IPTG for 4 h at 37°C. The filters were 
then scanned by using a FluorImager. (b) Scanned filters. E. coli containing pELG2-WT 
(splicing competent) and pELG2-∆ORF (splicing defective due to lack of LtrA protein) 
were mixed at a ratio of 1:10, plated on LB containing ampicillin, and subjected to the 
colony-based fluorescence assay described in panel (a). The top shows an optical scan of 
the filter, and the bottom shows the FluorImager scan, with splicing-competent colonies 
that produce GFP appearing black against a light background. 
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Figure 2.8 Summary of missense mutations in splicing-competent LtrA variants.  
Libraries of random LtrA mutants in pELG2 were screened by using the colony-based 
fluorescence assay to identify those that could efficiently splice the Ll.LtrB-∆ORF. 
Individual mutants were then retested by FACS assay, and those that had ≥ 50% wild-
type splicing activity were sequenced. The Figure shows the wild-type LtrA amino acid 
sequence, with amino acid substitutions or premature stop codons (asterisks) found in 
111 variants having ≥ 50% wild-type splicing activity indicated below. Conserved 
regions RT-0 to -7, and domains X, D, and En are delineated above. Consensus 
sequences for RT-0 to –7 (Xiong & Eickbush, 1992; Zimmerly et al., 2001) and domain 
X (based on current sequence alignments; F. Blocker, G. Mohr and A.M.L., unpublished 
data) are indicated above the LtrA sequence: b, basic; h, hydrophobic; n, nucleophilic; o, 
aromatic; N, amino acid residue involved in dNTP binding; P, amino acid residues 
involved in primer binding (“primer grip”); T amino acid residue involved in template 
binding (“template grip”). Domain X α-helices predicted by PredictProtein PHD 














Figure 2.9 Mutability plot based on unigenic evolution analysis of LtrA variants that 
efficiently splice the Ll.LtrB-∆ORF intron.  
The mutability value (M), which relates the frequencies of expected and observed 
missense mutations (fOmis and fEmis, respectively), was calculated for a 25-amino acid 
residue sliding window by using the equation M = (fOmis / fEmis) - 1 and plotted against the 
amino acid at the center of the window (Deminoff et al., 1995). Negative values indicate 
hypomutability, with a maximum value of -1 indicating no missense mutations, and 
positive values indicate hypermutability, which was normalized using the formula M = 
(fOmis/fEmis- 1)/(1/fOmis - 1), so that all values would fall between -1 and +1. χ2 values were 
calculated for each hypomutable region, as described in Materials and Methods, and p 
values are indicated below each region. The location of conserved RT sequence motifs 0-
7 and LtrA domain boundaries are shown on the X-axis, and the locations of three 
predicted α-helical regions in domain X are shown above. At the bottom is a schematic 
of HIV-1 RT with the fingers (gray), palm (open boxes), thumb (dots), connection 


























Figure 2.10 Reverse transcriptase assays.  
The bar graphs show RT activity of wild-type and mutant LtrA proteins assayed with 
poly(rA)/oligo(dT)18 (black bars) and Ll.LtrB/E2+10 substrates (white bars). The RT 
activities are expressed as percent wild-type activity assayed in parallel. The wild-type 
activities were ~2 x 106 cpm for poly(rA)/oligo(dT) and ~1.5 x 106 cpm for 
Ll.LtrB/E2+10. Data are the mean for at least three assays in each case, with standard 
deviations indicated by error bars. The schematic below shows the location of mutations 
in the LtrA protein, with protein regions delineated as in Figure 2.9. 
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Figure 2.11 RNA splicing assays for wild-type and mutant LtrA proteins.  
For presentation, the mutants are divided into three groups: (a) N terminus RT domain; 
(b) RT domain; and (c) domain X. Splicing time-courses were carried out with 20 nM or 
200 nM LtrA proteins and 20 nM 32P-labeled Ll.LtrB RNA (1:1 and 10:1 molar ratio, 
respectively) at 30°C, and products were analyzed in a denaturing 4% polyacrylamide 
gel. Data from splicing time-courses were best fit to an equation with two exponentials to 
obtain kobs for the fast and slow phases (k1 and k2, respectively). The biphasic kinetics and 
residual unreactive RNA under protein excess conditions are attributed to more slowly 
folding and unreactive RNA conformers (Saldanha et al., 1998). The numbers in 
parentheses indicate the proportion of input RNA that spliced in the fast and slow phases 




Figure 2.12 RNA binding assays.  
(a)-(c) Equilibrium binding assays. Mutants are divided into three groups as in Figure 11. 
Equilibrium binding was carried out by incubating 32P-labeled Ll.LtrB RNA (5 pM) with 
increasing concentrations of wild-type or mutant LtrA proteins for 1 h at 30oC, and then 
counting radioactivity in RNP complexes retained on nitrocellulose filters. Each binding 
assay was repeated at least three times with similar results. In panel (c), binding of a 32P-
labeled group I (GI) intron RNA (the Tetrahymena thermophila large subunit rRNA-
∆P5abc intron; Mohr et al., 1994) was tested as a control for binding specificity. For 
∆N10 and ∆20, similar weak binding was observed with incubation times ranging from 5 
min to 1 h. (d) koff determinations. koff was measured by forming complex between 20 nM 
32P-labeled Ll.LtrB RNA and 20 nM LtrA protein, then diluting 20-fold into reaction 
medium containing an 100-fold excess of unlabeled Ll.LtrB RNA and monitoring 
dissociation of the complex as a function of time by nitrocellulose filter binding. The data 
for WT, R98A, L100A, DK, and YAAA were best fit to equations with two exponentials, 
with the koff values given in the Figure being those for the slowly dissociating stable 
complex. The data for EYSC best fit an equation with a single exponential. The smaller 







Chapter 3 Identification of potential binding sites for DIVa and 
conserved catalytic core regions in a group II intron-encoded reverse 
transcriptase 
Mobile group II introns encode proteins that have reverse transcriptase (RT) and 
RNA splicing (“maturse”) activities (Lambowitz et al., 1999; Belfort et al., 2002; 
Lambowitz & Zimmerly, 2004; Pyle & Lambowitz, 2005). The intron-encoded protein 
(IEP) promotes splicing by binding specifically to the intron RNA, helps fold and 
stabilizes the catalytically active RNA structure (Matsuura et al., 2001). It then remains 
bound to the excised intron RNA in RNPs that promote mobility. Mobility occurs by a 
remarkable mechanism in which the excised intron RNA reverse splices directly into one 
strand of a DNA target site, and the IEP synthesizes a cDNA copy of the inserted intron 
RNA (Lambowitz & Zimmerly, 2004).  
The best-characterized mobile group II introns are the yeast mtDNA aI1 and aI2 
introns and the L. lactis Ll.LtrB intron. The proteins encoded by these introns have four 
conserved domains, denoted RT, X, DNA-binding (D), and DNA-endonuclease (En). The 
RT domain contains conserved sequence motifs RT-1 to RT-7 found in the fingers and 
palm domains of HIV-1 RT, but like other non-LTR-retroelement RTs has a series of 
insertions relative to HIV-1 RT (Xiong & Eickbush, 1990; Zimmerly et al., 2001). These 
include an extended N-terminal region, containing conserved motif RT-0, and internal 
insertions, denoted RT-2a, -3a, -4a, -7a, and ti. Domain X is a site of mutations that affect 
RNA splicing activity and corresponds at least in part to the RT thumb. Both the RT and 
X (thumb) domains are involved in interactions with the intron RNA (Cui et al., 2004). 
Domains D and En interact with and cleave the DNA target site during intron mobility 
(San Filippo & Lambowitz, 2002).  
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Studies with the Ll.LtrB intron showed that its IEP, denoted the LtrA protein, has 
a high-affinity binding site in intron subdomain DIVa, an idiosyncratic stem-loop 
structure that contains the ribosome-binding site (RBS) and initiation codon of the LtrA 
ORF (Wank et al., 1999; Singh et al., 2002; Watanabe et al., 2004). In an in vivo assay 
using the E. coli lacZ gene as a reporter, LtrA was shown to down-regulate its own 
translation by binding to the RBS. The binding of LtrA to the RBS presumably also 
prevents further ribosome entry into the intron, which would interfere with splicing 
(Singh et al., 2002). DIVa contributes to the specificity of the intron/maturase interaction, 
but by itself is not sufficient to dictate intron specificity. Replacing DIVa of the yeast aI1 
and aI2 introns with that of the Ll.LtrB intron did not enable LtrA to splice the modified 
aI1 and aI2 introns (Watanabe & Lambowitz, unpublished data). 
In addition to binding DIVa, LtrA makes weaker but critical contacts with 
conserved catalytic core regions to stabilize the catalytically active RNA structure. RNA 
footprinting experiments identified potential secondary binding sites in DI, DII, and DVI 
(Matsuura et al., 2001), and LtrA forms stable complexes with DI as well as DIV (Wank 
et al., 1999; Rambo & Doudna, 2004). Similar findings were made for the yeast aI2 
intron, whose IEP likewise has a high-affinity binding site in DIVa, but supports 
substantial maturase-promoted splicing in the absence of DIVa (Huang et al., 2003). In 
both the yeast and lactococcal introns, deletion of DIVa almost completely abolishes 
intron mobility (D’Souza & Zhong, 2002; Huang et al., 2003). This greater effect on 
intron mobility may reflect in part that the binding of the IEP to DIVa is critical for 
positioning the RT to initiate reverse transcription of the intron RNA (Wank et al., 1999).  
I previously developed an E. coli genetic assay for maturase activity by linking 
the splicing of the Ll.LtrB-∆ORF intron (referred to in this chapter as the wild-type 
intron) to the expression of GFP, and I used this assay in conjunction with unigenic 
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evolution analysis to delineate regions of the IEP required for RNA splicing (Cui et al., 
2004). Mapping of regions that are highly conserved in splicing-competent LtrA variants 
on a three-dimensional model of LtrA, constructed by threading on HIV-1 RT crystal 
structures, suggested an RNA-binding surface that includes the extended N-terminal 
fingers domain, regions around the template-primer binding track, and the back of the 
hand (Blocker et al., 2005). Biochemical analysis of mutants showed that small deletions 
at the N-terminus of LtrA abolished high-affinity intron binding and intron-specific RT 
activity, but maintained substantial splicing activity, while a domain X mutant retained 
high-affinity binding but completely lacked splicing activity (Cui et al., 2004). These 
findings suggested a model in which N-terminal regions of the RT domain interact with 
DIVa, while domain X interacts with conserved catalytic core regions. Consistent with 
this model, plant MatK proteins, degenerate maturases suggested to function in splicing 
multiple chloroplast group II introns (Vogel et al., 1999), have divergent RT domains, 
which lack recognizable N-terminal motifs RT-1 to RT-3, but retain a well-conserved 
domain X (Mohr et al., 1993). 
In this chapter, I developed a new E. coli genetic assay to screen for LtrA mutants 
capable of promoting residual splicing of an Ll.LtrB-∆ORF intron with DIVa deleted 
(referred to as the ∆DIVa intron). These mutants must retain interactions with the 
catalytic core, but need not maintain interactions with DIVa. By using this genetic assay 
in conjunction with unigenic evolution analysis and three-dimensional modeling, I 
identified regions of LtrA that are potentially involved in binding DIVa and the catalytic 
core.  
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3.1 IDENTIFICATION OF LTRA REGIONS REQUIRED FOR RESIDUAL SPLICING OF AN 
LL.LTRB-∆DIVA INTRON 
To identify regions of LtrA that promote residual splicing in the absence of DIVa, 
I used error-prone PCR to construct a library of LtrA variants containing random 
mutations. The LtrA library was swapped for the LtrA ORF in the plasmid pELG2-
∆ORF/∆DIVa, which contains the ∆DIVa intron and flanking exons, with the 3’ exon 
linked in-frame to the 2nd codon of the GFP ORF (Fig. 3.1). The LtrA protein library was 
expressed from a position just downstream of the 3’ exon so that mutations in protein 
coding sequence did not affect the intron RNA structure. Splicing of the intron leads to 
the expression of GFP, which is otherwise aborted by multiple stop codons present in the 
intron sequence. 
The residual splicing of the ∆DIVa intron is promoted by direct binding of LtrA 
to the catalytic core, so that amino acid residues required for binding DIVa need not be 
conserved in splicing-competent variants. I constructed a library of LtrA mutants in the 
∆DIVa background. Because residual splicing in the absence of DIVa results in only low 
GFP fluorescence, I identified splicing-competent LtrA variants by a colony immunoblot 
assay, in which I used an anti-GFP antibody to monitor GFP expression in individual 
colonies (Fig. 3.2). In each case, the ability of a mutant protein to splice the ∆DIVa intron 
was confirmed by RT-PCR. I sequenced 170 splicing-competent LtrA variants that 
satisfied these criteria, and these contained 575 missense mutations and 370 silent 
mutations (summarized in Fig. 3.3). 
To identify regions of LtrA required for splicing the ∆DIVa intron, I calculated 






in which fOmis is the observed frequency of missense mutations, and fEmis is the expected 
frequency based on the mutation frequency of the library and codon degeneracy. Figure 
3.4 shows the resulting mutability plot for LtrA-promoted splicing of the ∆DIVa intron, 
with a previous mutability plot for variants that efficiently spliced the DIVa-containing 
wild-type intron shown in dashed lines for comparison. 
Two regions (B and E) at the N-terminus of the RT domain immediately stand out 
as being required for efficient splicing of the wild-type intron, but not for the residual 
splicing of the ∆DIVa intron. Region B is centered on RT-1, while region E encompasses 
insertion RT-3a. Although both regions appear to be somewhat hypermutable (M > 0) in 
the ∆DIVa plot, χ2 calculations indicate that the apparent increase in mutation frequency 
is not statistically significant (p values > 0.1). 
Statistical tests identified two additional regions, A and H, that are also 
significantly constrained in variants that splice the wild-type intron, but not in those that 
splice the ∆DIVa intron (region A, p<0.001 and >0.05 for the wild-type and ∆DIVa 
introns, respectively; region H, p<0.01 and p>0.2 for the wild-type and ∆DIVa introns, 
respectively). Region A corresponds to the extended N-terminus of the protein, while 
region H is located in domain X and includes a small thumb-domain insertion, denoted ti 
(Blocker et al., 2005). Two other subregions at the beginning and end of region F appear 
more conserved for splicing the wild-type intron than the ∆DIVa intron, but χ2 tests 
indicated that the difference is not significant (p values <0.01 for both the wild-type and 
∆DIVa introns). 
The mutability plots raise the possibility that some of the insertions in LtrA 
relative to HIV-1 RT might be involved in DIVa binding. Figure 3.5 compares mutations 
tolerated in each of these insertions for splicing the wild-type and ∆DIVa introns. 
Strikingly, insertions RT-3a and ti, contained within regions E and H, respectively, were 
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highly conserved in variants that splice the wild-type intron (p<0.01 for RT-3a and 
p<0.05 for ti), but mutable in variants that splice the ∆DIVa intron (p>0.5 for RT-3a and 
p>0.2 for ti). By contrast, the other insertions were either similarly constrained for 
splicing the wild-type and ∆DIVa introns (e.g., RT-0, p>0.2 and RT-4a, p>0.1 for both 
introns), or less constrained for splicing the wild-type than the ∆DIVa intron (RT-2a, 
p>0.1 and p<0.01, and RT-7a, p>0.2 and p<0.05 for the wild-type and ∆DIVa introns, 
respectively). 
Regions C, F, and J in the mutability plots are significantly constrained in LtrA 
proteins that function in splicing both the wild-type and ∆DIVa introns (p values < 0.01). 
These regions are either required for maintaining LtrA structure, which is essential for 
LtrA function, or for binding the catalytic core to promote the splicing of both introns.  
Finally, several regions (D, G, I, and K) are more highly constrained in variants 
that splice the ∆DIVa intron than in those that splice the wild-type intron. The greater 
constraints on these four regions for splicing the ∆DIVa intron may reflect that the effect 
of disrupting weaker interactions with the catalytic core is amplified when the high-
affinity binding site in DIVa is deleted. It is also possible that in the absence of the high-
affinity binding site in the intron, other regions of the protein are exposed to bind the 
catalytic core, or structural changes in the intron RNA upon deletion of DIVa affect 
protein binding. 
3.2 MAPPING OF CONSERVED REGIONS ON A THREE-DIMENSIONAL MODEL OF LTRA 
Figure 3.6(a) and (b) show two views of a three-dimensional model of LtrA 
constructed by threading the LtrA sequence on the X-ray crystal structure of HIV-1 RT 
heterodimers (Blocker et al., 2005). In this model, LtrA is assumed to be a dimer 
(Saldanha et al., 1999; Rambo & Doudna, 2004) with one subunit (monomer A) having a 
structure analogous to the catalytic p66 subunit of HIV-1 RT and the second subunit 
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(monomer B) modeled based on the p51 subunit. The latter is an equivocal but necessary 
assumption since HIV-1 RT is the only available RT dimer structure (Figure 3.6(a) and 
(b); Blocker et al., 2005). 
Regions A, B, E, and H, conserved for efficient splicing of the wild-type intron 
but not for residual splicing of the ∆DIVa intron in the unigenic evolution analysis 
(Figure 3.4), are potentially involved in DIVa binding. In Figure 3.6(c) and (d), these 
regions are highlighted in red in the three-dimensional model of LtrA. Strikingly, regions 
A, B, and E of monomer A lie in proximity to each other in the extended N-terminal 
fingers domain, while part of region H is on the opposed surface of the monomer A 
thumb, potentially forming a binding pocket for DIVa.  
Regions C, F, and J are required for splicing both of the wild-type and ∆DIVa 
introns and are potentially involved in binding conserved catalytic core regions and/or 
play essential roles in maintaining protein structure. These regions are colored purple in 
the model in Figure 3.6(c) and (d). Regions C and F comprise major parts of the palm, 
while region J is in the thumb, facing away from the fingers. 
The remaining regions (D, G, I, and K; colored in blue in 3.6(c) and (d)) are more 
constrained in variants that splice the ∆DIVa intron than those that splice the wild-type 
intron. Region D is in palm. Regions G and I are major components of the thumb, 
whereas region K is an extension from the thumb into the DNA-binding domain. These 
regions are also potentially involved in interactions with the intron’s catalytic core. 
3.3 ANALYSIS OF SITE-DIRECTED MUTANTS 
To identify amino acid residues potentially involved in binding DIVa, I compared 
unigenic evolution data for LtrA variants that splice the wild-type and ∆DIVa introns to 
identify charged residues, particularly in regions A, B, E, and H, that were conserved for 
efficient splicing of the wild-type intron but not for residual splicing of the ∆DIVa intron. 
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Alanine substitutions of single or multiple positions were then constructed in both the 
pELG2-∆ORF and pELG2-∆ORF/∆DIVa backgrounds to test their effect on splicing of 
the wild-type and ∆DIVa intron, respectively. A total of 17 such mutants, along with N-
terminal deletion mutants ∆N10 and ∆N20, which were analyzed biochemically in 
Chapter 2, were compared for their ability to splice the wild-type and ∆DIVa introns in 
vivo by the FACS assay and RT-PCR, respectively.  The results are summarized in Table 
3.1. ∆N10 and ∆N20 were included because the previous biochemical analysis showed 
that they abolish high-affinity binding to the intron RNA, as expected for impaired 
interaction with DIVa (chapter 2; Cui et al., 2004). 
Mutations that specifically affect the binding of DIVa are expected to reduce the 
splicing efficiency for the wild-type intron, but have little or no effect on the residual 
splicing of the ∆DIVa intron. The following eight mutants satisfied these criteria: ∆N10, 
∆N20, R137A, KKS182,185,187→A (referred to as KKS), YKF191-193→A (referred to 
as YKF), Y204A, KKD407-409→A (referred to as KKD), DLE425-427→A (referred to 
as DLE) (Figure 3.7). These eight mutants were then subjected to Western analysis to 
assess whether the splicing defects for the wild-type intron might reflect decreased 
amounts of soluble and total LtrA protein (Figure 3.8(a)-(d)).  
∆N10, ∆N20, and a triple mutant YKF gave no detectable splicing of the wild-
type intron as judged by GFP expression in the FACS assay (Figure 3.7(a)) but were 
indistinguishable from the wild-type protein in their ability to splice the ∆DIVa intron, as 
judged by RT-PCR (Figure 3.7(b)). All three mutants gave less soluble protein than wild 
type in both the pELG2-∆ORF and pELG2-∆ORF/∆DIVa backgrounds. The expression 
levels of ∆N20 and YKF were lowest among all the mutants, about 5-10% of wild type, 
whereas ∆N10 was about 20-25% of wild type (Figure 3.8). In the structural model, N10 
and N20 are at the N-terminus, presumably structurally flexible. YKF in monomer A is 
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located within insertion 3a on the surface of the fingers region and may directly affect the 
interaction with DIVa. Interestingly, in monomer B, YKF is mostly at the dimer surface 
with a small part on the surface of the bottom of the predicted binding pocket. 
Two point mutations, R137A, and Y204A, decreased the splicing efficiency of the 
wild-type intron by 70-80% in the FACS assay (Figure 3.7(a)) but spliced the ∆DIVa 
intron at almost wild-type efficiency in the RT-PCR assay (Figure 3.7(b)). Both mutants 
gave high levels of soluble protein in the pELG2-∆ORF background, but about half of the 
wild-type level in pELG2-∆ORF/∆DIVa, even though the splicing efficiency with the 
∆DIVa intron was similar to that of the wild-type protein (Figure 3.8). In the structural 
model, R137 in monomer A is located within insertion 2a on the surface of the palm 
directly below the putative binding pocket for DIVa and is a surface residue in monomer 
B. Y204, which is located within RT-4 just downstream of insertion 3a, is on the surface 
of the fingers in monomer A and partially buried at the dimer interface in monomer B 
(Figure 3.5(e) and (f)). Thus both mutations could affect the interaction with DIVa 
directly. 
The remaining mutants that showed the desired phenotypes, KKS, KKD, and 
DLE, inhibited splicing of the wild-type intron by 60-80% in the FACS assay (Figure 
3.7(a)), but had no detectable effect on ∆DIVa splicing activity in the RT-PCR assay 
(Figure 3.7(b)). KKS gave wild-type level of soluble protein in the pELG2-∆ORF 
background but only about half of the wild-type level in pELG2-∆ORF/∆DIVa, while 
KKD and DLE gave wild-type level of soluble proteins in both backgrounds (Figure 3.8). 
KKS is located within insertion 3a and on the surface of monomer A in the structural 
model. However, all three of the residues are at the dimer surface in monomer B. KKD 
and DLE had 30-40% wild-type splicing in the FACS assay. KKD is in insertion ti, and 
DLE is located immediately down stream of the insertion. In monomer A of the model, 
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these residues are on the surface of the thumb, facing away from the prospective DIVa 
binding pocket. It is possible that the orientation of ti is incorrect in the model, or that 
these mutations affect binding of DIVa indirectly by affecting the structure of ti. In 
monomer B, residues in both KKD and DLE are also on the protein surface. 
It is worth noting that several mutants (YKF, KKS, Y204A) involve residues that 
are at the dimer interface in at least one monomer in the structural model, raising the 
possibility that, in addition to directly interact with DIVa, these positions could indirectly 
influence the LtrA/intron interaction by affecting dimerization of LtrA. 
 All six of the mutants identified above are excellent candidates for biochemical 
analysis to directly assess their effect on DIVa binding. 
3.4 DISCUSSION 
In this chapter, I screened an LtrA library for functional variants that spliced the 
Ll.LtrB intron in the absence of the high-affinity protein-binding site, DIVa. One hundred 
seventy mutants that remained active for splicing the ∆DIVa intron contained 575 
missense and 370 silent mutations. I used unigenic evolution analysis to identify regions 
conserved in LtrA variants that splice the ∆DIVa intron. A superimposition of these data 
with those for variants that splice the wild-type intron reveals three categories of regions: 
regions required for efficient splicing of the wild-type intron but not for residual splicing 
of the ∆DIVa intron; regions required for splicing both the wild-type and ∆DIVa introns; 
and regions that are more conserved in variants that splice the ∆DIVa intron than those 
that splice the wild-type intron (Figure 3.4).  
3.4.1 Three categories of regions 
Potential DIVa-binding regions are those conserved for the efficient splicing of 
the wild-type intron splicing but not for residual splicing of the ∆DIVa intron. Four such 
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regions were identified in the unigenic evolution analysis: regions A, B, and E in the RT 
domain and H in domain X. In Figure 3.5(c) and (d), these regions are shown in red in a 
structural model of LtrA based on an X-ray crystal structure of HIV-1 RT dimer. In the 
model, regions A, B, and E of monomer A are located next to each other in the extended 
fingers domain, while region H is located in the thumb domain partially facing the 
fingers, forming a potential binding pocket for DIVa. Figure 3.5(c) and (d) also displays 
the positions of insertions 3a and ti, which are located in regions E and H, respectively. 
These two insertions are frequent sites of mutations that gave the expected phenotype of 
inhibiting efficient splicing of the wild-type intron while preserving residual splicing of 
the ∆DIVa intron (see next section). 
Regions C, F, and J (colored in purple in Figure 3.5 (c) and (d)) were required for 
splicing both the wild-type and ∆DIVa introns. These regions span most of the palm 
domain, with a small extension to the base of the thumb (region J). They may bind the 
intron catalytic core and/or be required to maintain the core structure of the protein.  
Finally, four other regions (D, G, I, and K, colored in blue in Figure 3.5 (c) and 
(d)) were conserved only for splicing the ∆DIVa intron but not for efficient splicing of 
the wild-type intron. The greater constraints on these four regions for splicing of the 
∆DIVa intron may indicate that some weaker interactions with the catalytic core region 
of the RNA assume greater importance when DIVa is deleted. It is also possible that in 
the absence of DIVa, additional regions on the proteins surface are exposed to bind the 
catalytic core, or that RNA structural changes resulting from deletion of DIVa affect 
protein binding. 
3.4.2 Point mutations analyzed for identifying direct DIVa binding 
To support the involvement of regions A, B, E, and H in DIVa binding, it is 
important to identify residues in these regions that directly interact with DIVa.  Based on 
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the unigenic evolution analysis, I chose a series of positions mainly from the above 
regions for site-directed mutagenesis. Seventeen alanine-substitution mutants were 
constructed containing one to three clustered mutations per protein. All the mutants were 
first tested for their ability to splice the wild-type intron in pELG2-∆ORF in the FACS 
assay, and those that showed decreased splicing of the wild-type intron were then tested 
for their ability to promote residual splicing of the ∆DIVa intron in pELG2-∆ORF/∆DIVa 
by RT-PCR. Western analysis was carried out to assess whether impaired splicing of the 
wild-type intron might reflect decreased levels of soluble protein. Eight mutants, 
including ∆N10 and ∆N20, which were analyzed biochemically in chapter 2, showed the 
expected in vivo splicing phenotypes indicating their possible involvement in interaction 
with DIVa (see Table 3.1). 
The biochemical analysis of the ∆N10 and ∆N20 in chapter 2 showed that both 
mutants have dramatically decreased binding affinity for the wild-type intron, as expected 
for mutations that impair the binding of DIVa, but remain capable of splicing the wild-
type intron efficiently at the high protein and RNA concentrations used in in vitro assays 
(Cui et al., 2004). In vivo, both mutants gave greatly decreased splicing of the wild-type 
intron in the FACS assay (Figure 3.7(a)), while retaining the ability to promote splicing 
of the ∆DIVa intron in the RT-PCR assay (Figure 3.7(b)). The greatly decreased splicing 
efficiency for the wild-type intron in vivo presumably reflects that the concentrations of 
both intron and protein are much lower than those in in vitro assays, amplifying the 
importance of high-affinity binding to DIVa. The Western analysis revealed that both the 
∆N10 and ∆N20 mutants had reduced amounts of soluble protein in either the pELG2-
∆ORF or pELG2-∆ORF/∆DIVa backgrounds. In chapter 2, I demonstrated that the LtrA 
protein tends to be unstable in vivo when it cannot stably bind to the intron RNA (Cui et 
al., 2004). Thus, the relatively low level of ∆N10 and ∆N20 expression may result at least 
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in part from the weaker binding of these mutant proteins to the intron RNA. The 
structural effects of the N-terminal deletions could also decrease protein stability.  
All six alanine substitution mutants (R137A, KKS, YKF, Y204A, KKD, and 
DLE) involve surface residues in monomer A in the LtrA structural model, surrounding 
the putative DIVa binding pocket. Potentially, all these positions could interact directly to 
DIVa. Except for R137, all the mutated residues are located in either insertion 3a or ti, 
suggesting that these insertions may play a critical role in DIVa binding. R137 is in 
insertion 2a, located at the bottom of the pocket.  
In addition, in monomer B, several mutants (KKS, YKF, and Y204A) are at the 
dimer surface in the structural model, indicating a possible requirement of dimerization 
for DIVa binding but not for binding the catalytic core. It is also possible that these 
mutations affect the structure of another region of the protein involved in binding DIVa. 
Rambo & Doudna (2004) reported that the wild-type intron, DIVa, and DI, all bound the 
LtrA protein with a stoichiometric RNA:protein ratio of 1:2, and only upon binding of 
one of the above RNAs did the protein form a stable dimer. However, their results do not 
indicate whether dimerization is necessary for binding the cognate RNA species.  
In summary, the unigenic evolution analysis and site-directed mutations combined 
with three-dimensional structural modeling support the hypothesis that the extended N-
terminal finger region of LtrA is involved in high-affinity binding of DIVa, possibly 
forming a DIVa-binding pocket in combination with parts of the thumb domain, 
including insertion ti. Other regions of the RT and thumb (X domains) are potentially 
involved in binding the intron’s conserved catalytic core regions to promote formation of 
the active RNA structure. 
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3.5 SUMMARY 
Mobile group II introns encode RTs that bind specifically to the intron RNA to 
stabilize the catalytically active RNA structure for RNA splicing and reverse splicing. 
Previous studies with the L. lactis Ll.LtrB intron suggested a model in which the intron-
encoded protein, LtrA, binds first to a high-affinity binding site in DIVa, an idiosyncratic 
stem-loop structure at the beginning of the LtrA ORF, and then makes weaker but critical 
secondary contacts with the conserved catalytic core region. In the absence of DIVa, 
group II intron-encoded proteins can promote varying degrees of residual splicing by 
binding directly to the catalytic core. Here, we used an E. coli genetic assay that permits 
the rapid screening of LtrA mutant libraries in conjunction with unigenic evolution 
analysis to identify LtrA regions potentially required for interaction with different regions 
of the intron RNA. Regions required for efficient splicing of the wild-type intron, but not 
for residual splicing of a ∆DIVa intron, are potentially involved in DIVa binding and 
include the N-terminus, RT-1, RT-3a and a small insertion (ti) in the thumb/domain X 
region. In a three-dimensional model of LtrA, these regions comprise a potential RNA-
binding pocket that includes the extended N-terminal fingers domain and an opposed 
surface of the thumb. Regions required for splicing both the wild-type and ∆DIVa introns 
potentially interact with critical catalytic core regions and include an extended binding 
surface on the thumb and palm. Four regions, which include thumb and some surface 
residues on fingers, are more constrained in variants that splice the ∆DIVa intron but not 
the wild-type intron, potentially reflecting greater dependence on other catalytic core 
contacts when binding to DIVa is impaired. Analysis of site-directed mutants supports 
the hypothesis that the entended N-terminal fingers region and possibly part of the thumb 




Figure 3.1. E. coli genetic assay of LtrA-promoted splicing of the ∆DIVa intron.  
(a) Map of plasmid pELG2-∆ORF/∆DIVa. The plasmid contains an ltrB/GFP fusion 
cloned downstream of a T7lac promoter (arrow) and φ10 Shine-Dalgarno sequence (SD). 
The ltrB/GFP fusion is comprised of the first eight codons of the φ10 gene fused to a 5’-
exon segment (E1) of the L. lactis ltrB gene, the Ll.LtrB-∆ORF/∆DIVa intron (open 
rectangle), and a 3’-exon segment (E2), with E2 linked in-frame to the second codon of 
GFP (hatched). The LtrA ORF is cloned downstream of the GFP coding sequence. T1 
and T2 are E. coli rrnB transcription terminators. (b) Schematic showing splicing of the 
∆DIVa intron linked to the expression of GFP. Splicing leads to the expression of GFP 
with a short N-terminal extension (42 amino acid residues) corresponding to the φ10 
sequence and ligated exons. In the absence of splicing, translation is terminated by stop 










Figure 3.2 Colony-based immunoblot assay for GFP expression.  
(a) Flow chart of the assay. Colonies growing on plates containing LB medium plus 
ampicillin were duplicated onto nitrocellulose filters and then incubated on an absorbent 
pad saturated with LB medium containing ampicillin and IPTG for 4 h at 37°C to induce 
plasmid expression. The colonies were then lysed and subjected to immunoblot analysis, 
as described in Materials and Methods. (b) Scanned filters. E. coli cells transformed with 
pELG2-∆ORF/∆DIVa and with pELG1-∆ORF/∆DIVa (splicing competent and splicing 
defective, respectively) were mixed at a ratio of 1:10, then plated on LB medium plus 
ampicillin and subjected to colony based immunoblot assay as described in (a). The top 
shows an optical scan of the filter before treatment, and the bottom shows a 
chemiluminescence exposure of the filter after immunoblotting. Splicing-competent 
colonies producing GFP appear black against a light background. 
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Figure 3.3 Summary of mutations in the 170 LtrA variants that could promote splicing of 
the ∆DIVa intron.  
A library of random LtrA mutants was constructed in pELG2-∆ORF/∆DIVa background 
and screened by using the colony immunoblot assay to identify splicing-competent 
variants. Positive colonies were confirmed to have splicing activity by RT-PCR and 
sequenced. Amino acid substitutions are listed below the wild-type sequence, with the 
frequency of occurrence indicated as following: plain, 1X; bold, 2X; and underlined, ≥ 
3X. Numbers represent occurrence of silent mutations. Conserved regions RT-0 to RT-7, 
insertions RT-2a, -3a, -4a, and -7a, and domains X, D, and En are delineated above the 





Figure 3.4 Mutability plot based on unigenic evolution analysis of LtrA variants that 
splice the ∆DIVa intron.  
The mutability value (M) was calculated for a 25 amino acid residue-sliding window, as 
described in Materials and Methods, and mutability values were plotted against the amino 
acid at the center of the window. Negative values indicate hypomutability, with a 
maximum value of -1 indicating no missense mutations, and positive values indicate 
hypermutability. A region is considered significantly hypomutable if it has a p-value 
<0.05. A previous plot for LtrA variants that efficiently splice the wild-type intron is 
shown in dashed lines for comparison. The locations of conserved sequence motifs RT0-
7 and LtrA domain boundaries are shown on the x-axis.  Insertions RT-3a and ti are 










Figure 3.5 Comparison of mutations in insertion regions in LtrA variants that splice the 
wild-type and ∆DIVa introns.   
As in Figure 3.3, amino acid substitutions are listed below the wild-type sequence, with 
the frequency of occurrence indicated as following: plain, 1X; bold, 2X; and underlined, 
≥ 3X, and numbers represent the occurrence of silent mutations.  
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Figure 3.6 Three-dimensional model of LtrA.  
(a) and (b) are two views of the 3-D model of LtrA with monomer A in white and 
monomer B in cyan. Regions of interest are labeled as in Blocker et al. (2005). (c) and (d) 
are two views of LtrA with colored regions to differentiate conservation in LtrA variants 
that promote splicing of the wild-type and ∆DIVa introns. Red regions are conserved for 
efficient splicing of the wild-type intron, but not for splicing of the ∆DIVa intron. Blue 
regions are more conserved for splicing the ∆DIVa intron than the wild-type intron. 
Purple regions are conserved for splicing both the wild-type and ∆DIVa introns. 
Approximate positions of regions A-K from Figure 3.4 are labeled. Insertions RT-3a and 
ti are also labeled. (e) and (f) are two views of LtrA with monomer A in white and 
monomer B in cyan. Surface residues are in orange, and residues at the dimer interface 
















Table 3.1 Site-directed mutants of LtrA. 











∆N10 A N-ter - ++++ ++ ++ 
∆N20 A N-ter - ++++ + + 
*D56A B RT0 ++++ nt nt nt 
*S63A B RT0 ++++ nt nt nt 
KD75,76→A B RT1 ++++ nt nt nt 
*R85A B RT1 ++++ nt nt nt 
*R137A C RT2a + ++++ ++++ +++ 
*K182A E RT3a ++++ nt  nt nt 
*K185A E RT3a ++++ nt  nt nt 
*S187A E RT3a ++++ nt  nt nt 
*KKS E RT3a + ++++ ++ ++ 
*K192A E RT3a ++++ nt nt nt 
*YKF E RT3a - +++ + + 
*E200A E RT3a +++ ++++ nt nt 
*Y204A E RT4 + ++++ +++ +++ 
KK407,408→A H ti ++++ nt nt nt 
KKD  H ti ++ ++++ ++++ ++++ 
*R422A H ti +++ nt nt nt 
DLE H ti ++ ++++ +++ ++++ 
aRegions are defined by unigenic evolution analysis as in Figure 3.4. bWT refers to the 
wild-type intron, and ∆DIVa refers to the ∆DIVa intron. cSplicing activity and protein 
expression levels were expressed by ++++, wild-type level; +++, ≥ 50% wild-type level; 
++, ≥ 30% wild-type level; +, detectable; and -, undistinguishable from untransformed 
cells; nt, not tested. dKKS: mutant KKS182,185,187→A; YKF: mutant YKF191-
193→A; KKD: KKD407-409→A; DLE: mutant DLE425-427→A. Mutants with the 
phenotype expected for inhibition of DIVa binding are shaded in grey. Constructs made 
by Ms. Qin Wang are with an asterisk.  
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Figure 3.7 FACS and RT-PCR analysis of in vivo splicing with LtrA variants that are 
unable to efficiently splice the wild-type intron, but can promote residual 
splicing of the ∆DIVa intron.  
(a) FACS assay of in vivo splicing of the wild-type intron. (b) RT-PCR for in vivo 
splicing of the ∆DIVa intron.  
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Figure 3.8 Immunoblot analysis of LtrA proteins expressed from pELG2-∆ORF and 
pELG2-∆ORF/∆DIVa.  
(a) and (b) Total and soluble protein fractions from cells expressing the indicated LtrA 
proteins from pELG2-∆ORF. (c) and (d) Total and soluble protein fractions from cells 
expressing the indicated LtrA proteins from pELG2-∆ORF/∆DIVa. Samples were loaded 
based on O.D.595 measurement of cell density. Each transferred membrane was stained 
with AuroDye after blotting to confirm even loading. Proteins were separated in an 8% 
polyacrylamide/1% SDS gel, blotted to a nitrocellulose membrane, and probed with 
polyclonal anti-LtrA antibody (from Gary Dunny, U. Minnesota). Smaller bands in (a) 
and (c) are likely degradation products of LtrA. In (b) and (d), one larger band and one 
smaller band result from non-specific binding by the antibody, as they are also present in 
∆ORF lanes, which have no LtrA expresson. 
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Chapter 4: Expression of the Ll.LtrB intron RNA and IEP in 
mammalian cells  
The mobile group II intron Ll.LtrB now works extremely well for gene targeting 
in bacteria. Target site recognition requires base-pairing between the EBS and δ 
sequences of the intron RNA with the target DNA sequences, as well as interactions 
between the IEP (LtrA) and DNA sequences flanking the base-paired region (Guo et al., 
2000; Mohr et al., 2000). Guo et al. (2000) developed a genetic method to select modified 
introns that insert into essentially any plasmid-borne target gene from a combinatorial 
group II intron library.  Karberg et al. (2001) demonstrated that bacterial chromosomes 
could be targeted by the Ll.LtrB intron, and Zhong et al. (2003) developed highly 
efficient methods for selecting integration events by incorporating selectable markers into 
DIV of the intron, which is also valuable to make genome-wide knockouts. 
The intron RNA inserts into a target site in either the same or the opposite 
direction relative to that of target gene transcription. When it inserts into a coding 
sequence in the sense-strand orientation, the intron will be transcribed and could 
potentially be spliced out from the precursor RNA if and only if the IEP is supplied, 
resulting in a conditional disruption. Frazier et al. (2003) used a modified Ll.LtrB intron 
to deliver a phage-resistance gene (abiD) and an antibiotic-resistance gene (tetM) 
separately into the sense strand of the chromosomal mleS gene in Lactococcus lactis, and 
showed that it was possible to control the expression of mleS gene by regulating the 
expression of the LtrA protein. Generally, the use of group II introns to obtain conditional 
disruptions is limited by whether or not the sequences flanking the intron-insertion sites 
can support efficient splicing (Karberg et al., 2001). 
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Group II introns are minimally dependent on host-specific factors for mobility, 
and derivatives of the Ll.LtrB intron have been shown to work efficiently for gene 
targeting in a variety of Gram-negative and Gram-positive bacteria, including E. coli, L. 
lactis, Salmonella typhimurium, Shigella flexneri, and Staphylococcus aureus (Karberg et 
al., 2001; Zhong et al., 2003; Fraizer et al., 2003; and Zhong, Novick, & Lambowitz, 
unpublished). The general strategy to obtain retargeted group II introns (introns 
specifically targeting genes other than the wild-type target site) is to identify the best IEP-
recognition sequences and then modify the intron EBS1, EBS2, and δ sequences to base 
pair with the IBS1, IBS2, and δ’ sequences in the DNA target site (Guo et al., 2000; 
Figure 1.1).  Retargeted Ll.LtrB introns are now routinely designed by using a computer 
algorithm based on databases of efficiently targeted introns and their target sites (Perutka 
et al., 2004). This algorithm predicts multiple, rank-ordered target sites in virtually any 
gene and designes primer sequences for modifying the intron to insert efficiently into 
those sites. 
The ability to use the Ll.LtrB intron for efficient gene targeting is due largely to 
the development of an efficient E. coli expression system for this intron, which enabled 
extensive genetic and biochemical studies that characterized protein/RNA interaction, 
splicing, and targeting rules.  It is now of great interest to extend these methods to 
manipulate the more complex genomes and gene expression of higher organisms.  
Methods currently available for these purposes in higher organisms include homologous 
recombination (Thomas & Capecchi, 1987), antisense RNA (Green et al., 1986), and 
RNA interference (Fire et al., 1998). Homologous recombination has been widely used 
for generating gene knockouts. However, it is labor intensive and inefficient. Both 
antisense and siRNAs produce “knockdowns”, instead of “knockouts”, and are unstable, 
likely generating only transient effects. Once the input RNA molecules are degraded, the 
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expression of down-regulated genes may recover. Or plasmids expressing siRNAs could 
be integrated into the genome for lasting effects, however, carrying the risks resulting 
from random integrations. Group II introns insert in a highly site-specific manner into 
genes and disrupt them permanently or conditionally, controllable by the IEP expression 
(Karberg et al., 2001; Fraizer et al., 2003). Group II introns can also be used to generate 
site-specific double-strand breaks (DSB), which stimulate homologous recombination, 
enabling the introduction of smaller modifications, such as point mutations (Karberg et 
al., 2001). Homing endonucleases also cleave DNA sequence-specifically and generate 
DSBs. However, unlike group II introns, changing the specificity of homing 
endonucleases requires protein engineering of the enzymes (Epinat et al., 2003). In 
addition, group II introns are functional as vectors to deliver a desired gene to a specific 
location (Fraizer et al., 2003). If group II introns could be made to work efficiently in 
higher organisms, their impact on functional genomics and gene therapy would be 
profound.  
Guo et al. (2000) designed and selected group II introns that inserted efficiently 
into the HIV-1 provirus DNA and the human gene encoding the HIV-1 co-receptor CCR5 
in bacterial plasmid assays and showed that purified RNPs, when introduced via 
liposome-mediated transfection, retain some activity in human cells for insertion into a 
plasmid target site. However, the activity was very low, requiring nested PCR for 
detection. In part, this low efficiency reflects inefficient introduction of RNPs by the 
transfection procedure. In this chapter, I describe the development of a system to express 
the Ll.LtrB intron RNA and IEP, LtrA, in cultured mammalian cells.  The advantages of 
this approach are that DNA constructs for expressing the intron RNA and IEP can be 
easily and efficiently transfected into mammalian cells and potentially produce a 
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continuous supply of RNP particles for a few days, which can be especially critical if 
targeting can only occur during certain cell cycle or growth phases. 
To express the LtrA protein in mammalian cells, I found it necessary to optimize 
codon usage of the LtrA ORF to that preferred in human cells.  Here, I show that the LtrA 
protein expressed in this manner is abundant and active in mammalian cells, as judged by 
detection of Ll.LtrB intron-specific RT activity in nuclear lysate and by IEP-dependent 
splicing of the Ll.LtrB intron in vivo. Further, when a nuclear localization signal is fused 
to its C-terminus, the LtrA protein is correctly localized to the nucleus, as required for 
chromosomal targeting.  I also established stable cell lines that express active LtrA 
protein. The Ll.LtrB intron RNA could be expressed using a Pol I, Pol II, or Pol III 
promoter. However, intron RNA transcribed from a Pol I promoter spliced most 
efficiently in the presence of expressed LtrA protein in vivo Interestingly, when cells 
were provided with high concentrations of Mg2+ in the medium, the intron RNA could 
splice to some extent in the absence of the LtrA protein. Finally, I describe initial 
attempts to use the expression system for gene targeting. 
4.1 EXPRESSION OF THE LL.LTRB IEP, LTRA IN TISSUE CULTURE 
To express the LtrA protein in mammalian cells, I first cloned the LtrA ORF 
downstream of a human cytomegalovirus (CMV) immediate early promoter in the 
plasmid pCMV/myc/nuc (Invitrogen) to generate pCMV-LtrA (Figure 4.1(a); see also 
Materials and methods). In this construct, three tandem nuclear localization sequences 
(NLS) from simian virus 40 (SV40) and a c-myc epitope were fused to the C-terminus of 
the LtrA ORF. The CMV promoter is a constitutive promoter recognized by RNA 
polymerase II and leads to high-level expression of its downstream sequences (Spaete & 
Mocarski, 1985). Detecting no protein expression by using Western analysis with either 
an anti-LtrA antibody (Gary Dunny, U. of Minnesota; not shown) or an anti-myc 
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antibody (Invitrogen), I tried to improve LtrA expression by inserting a 133-bp 
intervening sequence (IVS, from vector pIRES, Clontech) immediately following the 
CMV promoter (pCMV-IVS, figure 4.1(b)), resulting in pCMV-IVS-LtrA (Figure 
4.1(c)). The IVS encodes a nuclear intron that is efficiently spliced following 
transcription, which could increase protein production (Le Hir et al., 2003). Again, when 
transfected with pCMV-IVS-LtrA, no LtrA expression was detected in HEK 293, HeLa, 
or COS-7 cells by using Western analysis (Figure 4.4, lane 3 and not shown). 
4.1.1 Codon optimization of the LtrA ORF 
I noticed that most codons of the LtrA ORF are highly unfavorable for 
mammalian cells, and suspected that this might contribute to its inefficient translation.  
Therefore, I modified the LtrA coding sequence by changing every codon to the most 
favored one in higher eukaryotes (Figure 4.2) based on reported codon usages (Haas et 
al., 1996).  The most common way of synthesizing a gene is to use overlapping primers 
as templates, amplify the entire sequence in several rounds of PCR, and then clone the 
sequence into an expression vector.  A major problem with this strategy is that the longer 
the sequence being synthesized, the greater the chance for introducing mutations in each 
clone, during both primer synthesis and PCR.  Fixing the mutations is time-consuming 
and costly.  To avoid this problem, I divided the codon-optimized LtrA sequence, which 
included an SV40 nuclear localization signal (NLS) fused at the C-terminus, into six 
segments of about 300-bp in length, each of which was flanked by two restriction sites 
unique to the segment.  Oligonucleotides of 98- to 120-base long were synthesized and 
used as overlapping templates, and short primers of 30-45 bases with common restriction 
sites (HindIII and XbaI) at their 5’ ends were used to amplify each fragment by PCR 
(Figure 4.3, also see section 6.2).  The PCR product of each fragment was then cloned 
into the pBluescriptKS vector individually for sequencing, except for those of the last two 
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segments at the C-terminus, which were PCR amplified into one piece, then cloned and 
sequenced.  The complete LtrA sequence was obtained by ligating all the mutation-free 
segments after restriction enzyme digestions (see Figure 4.3, bottom panel).  On average, 
only one out of five subclones sequenced was free of mutations.  Thus, the chance of 
having an intact clone of the full-length ORF would be around one in 56, which is 
1.5x104, if the traditional strategy were used.  On the contrary, I only needed to sequence 
about 40 subclones to obtain the correct codon-optimized LtrA clone, designated as pKS-
hLtrA (Figure 4.1(d)), where hLtrA stands for the humanized LtrA gene. 
4.1.2 Codon-optimized LtrA was abundantly expressed in human cells 
The expression vector phLtrA was constructed by cloning the hLtrA ORF into the 
vector pIRES (Clontech; Figure 4.1(e)). The hLtrA gene is preceded by the immediate 
early CMV promoter and an IVS, as described above, and followed by a C-terminal 
fusion of the SV40 nuclear localization signal (NLS) and the SV40 poly A signal (pA).  
When transfected into HEK 293 cells, hLtrA was expressed well as shown in Western 
analysis in Figure 4.4a, lane 5, compared to no LtrA expression in untransfected cells 
(lane 2), cells transfected with vector pCMV-IVS (lane 3), or with pCMV-IVS-LtrA, 
encoding the non-codon-optimized LtrA ORF (lane 4). I also successfully obtained HEK 
293 stable cell lines expressing hLtrA by selecting for neomycin-resistance clones after 
electroporating the cells with BamHI-linearized phLtrA DNA (Figure 4.1(e)). However, 
the expression level in stable cell lines was always lower than that in transiently 
transfected cells (Figure 4.4(a), lanes 6 and 7). phLtrA and pCMV-IVS-LtrA have 
different vector backbones: pIRES and pCMV-IVS, respectively. In order to exclude any 
possible effects of vector backbone on protein expression, I replaced the hLtrA ORF with 
the non-optimized bacterial LtrA ORF in phLtrA to generate pLtrA (Figure 4.1(f)). pLtrA 
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did not give a detectable amount of LtrA protein (Figure 4.4(b), lane 2), just like pCMV-
IVS-LtrA.  
In Western analysis, a high-molecular weight band (>200 kDa) was present in 
variable amounts in some phLtrA samples (Figure 4.4(a), lane 5, about 1/3 of the amount 
of hLtrA and Figure 4.4(b), lane 4, less than 1/4 of the amount of hLtrA). When 
preparing the samples in Figure 4.4(b), I noticed that after being boiled in SDS-
containing gel-loading buffer, each sample still had insoluble materials, which were 
pelleted with a two-minute centrifugation. The supernatant was loaded to lane 4, while 
the pellets were then dissolved in more loading buffer, boiled, and loaded in lane 5. Lane 
5 does not show the large band, suggesting that it might be aggregated hLtrA protein, 
which is not dissociated when the amount of SDS in the loading buffer is limiting. 
Consistent with this hypothesis, the larger band was absent in phLtrA stable cell lines, 
where the hLtrA expression level was much lower (Figure 4.4(a), lanes 6 and 7).  
4.1.3 Localization of hLtrA  
To be able to target chromosomal DNA, intron RNPs must enter the nucleus. 
Thus, in the expression system, it is essential that the hLtrA protein is localized to the 
nucleus after translation. Using immunofluorescence, I found that LtrA expressed from 
transiently transfected phLtrA was localized to the nucleus in HEK 293 cells (Figure 
4.5(a)) and COS-7 cells (Figure 4.5(b)). The LtrA protein expressed in the phLtrA stable 
cell lines was also localized to the nucleus (Figure 4.5(c)). By contrast, when COS-7 cells 
were transfected with construct phLtrA∆NLS (Figures 4.1(g)), LtrA was localized in the 
cytoplasm (Figure 4.5(d)), indicating that an NLS is necessary to direct the hLtrA protein 
to the nucleus. Interestingly, in transfected COS-7 cells, hLtrA expressed from phLtrA 
was localized to the nucleus but seemed to avoid nucleolar regions (Figure 4.5(e)), 
whereas in HEK 293 cells, the nuclear localization of hLtrA seemed uniform.   
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The intriguing non-nucleolar localization of hLtrA in COS-7 cells could also be 
an indication of protein aggregation, as suggested by Western analysis (last section). A 
difference between COS-7 cells and HEK293 cells is that the former constitutively 
expresses the SV40 T–antigen and supports replication of plasmids carrying the SV40 
replication origin embedded in the SV40 promoter, as is the case for phLtrA. Because of 
phLtrA replication, more hLtrA protein was produced in COS-7 cells than in HEK 293 
cells, indicated by stronger singnals in both immunofluorescence and Western analysis in 
COS-7 cells (not shown), and consequently more hLtrA aggregation occurred in COS-7 
cells. It is possible that the aggregation occurs after the hLtrA protein enters the nucleus. 
The high density of nucleolar regions (Olson, 2004) may prevent large aggregates from 
spreading into those areas. Taken together, the localization and Western analysis data 
raise the possibility that hLtrA aggregation might occur in the cells under high expression 
conditions, which could potentially affect the intracellular localization and function in 
splicing and targeting.  
Consistent with the aggregation hypothesis, our collaborator, Huatao Guo, 
observed that without an NLS, the LtrA protein expressed from a construct containing a 
similarly codon-optimized LtrA ORF under the CMV promoter was localized to the 
nucleus shortly after transfection, likely before enough protein is made to aggregate, and 
most hLtrA was cytoplasmic 48 h after transfection. In addition, in order to observe 
nuclear localization, it was necessary to transfect only minimal amount of DNA (personal 
communication). A possible explanation is that LtrA is highly basic, and the positive 
charges on the hLtrA protein surface may have functioned as nuclear localization signals 
until the hLtrA protein starts to aggregate in the cytoplasm, preventing the protein from 
entering the nucleus. An authentic NLS (as the one in phLtrA) is likely more efficient for 
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directing the hLtrA protein into the nucleus, so that some protein may aggregate in the 
nucleus rather than in the cytoplasm where it is made.  
Another indication of aggregation is that a low percentage (<1%) of cells 
transiently transfected with phLtrA had cytoplasmic localization of LtrA, usually with 
immunofluorescence signal several fold stronger than that of nucleus-localized LtrA (not 
shown), suggesting that these cells received more copies of phLtrA and had a higher level 
of hLtrA expression. At the same time, stable cell lines expressing hLtrA from integrated 
copies of phLtrA had substantially lower expression of the hLtA protein (in both 
immunofluorescence and Western analysis) and nuclear localization in all observed cells. 
4.2 EXPRESSION OF THE INTRON RNA 
To express the intron RNA, I first cloned the intron with flanking exon sequences 
into vector pEGFP-N1 (Clontech), under a CMV promoter, to generate pEGFP-N1-
∆ORF (not shown). Using RT-PCR on total RNAs of transfected HEK 293 cells, I could 
detect unspliced precursor but not ligated exons (not shown). In order to find optimal 
conditions for intron expression, I designed a series of expression vectors using various 
promoters, including the human RNA polymerase I promoter (Pol I), the CMV promoter 
in conjunction with a nuclear retention sequence from U3 snRNA (Speckmann et al., 
1999) fused to the 3’-end of E2 (Pol II), the U3 snRNA promoter (Pol II) with different 
3’ ends, and the U6 snRNA promoter (Pol III).   
Figure 4.6 shows the different constructs used to express the Ll.LtrB ∆ORF 
intron. Each construct contains the Ll.LtrB-∆ORF intron and flanking LtrB exon 
sequences (172-180 bp of E1 and 90 bp of E2). Construct pHHWT uses the human Pol I 
promoter. pcDNA∆ORF/NL uses the CMV promoter and the U3 nuclear retention 
sequence. In pTZU3+27∆ORF, intron expression is driven by the U6 snRNA promoter. 
The two pBSU3∆ORF constructs both use the U3 snRNA promoter and are identical 
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except that the sequences downstream of E2 are different. pBSU3∆ORF/NL has the U3 
nuclear retention sequence and a pA signal, and pBSU3∆ORF.500 has instead 500 bp of 
genomic sequence that immediately follows the human telomerase RNA (hTR) and has 
been shown to improve the telomerase RNA expression level even when the RNA was 
under the U3 snRNA promoter instead of its endogenous promoter (Fu & Collins, 2003).  
To detect splicing, each intron expressing-construct was either cotransfected with 
phLtrA into HEK 293 cells or transfected into phLtrA stable cell lines. Total RNA was 
isolated 48 h post transfection, and splicing of Ll.LtrB RNA was assessed by RT-PCR. 
As illustrated in figure 4.7(a), right panel, primers used for both RT and PCR anneal to 
the two ends of the exons. Ligated exons resulting from RNA splicing give a smaller 
product than that from unspliced precursors. The left panel in figure 4.7(a) shows the 
representative RT-PCR results. pHHWT (Pol I), pcDNA∆ORF/NL (Pol II), and 
pTZU3+27∆ORF (Pol III) were transfected into phLtrA stable cell lines #25 and #38, 
respectively. pHHWT was transfected into HEK 293 cells as a control. Precursors were 
readily detectable in all the constructs.  However, ligated exons were only observed in 
stable hLtrA cell lines expressing the Pol I construct (pHHWT). The correct exon 
junction was confirmed by sequencing the RT-PCR products (not shown). In some other 
experiments, weak ligated exon bands were seen, but not consistently, in cells transfected 
with Pol II and Pol III constructs. However, those bands were present in too low amounts 
to be sequenced. Figure 4.7b shows a different experiment where in addition to these 
above three constructs, the two pBSU3 constructs were also tested. Neither gave ligated 
exons. For the pHHWT (Pol I) construct, cotransfection with phLtrA and transfection 
into phLtrA stable cell lines resulted in similar intron expression levels and splicing 
efficiency. 
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In addition, the hLtrA expression cassette was cloned into the pHHWT construct 
to make pHHWT-hLtrA (not shown). When transfected into HEK 293 cells, pHHWT-
hLtrA gave similar intron expression and splicing efficiency as cotransfection of pHHWT 
and phLtrA in RT-PCR (not shown). 
4.3 OPTIMIZING SPLICING—THE MG2+ EFFECT 
A key condition for optimum splicing could be free Mg2+ concentrations in vivo. 
The Ll.LtrB intron has Mg2+ optima of ~5 mM for protein-dependent splicing and 10-20 
mM for reverse splicing into DNA in vitro (Matsuura et al., 1997; Saldanha et al., 1999). 
In vivo, Mg2+ concentration is also critical for group II intron splicing. Studies in the 
yeast mt system have shown that mutations in the putative membrane transport proteins 
MRS2 and Lpe10, which decrease intramitochondrial Mg2+, strongly inhibited the 
splicing of all four mt group II introns, while having little effect on the splicing of group I 
introns or other mt RNA processing reactions (Gregan et al. 2001a, b). Although human 
cells contain a total of 30 mM Mg2+, only a small fraction of that (1-2 mM) is free Mg2+ 
(Ausubel et al., 1994; Romani & Scarpa, 2000). Elevated free Mg2+ concentrations may 
promote splicing in vivo. Here I tried to increase Mg2+ concentration in growth medium to 
see whether splicing could be improved. 
First, I tried adding 20 mM of extra Mg2+ (10 mM each of MgCl2 and MgSO4) to 
the standard growth medium, DMEM, used in my experiments, which already contains 
0.82 mM Mg2+. I also used the Leibovitz L-15 medium (ATCC, Manassas, VA), which 
contains higher Mg2+ (1.82 mM). Neither gave increased efficiency of LtrA-promoted 
splicing in RT-PCR (not shown). 
Bojanowski & Ingber (1998) applied up to 65 mM Mg2+ in the culture medium to 
decondense the chromosomes in living cells. Upon addition of extra Mg2+ into the 
medium, the authors observed instant but reversible unfolding of chromosomes. Thus, in 
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addition to potentially facilitating splicing, high Mg2+ concentrations might help make 
genomic targets more accessible. However, these authors only exposed the cells to high 
Mg2+ for up to 90 sec and found all effects reversible.  
I first tested how long cells could sustain high Mg2+ concentrations in the 
medium. I incubated HEK293 cells in growth medium supplemented with 80 mM of 
MgCl2 for different lengths of time.  Immediately after adding MgCl2, the cells looked 
different morphologically-- visible nuclei and nucleoli disappeared, and the contour of 
cells became smoother. After about an hour, both nuclei and nucleoli started to reappear, 
and cells assumed a more (but not completely) normal morphology. When high Mg2+-
containing medium was replaced by fresh medium without extra Mg2+, the nuclei and 
nucleoli reappeared within seconds. Notably, after being exposed to 80 mM of Mg2+ for 4 
h, the cells recovered and divided normally when placed overnight in the regular 
medium, demonstrated by lack of increased cell death or detectable morphological 
changes compared to untreated cells. These observations suggest that increased Mg2+ 
concentration in medium can result in at least a transient increase in intracellular Mg2+ 
concentration.  
Unexpectedly, when I incubated 293 cells transfected with the Pol I intron 
construct with 80 mM Mg2+ for 1 h and 2 h, the intron spliced independently of the LtrA 
protein (Figure 4.8(a), lanes 1-4). The Mg2+-induced splicing seems to be more efficient 
than that in LtrA-expressing cells at low Mg2+ (Figure 4.8(a), lanes 3, 4, and 5). Mg2+ 
increased splicing efficiency in LtrA-expressing cells to a similar level (lanes 3, 4, 7, and 
8). RT-PCR of the same RNA samples with hLtrA primers proved that there was no LtrA 
contamination in Mg2+-treated cells (Figure 4.8(b)). In order to exclude the possibility of 
intron splicing in vitro during preparation in the presence of 80 mM of Mg2+, I washed 
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the cells with 0.5 M EDTA and included 80 mM EDTA throughout the preparation 
precedure. 
The Mg2+-induced effect could result from either self-splicing of the intron or 
intron splicing requiring some other cellular proteins. Potentially, in cells with genes 
containing inserted group II introns, conditional disruptions might be obtained by simply 
increasing the ambient Mg2+ concentration instead of providing the LtrA protein. 
4.4 PRILIMINARY EVIDENCE THAT LTRA EXPRESSED IN MAMMALIAN CELLS HAS RT 
ACTIVITY 
In addition to splicing activity, I wanted to know whether the hLtrA expressed in 
mammalian cells has RT activity. It is possible that the bacterial protein might be post-
translationally modified in mammalian cells in ways that decrease its activities. Nuclear 
lysates were prepared by breaking the cell membrane with hypotonic buffer and 
homogenization (Eperon & Krainer, 1993; see section 6.2). RT assays were carried out 
both with the artificial template-primer substrate poly(rA)/oligo(dT)18 and with a natural 
substrate mimic denoted Ll.LtrB/E2+10 (Wank et al., 1999; San Filippo & Lambowitz, 
2002; Cui et al., 2004).  The latter consists of the Ll.LtrB RNA (in vitro transcript 
containing the Ll.LtrB-∆ORF intron and flanking exons) with an annealed 20-mer DNA 
primer (E2+10), whose 3’ end corresponds to that of the cleaved bottom strand normally 
used as the primer for TPRT.  
Figure 4.9 shows RT activities in nuclear lysates from different cells. The assays 
were performed twice on the same batch of nuclear lysate with reproducible data. The 
nuclear lysates were made at approximately the same cells/volume ratio to help normalize 
the total protein level. In the Ll.LtrB/E2+10 RT assay (Figure 4.9(a), left panel), cells 
expressing LtrA had substantial RT activity compared to untransfected 293 cells under 
high salt conditions (450 NMT: 450 mM NaCl, 5 mM MgCl2, and 40 mM Tris-HCl; pH 
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7.5; chapter 2). In 100 NMT (100 mM NaCl, 5 mM MgCl2, and 40 mM Tris-HCl, pH 
7.5), all cells had similar activity, likely from endogenous polymerases. Although 
transient expression of hLtrA generates much more protein than either of the two stable 
cell lines (Figure 4.4), samples “hLtrA#25” and “hLtrA” have similar activity, possibly 
because a large portion of the hLtrA protein in transiently transfected cells aggregates, as 
suggested by the previous immunofluorescence and Western assays.  
The poly(rA)/(dT)18 assay was carried out in 100 NMT conditions. Cells 
expressing LtrA showed only background level of activity in the polyrA/(dT)18  assay, 
similar to untransfected 293 cells. In addition, when purified LtrA was mixed with HEK 
293 lysate, the poly(rA)/(dT)18 activity was decreased to 20% of that without the cell 
lysate, indicating that the cell lysate is inhibitory to the reaction.  
These experiments only qualitatively demonstrate that there was RT activity 
associated with hLtrA and do not indicate the specific activity. Whether or not the protein 
has full RT activity is still an open question. 
4.5 PLASMID TARGETING AND HOMOLOGOUS RECOMBINATION WITH THE LACZ 
REPEAT CONSTRUCT 
For group II intron targeting, the intron splices and forms RNPs with LtrA, 
recognizes, and inserts into the top strand of a DNA target, whereas LtrA cleaves the 
bottom strand and initiates reverse transcription. Finally, cellular mechanisms complete 
the reaction by second-strand synthesis and gap repair. The results above establish that 
the splicing step can occur in mammalian cells. Although it would be ideal if we could 
detect the end product (complete insertion) of targeting, it is desirable to detect cleavages, 
indicating that RNPs are functional in vivo. And cleavage, as an intermediate step, would 
occur more frequently than full reverse splicing (Dickson et al., 2004). 
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Here, I describe a plasmid system using lacZ as a reporter to detect potential 
cleavages by Ll.LtrB RNPs expressed in human cells. Double-strand breaks, such as 
those generated by intron RNPs on target sites, stimulate homologous recombination in 
mammalian cells.  Although at the genome level, homologous recombination is a low-
efficiency event, it is very efficient on plasmid and can occur with homologies as little as 
14 bp (Rubnitz & Subramani, 1984). I designed a system similar to that used in Epinat et 
al. (2003), where the authors demonstrated that with a direct repeat configuration (Figure 
4.10(b)), lacZ function could be restored when a double-strand break was generated by a 
homing endonuclease that site-specifically cleaves between the repeats.   
A reporter construct was made so that the middle 300 bp of the 3-kb lacZ gene 
repeats itself with a wild-type Ll.LtrB target sequence (45 bp) and some flanking 
sequence in between (Figure 4.10(a), (b)). After cleavage occurs, cellular exonucleases 
digest the free ends from 5’ to 3’ end (resection). The repeat sequences will anneal to 
each other after becoming single-stranded, and extra sequences will be degraded and gaps 
and nicks will be fixed to form a complete copy of the lacZ gene. 
For a negative control, I transfected HEK 293 cells with the reporter plasmid 
alone. As positive controls, the reporter plasmid was either linearized by using BsrGI 
sites between the repeats, or incubated with RNPs under conditions that give cleavage 
and reverse transcription (with or without dNTPs, both gave similar results). After phenol 
extraction, both plasmids were transfected into the cells. Fourty-eight hours after 
transfection, cells were fixed and stained for β-galactosidase activity. Some cells (about 
0.1%) in the negative control turned blue, indicating low background level of 
homologous recombination (the tranfected DNA was prepared using a CsCl gradient and 
should mostly be supercoiled, free of nicks or breaks; Figure 4.10(c), left). It is worth 
noting that given the very low frequency of the spontaneous homologous recombination 
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events, the chance for more than one plasmid in each cell to go through the process is 
very small. So it is reasonable to assume that the blue staining resulted from a single copy 
of lacZ. The linearized plasmid gave about 30-40% blue cells, approaching the 
transfection efficiency, implying at least one of the copies of linearized DNA that entered 
each cell had undergone homologous recombination. The RNP-treated sample gave about 
2% blue cells, at least 10 times less efficient than the linearized sample, indicating that 
the RNPs do not cleave 100% of the target sites in vitro.   
However, I tried to co-transfect intron and hLtrA expression vectors into the cells 
with the reporter plasmid, I did not observe increased homologous recombination as a 
result of RNPs cleaving the reporter. Increasing RNP production and activities by 
optimizing both the protein and intron RNA expression is crucial. 
4.6 DISCUSSION 
In this chapter, I showed that the Ll.LtrB intron and its IEP could be expressed in 
human cells for RNP production.  I found that the expressed IEP has both maturase (RNA 
splicing) and RT activities.   
To express the LtrA protein in mammalian cells, it was necessary to resynthesize 
the ORF using human-preferred codons. Human cells tolerate at least moderate levels of 
constitutively expressed hLtrA protein so that stable cell lines expressing hLtrA were 
selected (Figure 4.4). hLtrA with a C-terminal NLS fusion expressed both transiently and 
stably, is localized mainly in the nucleus (Figure 4.5). Splicing of the Ll.LtrB intron RNA 
was detected at least with the human RNA polymerase I promoter-driven constructs 
(Figures 4.7). In addition to splicing, hLtrA also has RT activity (Figure 4.8), which is 
essential for targeting.  
However, several lines of evidence suggest that hLtrA may aggregate in the cells. 
First, I found a band several times larger than LtrA in Western analysis in transiently 
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transfected cells (with higher hLtrA expression level) disappears when more SDS-
containing buffer was used to dissolve the cells. This band appeared in variable amounts 
relative to hLtrA in different experiments. Second, some cells transiently transfected with 
phLtrA showed cytoplasmic localization when stonger immunostaining signal was 
observed, indicating of increased hLtrA expression. And hLtrA was localized to the 
nucleus in COS-7 cells, where phLtrA can replicate, but avoided the dense nucleoli. 
Lastly, although transient transfection resulted in higher hLtrA expression than stable 
hLtrA-expressing cell lines, similar RT activity was detected in both transiently and 
stably transfected cells. Taken together, these findings suggest that hLtrA is likely to 
aggregate in human cells when expression is relatively high, as in transient transfections. 
The expression system needs to be optimized to express the maximum amount of soluble 
protein. It would also be worthwhile to assess whether post-translational modifications 
negatively affect LtrA function. Both splicing and RT activities could be improved by 
preventing deleterious modifications.  
The Ll.LtrB RNA was expressed from pol I, pol II, and pol III promoters. 
However, only Ll.LtrB RNA expressed from a pol I promoter showed reporducible LtrA-
dependent splicing in vivo. For all constructs tested, the level of expressed Ll.LtrB RNA 
was so low that the RNA beingwas only detectable by RT-PCR, but not by Northern 
hybridizations. The similar intron RNA expression levels from different promoters, 
despite their different strengths for transcription, raises the possibility that some cellular 
mechanism, such as microRNAs, RNAi, or nucleases, may control how much the Ll.LtrB 
RNA can be maintained in the cell. This aspect should be investigated along with other 
ways to optimize intron production. 
By testing how extracellular Mg2+ can affect intron splicing, I found surprisingly 
that the Ll.LtrB intron expressed in HEK 293 cells spliced without LtrA when high 
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concentrations of Mg2+ were added to the growth medium (Figure 4.8(a)).  An attractive 
aspect of this Mg2+–induced splicing is that it might be used to obtain conditional 
disruptions for genes containing group II introns. Instead of introducing LtrA into the 
cells, merely adding Mg2+ into the medium will induce splicing of the inserted intron. 
Finally, I established a plasmid reporter system to detect RNP cleavages of a 
target site. Essentially, once RNPs cleave the target site between repeated sequences of 
the reporter and produce double-strand breaks, 5’ resection occurs from the break points 
and repeated sequences become two complementary single strands. Homologous 
recombination through single-strand annealing will generate a functional copy of the 
reporter. Here, I used lacZ as the reporter gene and proved the system worked with both 
negative and positive controls. However, I have not observed homologous recombination 
stimulated by breaks resulting from in vivo expressed Ll.LtrB RNPs cleaving the target 
site. This system can also be used to measure RNP activity by incubating RNPs with 
reporter plasmid in vitro before transfecting the plasmid into the cells to allow 
homologous recombination. 
4.7 SUMMARY 
Both the LtrA protein and the Ll.LtrB intron RNA were expressed in human cells. 
The LtrA protein is mostly localized in the nucleus and has both maturase and RT 
activities. The protein may be aggregated under some conditions. Notably, I also 
observed LtrA-independent splicing of the Ll.LtrB intron in vivo, when 80 mM MgCl2 
was added to the growth medium in human cells. In addition, a plasmid assay was 
developed to detect RNP cleavage activity in vivo. 
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Figure 4.1 Constructs for expressing LtrA in human cells.  
(a) pCMV-LtrA contains the LtrA ORF under a CMV promoter and with C-terminal NLS 
fusion. pA is a poly A signal, and ori is an E. coli replication origin. (b) pCMV-IVS is an 
intermediate construct that contains a short (132 bp) spliceosomal intron (IVS) cloned 
downstream of the CMV promoter to improve protein expression (Le Hir et al., 2003). (c) 
pCMV-IVS-LtrA has LtrA cloned downstream of the IVS and also has the C-terminal 
NLS. (d) pKS-hLtrA is an intermediate construct that contains the full-length codon-
optimized LtrA sequence. There is no promoter upstream of hLtrA ORF to drive 
transcription. (e) phLtrA is the expression vector for hLtrA with the ORF cloned 
downstream of the CMV promoter and the IVS sequence and an SV40 NLS fused to the 
C-terminus of the protein. (f) pLtrA was constructed by swapping the hLtrA ORF with 





Figure 4.2 DNA sequence of hLtrA ORF.  
The Kozak sequence is in bold, italic, and lower case at the N-terminus. The translational 
initiation codon ATG is in bold immediately following the Kozak sequence. At the C-
terminus, the SV40 NLS is in bold and italic lower case immediately preceding the stop 





Figure 4.3 Schematic of cloning strategies for constructing the hLtrA ORF.  
Horizontal bars represent overlapping synthetic DNA oligonucleotides used as templates 
in PCR reactions. Arrowheads showed smaller primers used to amplify each segment. 
Letters next to arrowheads represent restriction sites that were later used in cloning. The 
letter at the end of each short arrow R: EcoRI; H: HindIII; X: XbaI. Grey arrows 
represent the two complementary oligonucleotides used to amplify segments 5 and 6 into 
one piece. Each segment was flanked by two restriction sites that are unique within the 
fragment and were later used to ligate all the pieces together.  
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Figure 4.4 Western analysis showing expression of the codon-optimized LtrA construct. 
(a) hLtrA expresses well in transiently and stably transfected HEK 293 cells (lanes 5 to 
7), whereas no hLtrA expression was detected in untransfected 293 cells (lane 2), 293 
cells transfected with pCMV-IVS (lane 3), or pLtrA (LtrA without codon optimization; 
lane 4). LtrA protein purified from E. coli was run as a positive control and size marker 
(lane 1). (b) hLtrA expression in transiently transfected 293 cells compared to no 
detectable expression from pLtrA, which is identical to phLtrA except that the ORF is not 
codon-optimized (lane 3) or untransfected 293 cells (lane 2). Lanes 4 and 5 were from the 
same sample. Lane 4 was loaded with the supernatant of the sample after boiling in SDS-
containing loading buffer, and lane 5 was loaded with the pellet portion after boiling 
again with more SDS buffer. Lane 1 is LtrA purified from E. coli. 
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Figure 4.5 Localization of hLtrA.  
An anti-LtrA antibody was used in immunofluorence assay, where the secondary 
antibody was conjugated with FITC. (a) to (d) show the localization of hLtrA in cells and 
from constructs indicated in the figure. The left panel is LtrA immuno-staining; the 
middle panel is nuclei stained with Hochest dye; and the right panel is the 
superimposition of the first two. (e) is an enlarged image of the left panel of (b). 
 112
 113
Figure 4.6 Constructs used to express the intron RNA.  
E1 and E2 denote exons 1 and 2, respectively. ∆ORF represents the ∆ORF version of the 
Ll.LtrB intron. pA is a poly A signal. T is a transcriptional terminator. NL is the nuclear 
localization sequence from the U3 snRNA. An arrow shows the position of the indicated 
promoter. hTR500 in (e) represents the 500 bp non-transcribed sequence downstream of 
the human telomerase RNA. Ori is a replication origin. Among these constructs, Ms. 







Figure 4.7 RT-PCR results of intron expressed from the constructs in figure 4.6.  
(a) Splicing of different constructs in 293 cells or hLtrA stable cell lines. Pol I, Pol II, and 
Pol III refer to pHHWT, pcDNA∆ORFNL, and pTZU6+27∆ORF, respectively. (b) In 
vivo splicing in HEK 293 cells with pBSU3∆ORFNL and pBSU3∆ORF.500. n.s. stands 










Figure 4.8 Mg2+-induced splicing of the Ll.LtrB intron.  
(a) RT-PCR demonstrating Mg2+-induced splicing in human cells. Cells transfected with 
pHHWT (lanes 1 to 4) or cotransfected with pHHWT and phLtrA were incubated with 
different concentrations of Mg2+, 0, 20, or 80 mM, respectively (lanes 5 to 8). After cells 
were incubated in 80 mM of Mg2+ for 1 h or 2 h, Mg2+ was diluted to 20 mM with fresh 
medium and cells were all harvested after 3 h of the initial addition of Mg2+. (b) RT-PCR 
of all the RNA samples in the left panel with hLtrA primers.  
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Figure 4.9 RT assays using nuclear lysates. 
hLtrA#25 and hLtrA#38 are HEK 293 cell lines stably expressing hLtrA. 293 and 293-
1/2 represent non-transfected cells, and in 293-1/2, only half amount of the lysate was 
used. LtrA stands for 0.5 µg of purified LtrA protein. LtrA+293 lysate is the mixture of 
purified LtrA and 293 lysate. (a) The Ll.LtrB/E2+10 RT assay. Reaction media were as 
indicated. 450 NMT stands for 450 mM NaCl, 5 mM MgCl2, and 40 mM Tris-HCl (pH 
7.5), and 100 NMT is identical except that the NaCl concentration is 100 mM. (b) 
Poly(rA)/oligo(dT)18 assay (see section 6.1.10). 
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Figure 4.10 A plasmid system for detecting homologous recombination stimulated by 
RNP cleavage of a target site.  
(a) The reporter plasmid. The lacZ HR box contains a CMV promoter, a lacZ ORF with 
the middle portion (from 1.3 kb to 1.6 kb downstream of the ATG codon) directly 
repeating itself, with the two repeats separated by an insertion including 45 bp of wild-
type target site and 500 bp flanking sequences on either side. (b) A comparison of the 
wild-type lacZ gene and the modified lacZ gene in the HR box. The open boxes represent 
the 300-bp repeated sequence. (c) shows that the system works to detect homologous 
recombination. HEK 293 cells were transfected with untreated reporter plasmid, reporter 
plasmid linearized between the repeats by BsrGI digestion, and reporter plasmid 
preincubated with RNP particles in vitro. After transfection, the cells were fixed and 






Chapter 5: Using purified RNP to target the mammalian genomes 
An alternative way of using group II introns in gene targeting is to deliver purified 
RNPs directly to cells.  In order to target the chromosomes, group II intron RNPs must be 
in proximity of their targets when the chromosomes are structurally accessible.  
Practically, it is feasible to obtain large quantities of highly active RNPs either from E. 
coli expression or by reconstituting them using purified LtrA protein and self-spliced 
intron RNA. Unlike plasmid DNA used for intorn expression, which could integrate 
randomly into the genome, RNPs turn over relatively fast and are less likely to have long-
lasting adverse effects on the cells. However, disadvantages of using RNPs include low 
transfection efficiency and short shelf life, thus less exposure to the targets than in the 
case of expressing RNPs in vivo.  Guo et al. (2000) showed that RNP particles could be 
delivered into human cells by lipisome-mediated transfection and were able to insert into 
a plasmid-born target site.  However, the reaction was very inefficient and required 
nested PCR to detect the insertion product.  In addition, it was not clear where in the cell 
the targeting event occurred. Obviously, to target chromosomes, RNPs must enter the 
nucleus and stay active there. A major obstacle of using RNPs for genomic disruption is 
how to introduce RNP particles into the nucleus efficiently.  Another factor to be 
determined is whether RNPs could access targets within chromatin structures. 
In this chapter, I describe in vitro experiments showing that the Ll.LtrB intron can 
target mammalian genomes and in vivo evidence that a modified Ll.LtrB intron inserted 
into an rDNA target site.  I first showed that RNPs could insert into even single-copy 
target sites in purified genomic DNAs. Then I showed RNPs inserted successfully into 
target sites in nuclear lysates, where target genes are in chromatin structures. Additional 
buffer was not necessary in some reactions, indicating nuclear lysates contain sufficient 
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Mg2+ and proper ionic strength for targeting reactions to occur. I also tested different 
ways of introducing purified RNPs into cells, including injection and electroporation.  
Lastly, I detected an insertion event into the rDNA gene in HEK 293 cells with RNP 
electroporation.  
5.1 IN VITRO GENOMIC TARGETING WITH RNPS 
To demonstrate the feasibility of using RNPs to target the human genome, I tested 
whether group II intron RNPs could integrate into specific target sites in the context of a 
complex genome in vitro. 
5.1.1 Targets with different copy numbers 
I chose several chromosomal targets with different copy numbers to test the 
sensitivity of group II intron gene targeting. Introns against each target were either 
selected using a random library (Guo et al., 2000) or designed using a computer 
algorithm (Perutka et al., 2004).  
The human LINE-1 (L1) retrotransposon is a good target because there are about 
50,000 copies of L1 sequences per human cell, which comprise apporximately 17% of 
the human genome. The majority of L1s have 5’ deletions (Brouha et al., 2003). An 
efficient intron (L1-2458a, 115% wild-type efficiency in an E. coli plasmid assay) was 
selected from the random intron library constructed by Guo et al. (2000). This intron 
targets the middle portion of the 6-kb L1 sequence (Figure 5.1; D’Souza & Lambowitz, 
unpublished).  
rDNA genes have a medium copy number of 400 per diploid human cell (Yoon et 
al., 1995; Gecheva et al., 1996). The copy number is higher in multiploid cell lines. In 
addition to having multiple copies, rDNA genes have the advantage of being actively 
transcribed in fast growing cells and thus may be highly accessible to RNPs. Several 
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introns were designed to target different locations in the 45S rDNA and tested using the 
E. coli mobility assay (Guo et al., 2000). The most active one (rDNA-16280a, 70% wild-
type efficiency) was used in the experiments below (Figure 5.1).   
Two low copy number targets are mouse hypoxanthine phosphoribosyl 
transferase (mHPRT) and Herpes Simplex Virus (HSV) thymidine kinase (TK) gene, 
both of which are selectable (Mansour et al., 1988; Horie et al., 1994; Cannon et al., 
1999). The HPRT gene is an endogenous gene located on the X-chromosome, and thus 
present in single-copy in male diploid cells, such as mouse ES cell lines. An efficient 
intron (mHPRT-144s, 75% wild-type efficiency) was designed using the computer 
algorithm to target the sense strand of the gene (Figure 5.1).  
The HSV-TK gene was introduced into HEK 293 and NIH 3T3 cell lines on a 
Murine Leukemia Virus (MLV) vector by Bruce Sullenger’s laboratory at Duke 
University, and single-copy clones were used in the experiments described in this 
chapter. I selected an intron (TK-61s, 105% wild-type efficiency) with wild-type 
frequency against the HSV-TK gene from the random library (Guo et al., 2000).   
5.1.2 In vitro TPRT-PCR with purified chromosomal DNAs 
First, I wanted to find out whether group II intron RNPs were able to identify their 
targets in the complex mammalian genomes. I purified chromosomal DNA from HEK 
293 cells and a clone of NIH 3T3/TK cells (stable cell lines derived from a mouse cell 
line, NIH 3T3, containing a single copy of the HSV-TK gene). RNPs were either purified 
from E. coli by affinity chromatography (rDNA) or reconstituted in vitro (L1, TK, and 
mHPRT) (see methods). RNPs against rDNA and L1 were incubated with the HEK 293 
DNA, whereas RNPs against TK and mHPRT were incubated with the NIH 3T3/TK 
DNA in the target DNA-primed reverse transcription assay (TPRT; see methods). 
Following TPRT, PCR was used to detect insertion junctions with an intron primer and a 
 122
target site primer in each reaction (Figure 5.2(a)).  Nested PCR was performed when 
necessary. All PCR-amplified bands of expected size were sequenced to confirm the 
correct junctions. 
Figure 5.2(b) shows that incubation of L1 and rDNA RNPs with the HEK 293 
DNA resulted in readily detectable 3’ junctions. The 3’ junction of the L1 insertion site 
(lane 3) only required one round of PCR, while nested PCR was necessary to detect the 
3’ insertion junction of the rDNA target (lane 1). Incubation of the wild-type RNP with 
the chromosomal DNA resulted in nonspecific amplifications (lanes 2 and 4). The 5’ 
junction was more difficult to detect, presumably because the intron RNA may insert 
partially into the target to form only the 3’ junction, and/or even when the insertion is 
complete, reverse transcription of the RNA insertion may not be complete (see Figure 
1.4). In addition, non-optimal PCR conditions may also be a factor. In lane 7, only a faint 
band of L1 5’ insertion junction was amplified by one-step PCR, unlike that of the 3’ 
junction (lane 3). On the other hand, the 5’ junction was readily detectable in rDNA 
samples (lane 5). However, I could not exclude that it resulted from template switching 
during PCR. All the RNP preparations contain small amount of contaminating intron-
donor plasmid DNA, which shares up to 12 bp of homology with the target site (Figure 
5.2(d)). When the GC content is high, e.g., 100% GC in IBS sequences of the rDNA 
target, nested PCR would pick up low amounts of template-switching products.  In fact, I 
was able to obtain the same band as that in lane 5 by including both the donor plasmid 
and the 293 DNA as templates in nested PCR (not shown). 
Figure 5.2(c) shows that RNPs were able to target low copy number targets in 
mammalian genomes.  NIH 3T3 DNA was incubated with TK and mHPRT RNPs, 
respectively. PCR amplified TK and mHPRT 3’ junctions with respective target primers 
(lanes 1 and 4). Primers of one target site did not amplify the insertion junction in the 
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DNA treated with the other RNP preparation (lanes 2 and 3), demonstrating specific 
insertion. The mHPRT RNP gave a specific 5’-insertion junction (lanes 7 and 8). 
However, TK targeting did not give a detectable 5’ junction (lane 5), which could be due 
to non-optimal PCR conditions for this primer/template combination. 
It is worth noting that, in another experiment, when I used less concentrated RNP 
preparations and a different preparation of DNA, I was able to amplify the 3’ junction of 
targeted mHPRT only marginally, and TK was not detectably inserted (not shown). In yet 
another experiment, I was able to obtain good amplifications of the 5’ junction of 
targeted L1 (dramatically better than Figure 5.2(b), lane 7) using one-step PCR. So RNP 
concentration and DNA purity may greatly affect the targeting efficiency in vitro.   
Together, these results showed that RNPs are able to insert specifically into 
mammalian genomic DNA targets, including single-copy genes.  
5.1.3 In vitro TPRT with nuclear lysates 
Next, I used nuclear lysates as targets in the TPRT assay to find out whether 
RNPs could access the chromosomal targets within chromatin structures.  I made nuclear 
lysates by first treating the cells with a hypotonic buffer (10 mM HEPES and 10 mM 
KCl, pH 8.0) and then homogenizing (Eperon & Krainer, 1993). I avoided sonication of 
the nuclear pellets so that chromosomal DNA stayed relatively intact. Instead, three 
cycles of freezing and thawing were applied to the nuclear pellets to break the nuclear 
membrane. Complete separation of the nucleus from the cytoplasm is not critical for my 
purposes.  
In TPRT assay, I incubated intron RNPs and nuclear lysate with 2 mM dNTPs 
and with or without Mg2+-containing RT buffer. Unlike targeting L1 in the purified 
chromosomal DNA, detection of the 3’ junction of L1 in nuclear lysate required nested 
PCR (lanes 5 and 6). Lane 7 shows the insertion junction was produced specifically by 
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RNPs against L1 but not by those against rDNA. The difference between lanes 5 and 6 is 
that RT buffer (40 mM Tris-HCl, pH 7.5, 10 mM KCl, 10 mM MgCl2, 5 mM DTT) was 
included in the TPRT reaction of lane 5 but not in that of lane 6. Similar results in these 
two lanes suggest that additional Mg2+ is not necessary for targeting to occur in the 
lysate. The 5’ junction was not detected for L1 in the lysate. Unlike the situation for 
targeting purified chromosomal DNA, nuclear lysates probably contains nucleases, which 
could potentially digest the inserted intron RNA, causing the RT reaction to run off the 
template and lowering the detection of 5’ junction.  
Nested PCR did not amplify the 3’ junction of targeted rDNA specifically (lane 1) 
and gave a nonspecific band in the reaction of L1 RNP-treated lysate with rDNA primers 
(lane 2). In another experiment, I was able to use a different batch of in vivo RNP to 
target rDNA in lysate (not shown). The 5’ junction was amplified, but again, it may have 
resulted from template switching (lane 3). I did not test the two low copy targets in the 
nuclear lysate.  
5.2 DELIVERY OF RNPS BY INJECTION  
Injection is the most certain way to deliver RNP into the nucleus. In collaboration 
with the Transgenic Mice Facility on campus, we tried to inject RNPs into fertilized 
mouse eggs. Ms. Shanon Maika performed the injections for me. However, a limiting 
factor is that one could only feasibly inject a relatively small number (about 100) of eggs 
at a time, which may not be sufficient to find rare events. In addition, RNP preparations, 
especially those more concentrated than 1 µg/µl, tend to clog the injection needles, 
further lowering the number of eggs and the amount of RNPs per egg being successfully 
injected.  
We have tried to inject mHPRT and rDNA RNPs, both purified from E. coli, and 
neither resulted in targeting events that were detectable by nested PCRs. On the other 
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hand, others in the lab injected RNPs to Xenopus oocytes, zebra fish and Drosophila 
embryos and observed targeting events in plasmid-born targets, with efficiency directly 
related to the RNP concentration (Watanabe, Vernon, & Lambowitz, unpublished). These 
other systems use needles with larger diameters, hence no clogging, and allow larger 
injection volumes than in the case of mouse egg injection. Injection remains an attractive 
means for introducing RNPs into the nucleus. Improvement could be made in RNP 
preparation to increase both concentration and solubility. 
5.3 FEASIBILITY OF USING ELECTROPORATION TO DELIVER RNPS INTO THE CELLS 
Lipid-mediated transfection reagents are commonly used for delivery of nucleic 
acids into cells. However, the presence of protein greatly decreases transfection 
efficiency. Peptide vectors are useful in delivering proteins (Morris et al., 2001). 
However, I could not detect binding between the peptide vectors (MPG and chariot) and 
RNPs. Electroporation induces transient openings on the cytoplasmic membrane, which 
allows molecules of all sizes and types to enter the cell. A drawback of electroporation is 
that cell survival rate is usually much lower than lipid-mediated transfection.  
Many groups have used electroporation to successfully deliver nucleic 
acid/protein complex, including influenza viral (Li et al., 1995) and DNA transposon 
complex (Reznikoff et al., 2004).  
5.3.1 Testing electroporation conditions for RNP 
To test whether electroporation delivers RNP into cells, I used an RNP 
preparation with an N-terminal GFP fusion if LtrA (see methods) to electroporate HEK 
293 cells.  Among the conditions tested, settings with voltage at 230 v and capacitance at 
100 µF or 250 µF, labeled as (230 v, 100 µF) and (230 v, 250 µF) in Figure 5.4(a), 
respectively, gave best results when 2x106 cells were mixed with 10 µg of RNP in 0.4 ml 
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of ice-cold PBS.  Twenty-four hours post electroporation, the majority of the cells were 
transfected, as judged by fluorescence microscopy (not shown). An immunofluorescence 
assay using an anti-LtrA antibody on the same set of cells showed similar staining pattern 
(Figure 5.4(a)) with stronger fluorescence intensity because the secondary antibody was 
conjugated with fluorescein, which has the same spectrum as GFP. RNPs were in 
speckles in the cells, some in the cytoplasm and some in the nucleus. An NLS fusion on 
the LtrA protein in RNPs may direct more RNP particles into the nucleus. In addition, 
electroporated cells showed weak but uniform increase increase in fluorescence intensity 
compared with untransfected cells (Figure 5.4(b)).  
5.3.2 Electroporation does not impair RNP activity 
To find out whether RNPs would remain active after electroporation, I diluted 10 
µg of anti-rDNA RNPs in 400 µL of ice-cold PBS and subjected them to electroporation 
conditions. RNPs were then concentrated to the original volume before dilution by using 
a Microcon column (Millipore) and compared in a TPRT assay, which uses 32P-labeled 
dTTP to trace cDNA synthesis, with untreated RNPs and RNPs diluted and re-
concentrated but not subjected to electroporaton. No difference in activity could be 
detected among the samples (not shown). Thus, electroporation conditions per se do not 
affect RNP activity.  
5.4 In vivo homing by RNP electroporation 
I electroporated HEK 293 cells and HEK 293 cells treated with sodium butyrate 
with RNPs against rDNA using similar conditions (230 v, 250 µF). The RNPs were 
purified from E. coli, and the LtrA protein in the RNP had a C-terminal fusion of the 
NLS of the HIV-1 Tat protein. Sodium butyrate is a histone deacetylase inhibitor, which 
keeps histones acetylated and helps relax the constraint of histone tails on chromosomal 
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DNA (Chen & Picaard, 1997). After electroporation, cells were seeded into growth 
medium and grown overnight. Twelve hours later, I added MgCl2 and MgSO4 to a final 
concentration of 10 mM each.  Chromosomal DNA was prepared 72 hours after 
electroporation, and nested PCR was used to detect targeting events.   
Figure 5.5 shows that the 3’ junction of a targeted rDNA copy was amplified from 
electroporated 293 cells but not from electroporated 293 cells treated with sodium 
butyrate. The amplified band was gel-purified and sequenced to confirm the correct 
junction sequence. The 5’ junction was not tested because of the interference of template 
switching (see section 5.1.2). Thus, RNPs are able to target chromosomal genes in vivo, 
and sodium butyrate did not help targeting. On the contrary, it seemed to prevent it from 
occurring.  The in vivo genomic targeting is likely a very low-frequency event. However, 
improved in vitro preparations of highly concentrated RNPs may increase the targeting 
efficiency. 
5.5 DISCUSSION 
In this chapter, I used RNPs either purified from E. coli or reconstituted in vitro in 
both in vitro and in vivo experiments to target the chromosomal genes of human or mouse 
cells. The purpose of the in vitro experiments was to test whether the RNPs could find 
their targets in complex mammalian genomes and function under conditions in nuclear 
lysates without additional salt and Mg2+.  
Group II intron RNPs were able to target genes in purified chromosomal DNA 
and nuclear lysates in vitro. The in vitro experiments demonstrated that RNPs were able 
to identify and insert into their targets in the context of whole human and mouse genomes 
(Figures 5.2 and 5.3).  However, in vitro targeting was not efficient, judged by the fact 
that even with rDNA (400 copies/cell), nested PCR was required to detect insertions.  On 
the other hand, nested PCR also detected insertions into low copy number, even single-
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copied, genes in purified chromosomal DNAs (Figure 5.2(b)). Targeting was successful 
in nuclear lysates albeit less efficient. When targeted in purified DNA, L1 insertion 
junctions were detected by one-step PCR, whereas in lysates, nested PCR was required 
(Figure 5.2(a), lane 3, and Figure 5.3, lanes 5 and 6). And nested PCR readily detected 
insertions into rDNA target in purified chromosomal DNAs but not in lysates (Figure 
5.2(a), lane 1, and Figure 5.3, lane 1). However, Mg2+-containing buffer was not 
necessary (Figure 5.3, lanes 5 and 6). Apparently, chromatin structures did not block the 
access of RNPs to chromosomal targets, and lysates could support the reaction without 
additional Mg2+. However, it was not clear whether the insertion was complete because 
the PCR used to detect the 5’ insertion junction was complicated by template switching. 
But it is reasonable that less 5’ insertion junction is formed than the 3’ junction. The 
formation of the 5’ junction requires complete reverse transcription of the inserted intron 
RNA, whereas the 3’ junction needs less than 200 bp of reverse transcription to be 
detected by the 3’ end intron primers used in TPRT and PCR reactions. Incomplete 
reverse transcription could be due to either low processivity of the RT, or degradation of 
the inserted RNA template under the conditions in the experiments.  
Injection and electroporation were the two major methods tested in this work to 
deliver RNPs into cells. In the mouse injection experiments, I could not detect any 
targeting event either on chromosomes or when target plasmid was co-injected with 
RNPs. The injection approach is largely limited by the relative low numbers (about 100) 
of eggs that could be injected in each experiment, compared to 106 to 107 cells used in 
electroporation experiments. For detection of a rare event, the difference in cell numbers 
could be critical. However, injections into Xenopus oocytes and zebra fish and 
Drosophila embryos were successful for plasmid targeting. The difference may be 
technical. The volume of RNPs that can be injected into mouse eggs is much smaller than 
 129
that for Xenopus oocytes, zebra fish or Drosophila embryos, and the RNP concentration 
needs to be below a certain level (about 1 µg/ml) to avoid clogging the smaller needles 
used for injecting mouse eggs. New methods of preparing RNPs with higer 
concentrations and solubility may improve the efficiency of injection. 
I showed that RNPs could be incubated under electroporation conditions without 
losing activity. By using electroporation, I was able to detect an insertion event in 45S 
rDNA in HEK 293 cells.  On one hand, targeting under current conditions is a rare event. 
Many factors could potentially affect the reactions. RNP preparations may differ in 
activity from batch to batch. Standardizing reaction conditions would be helpful.  
In short, the group II intron Ll.LtrB was able to target mammalian genomes. It 
will be necessary to improve targeting efficiency so that group II introns would be 
generally useful for functional genomics and gene therapy. 
5.6 SUMMARY 
In this chapter, I explored the possibility of using RNPs to target mammalian 
chromosomal genes. First, I showed that RNPs targeted even a single-copy gene in 
purified mouse genomic DNA. Second, I demonstrated that RNPs were able to disrupt 
targets within chromatin structures in nuclear lysates, and nuclear lysates had sufficient 
Mg2+ and salt for targeting to occur. Third, I established that RNPs could be introduced 
into cells by electroporation, and I was able to detect a targeting event in the human 
rDNA gene. Increasing targeting efficiency will be necessary for this to be a generally 
useful procedure. 
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Figure 5.1. Retargeted introns used in this chapter and their mobility frequency in a 
plasmid assay in E. coli. 
Each target is listed with the gene name and -1 position of the insertion site in the gene. s, 
sense strand insertion; a, anti-sense strand insertion. EBS and δ sequences of each intron 
are aligned to IBS and δ’ sequences of the respective target. Base-paired nucleotides are 
connected with a vertical bar. Residues in IBS and δ’ sequences of the target site are 
numbered according to Guo et al. (2000). Nucleotides at positions -12, -7, +1, and +5 are 
in bold. The plasmid-base mobility assay was done by cotransforming a donor plasmid 
expressing the intron RNA and IEP and a recipient plasmid carrying a promoterless 
tetracycline-resistance gene proceeded by a specific target site. The intron RNA carries a 
T7 promoter in DIV, which will result in tetR expression upon intron insertion into the 
target site. The mobility frequency refers to percentage of tetracycline-resistant cells 
among all transformed cells. The mobility frequencies of retargeted introns were 




Figure 5.2 RNPs were able to insert into target sites in purified chromosomal DNAs. 
(a) Schematic showing PCR amplification of intron/target site junction following a TPRT 
reaction. In each PCR reaction, one intron primer and one target primer were used. In 
nested PCR, two sets of intron/target primers were used in consecutive PCR reactions. (b) 
PCR of in vitro targeting of rDNA and L1 retrotransposon in HEK 293 DNA. RNP and 
primers used are indicated at the top of each lane. rD, rDNA; L1, the L1 retrotransposon; 
WT, the wild-type Ll.LtrB intron RNP. Lanes 1, 2, 5, and 6 show products of nested 
PCRs. The remaining lanes show products of one-step PCRs. (c) Nested PCR of in vitro 
targeting of the mouse HPRT gene and the HSV-TK gene. As in (b), RNPs and primers 
are labeled above the lanes. HP, mHPRT; TK, HSV-TK. (d) Schematic showing the GC-
rich homologous region between the rDNA donor plasmid and target site, resulting in 
template switching detected in nested PCR. An asterisk was placed to the right of each 







Figure 5.3 Nested PCR showing L1 interruption by specific RNPs in nuclear lysates.   
TPRT reactions were done with or without added Mg2+-containing buffer (40 mM Tris-
HCl, pH 7.5, 10 mM KCl, 10 mM MgCl2, 5 mM DTT) for L1 targeting. Lanes 5 and 8 
were with added buffer, and lanes 6 and 9 were without the buffer. All contained 2 mM 
dNTPs. Each RNP was used as a negative control for the other target site (lanes 2, 4, 7, 
and 10). The single band in lane 2 was sequenced and shown to result from nonspecific 
amplification of the rDNA. The bands in lanes 5 and 6 were confirmed to have the 
correct 3’ integration junction for L1 by sequencing. All the bands in lane 1 resulted in 
nonspecific amplification. Each correct PCR product is indicated by an asterisk. 
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Figure 5.4 Electroporation of RNPs into cells.  
(a) GFP fused to the N-terminal of the LtrA protein was visualized with a fluorescence 
microscope (left panel). In a superimposition to the nuclear staining (middle panel), GFP 
is shown to be in or around the nuclei. (b) Cells from (a) were trypsinized and measured 
with a Fluorescence-activated Cell Sorter (FACS). Electroporation conditions are 
indicated on the left. The histograms on the left show the shift in fluorescence intensity 
upon electroporation of GFP-containing RNP complex (with filter FL1, 530±30 nm). The 





Figure 5.5 In vivo targeting of the rDNA gene in HEK 293 cells. 
HEK 293 cells and sodium butyrate (NaBu, 3 mM)-treated HEK 293 cells were 
electroporated (230 v, 250 µF, 2x106 cells in 400 µl PBS) with RNPs against rDNA. 
Chromosomal DNAs were purified (see methods) 72 h after electroporation. Nested PCR 
were done to detect insertion junctions. Lanes 1-4 show PCR products obtained using 
rDNA primers to detect rDNA in the purified chromosomal DNA. Lanes 5-8 were 
amplified as shown in Figure 5.2(a). The specific band in lane 7 (a white arrowhead on 
the right) was confirmed as correct junction by sequencing. 
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Chapter 6 Materials and methods 
6.1 MATERIALS AND METHODS FOR STUDYING LTRA-PROMOTED SPLICING OF THE 
LL.LTRB INTRON IN E. COLI 
6.1.1 E. coli strains and growth conditions 
E. coli HMS174(DE3) (Novagen, Madison, WI) was used for in vivo splicing 
assays; BL21(DE3) and Rosetta (DE3) (Novagen) were used for LtrA protein expression; 
and DH10B and DH5α were used for cloning. Bacteria were grown in LB medium. 
Ampicillin and chloramphenicol were added at 100 µg/ml and 25 µg/ml, respectively. 
6.1.2 Recombinant plasmids  
Plasmids used for in vivo splicing assays contain ltrB/GFP fusions cloned 
downstream of the phage T7 promoter and φ10 gene Shine-Dalgarno sequence in the 
vectors pAT or pET, which are derivatives of pACYC184 and pET-11a (New England 
Biolabs, Beverly, MA), respectively (see below). The ltrB/GFP fusions consist of the first 
eight codons of φ10 linked in-frame to a segment of the L. lactis ltrB gene (58 bp of exon 
1 (E1), the Ll.LtrB intron, and 38 bp of exon 2 (E2)), with E2 linked in frame to codons 2 
to 238 of the GFP ORF. The GFP ORF used here was derived from that in pGFPuv 
(Clontech, Palo Alto, CA) by introducing amino acid substitutions F64L and S65T to 
improve performance in FACS assays (Cormack et al., 1996). pAT and pET were derived 
from their parent vectors by inserting E. coli rrnB T1 and T2 transcription terminators to 
mitigate the effect of strong T7 RNA polymerase transcription on plasmid stability. pAT 
contains a T1 terminator (250-bp AatII/SalI fragment of pKK232-8; Amersham 
Pharmacia; Piscataway, NJ) inserted between the NruI and SalI sites of pACYC184, and 
T1 + T2 terminators (0.9-kb PCR product of pKK232-8 synthesized with primers T1T2-
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5'ClaI (5’-GAACATATCGATAGCGTCCGCCATC) and T1T2-3'XbaI (5’-
AGCACGATCTAGAGCACCCGTGGC) inserted between the pACYC184 ClaI and 
XbaI sites. pET contains T1 and T2 terminators (960-bp ClaI/SspI fragment of pAT) 
inserted between the ClaI and SalI sites of pET11a. 
Plasmids in the pALG1 series contain ltrB/GFP fusions with the wild-type (2.6-
kb) Ll.LtrB intron or its mutant derivatives cloned in pAT. pALG1-WT contains the 
wild-type Ll.LtrB intron recloned from pLI1 (Matsuura et al., 1997). pALG1-∆ORF 
contains a mutant intron deleted for most of the intron ORF (positions 691-2286) 
(Matsuura et al., 1997), and pALG1-∆DV contains a mutant intron deleted for DV 
(positions 2398-2492) (Guo et al., 2000). The 0.9-kb ∆ORF intron in pALG1-∆ORF has 
the same sequence at the wild-type intron, except for an MluI site inserted in domain IV 
during construction of the deletion. 
Plasmids in the pALG2 series contain ltrB/GFP fusions with the 0.9-kb Ll.LtrB-
∆ORF intron and have the LtrA protein expressed from the downstream cis position. 
pALG2-WT was derived from pALG1-∆ORF by inserting a 1.8-kb PCR product 
containing the LtrA ORF (amplified from pLI1 (see below) with primers 5’-
GGACTAGTGATTAGGGAGGAAACCTC and 5’-GGG-
GGCCCGTTCGTTCGTAAAAATTCACTTG) between the SpeI and ApaI sites of 
pALG1-∆ORF. pALG2 derivatives with deletions of various intron domains were 
constructed by swapping in the 0.9-kb PvuI/KpnI fragments of previously constructed 
pGM-∆ORF-based plasmids containing the deletions (Wank et al., 1999).  
pELG1-∆ORF contains a GFP fusion with the 0.9-kb Ll.LtrB-∆ORF intron 
constructed by ligating the 1.9-kb BglII/ClaI fragment of pALG1-∆ORF between the 
corresponding sites of pET. This plasmid was used for the insertion of LtrA mutant 
libraries at the downstream cis position for unigenic evolution analysis (see below). 
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pELG2-WT contains the same GFP fusion with the 0.9-kb Ll.LtrB-∆ORF intron and the 
LtrA protein expressed from the downstream cis position. It was constructed by 
simultaneously inserting the 1.9-kb BglII/SpeI fragment containing the ltrB/GFP fusion 
of pALG1-∆ORF and a 1.8-kb PCR product containing the LtrA ORF [amplified from 
pLI1 with primers LtrA 3’-ClaI (5’-
GGGGGCATCGATGCCCTTCGTTCGTAAAAATTCA) and LtrA 5’-SpeI (5’-
GGGACTAGTACTTTAAGAAGGAGATATACATATG) and digested with ClaI and 
SpeI] between the ClaI and BglII sites of pET. 
Two related constructs were used to express the LtrA protein in trans: pLI1P, 
which contains the LtrA ORF cloned downstream of the phage T7 promoter in pET-11a 
(Matsuura et al., 1997) and pET-LtrA, which contains the LtrA ORF cloned downstream 
of the phage T7 promoter in pET. pET-LtrA was derived from pELG2-WT by replacing a 
1.9-kb BglII/SpeI fragment containing the T7-ltrB/GFP fusion with a double-stranded 
DNA oligonucleotide containing the T7 promoter flanked by BglII and SpeI sites. Both 
constructs gave splicing efficiencies similar to that of pALG1-∆ORF in FACS assays, but 
pLI1P contains additional DIV[3’]-E2 sequences, which prevents its use in RT-PCR and 
primer extension assays. 
pALE contains the ligated ltrB exon sequence (132-bp RT-PCR product amplified 
from spliced ltrB RNA with primers 5’-
CCAAGCTTAGGTGGCGAATATGAATTTGTG and 
CCCTGCAGTTGCCAGTATAAAGATTCGTAG) cloned downstream of the T7 
promoter between the HindIII and PstI sites of pALG1-∆ORF. 
pGM∆ORF, used to synthesize in vitro transcript substrates for biochemical 
assays, contains a 0.9-kb Ll.LtrB-∆ORF intron, cloned behind the phage T3 promoter in 
pBSKS+ (Stratagene, LaJolla, CA) (Saldanha et al., 1999). This plasmid has 
 141
compensatory base changes (U208C, A341G) at two positions in the intron’s DId(iii) 
stem that introduce a HindIII site to facilitate mutagenesis (Saldanha et al., 1999). These 
changes were confirmed to have no effect on the rate of in vitro splicing at 1:1 molar 
ratio of LtrA protein. 
pELG1-∆DIVa and pELG2-∆DIVa were constructed from pELG1-∆ORF and 
pELG2-∆ORF, respectively, by swapping in the 0.9-kb PvuI/KpnI fragments of the 
previously constructed plasmid pGM-∆ORF/∆DIVa (Wank et al., 1999). 
LtrA mutants were constructed as described previously via a two-step PCR with 
Vent polymerase, with the desired modifications introduced via one of the primers (San 
Filippo et al., 2002). The PCR products containing the mutations were digested with 
restriction enzymes and swapped for the corresponding segments of the LtrA ORF in 
either pELG2-∆ORF, pELG2-∆DIVa, or the intein-based expression vectors pImp-1P 
(Saldanha et al., 1999) or pImp-10P. The latter is a derivative of pImp-1P with silent 
mutations that introduce restriction sites EagI (positions 746-751), SacI (positions 1333-
1338), BglII (positions 1666-1671), SacII (positions 1880-1885), BamHI (positions 2042-
2047), and AatII (positions 2213-2218), thereby facilitating the construction of mutant 
proteins. Regions that were generated by PCR were sequenced to confirm the 
introduction of the mutation and absence of any adventitious mutations. 
6.1.3 FACS assay of maturase-promoted group II intron splicing 
A single E. coli colony freshly transformed with a pAT- or pET-based plasmid 
containing an ltrB/GFP fusion was inoculated into 1 ml of LB medium containing 
ampicillin and grown overnight at 37°C. Fifty µl of the overnight culture was then 
inoculated into 1 ml of fresh medium, grown with shaking at 37°C to O.D.595 = 0.4, and 
induced with 0.1 mM IPTG for 3 h. Cells were collected by centrifugation, resuspended 
in phosphate-buffered saline (PBS, 140 mM NaCl, 2.7 mM KCl, 9 mM Na2HPO4, 1.6 
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mM KH2PO4, pH 7.4) and analyzed using a FACS Caliber (Becton Dickinson, 
Immunocytometry Systems, San Jose, CA), with filter FL1 (530 ± 30 nm). The results 
were analyzed with the CELLQuest program (Becton Dickinson). 
6.1.4 Immunoblotting 
Cells were grown and induced with IPTG, as described above for FACS assays. 
To prepare total protein for SDS-PAGE, half of the cells were pelleted by centrifugation, 
dissolved in 1X SDS-PAGE loading buffer, boiled for 3 min, and microfuged for 5 min 
to pellet any residual insoluble material. Soluble protein was prepared by incubating the 
other half of the cells with lysozyme (400 µg/ml) for 15 min on ice, followed by three 
cycles of freezing-thawing between -80°C and room temperature, and then microfuging 
for 5 min to pellet insoluble material. Total and soluble proteins were electrophoresed in 
an 8% polyacrylamide/1% SDS gel, which was transferred to a nitrocellulose membrane 
with a Hoefer SemiPhor blotter (Amersham Pharmacia Biotech, Piscataway, NJ). The 
membrane was blocked with 3% dry milk (Nestle USA Inc., Solon, OH) and 1% bovine 
serum albumin (Sigma, St. Louis, MO) in TTBS (25 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 2.5 mM KCl, 0.5% Tween 20) for at least 1 h at room temperature, and then 
incubated for 1 to 2 h with a 1:1000 dilution of a rabbit polyclonal anti-LtrA antibody 
preparation (obtained from Dr. Gary Dunny, Univ. of Minnesota). The blots were washed 
with TTBS four times at room temperature for five min each time, then incubated with 
goat anti-rabbit secondary antibody (Pierce, Rockford, IL) at 1:100,000 dilution for 1 h at 
room temperature, washed another four times in TTBS, and developed with SuperSignal 
West Pico Chemiluminescent substrate (Pierce). After development, the blots were 
stained with AuroDye Forte (Amersham Biosciences) to confirm equal loading. 
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6.1. 5 RT-PCR assay of in vivo RNA splicing 
RT-PCR was carried out on total cellular RNA, which was isolated as described 
(Belfort et al., 1990) and further purified with a Qiagen RNeasy mini kit (Qiagen, Inc., 
Valencia, CA). For the initial reverse transcription reaction, 5 µg of RNA was mixed with 
1 pmole of primer PPI (5’-GTTCTTCTCCTTTACTC) in 50 mM Tris-HCl, pH 7.5, 60 
mM NaCl, 10 mM DTT and annealed by heating to 60°C for 3 min and then chilling on 
ice. After additions to give 1.8 mM MgCl2 and 125 µM of each dNTP, the reaction was 
initiated by adding M-MLV RT (6 units; Invitrogen, Carlsbad, CA), incubated at 48°C 
for 30 min, and terminated by adding EDTA to 10 mM. 1/20 of the product was then 
used as a template for PCR in 50 µl of reaction medium containing 2.5 units Taq DNA 
polymerase (Invitrogen), 150 µM dNTPs, 3.5 mM MgCl2, 1X PCR buffer, and 25 pmoles 
each of primers PPI (see above) and PHIII (5’-CATATGGCTAGCATGACTGG) for 16 
cycles of 94°C for 30 sec, 50°C for 30 sec, and 72°C for 1.5 min. The products were 
analyzed in a 1.0% agarose gel containing ethidium bromide (0.5 µg/ml). 
6.1.6 Poisoned primer extension assay of in vivo splicing 
Cellular RNA (5 µg), isolated as described above, was annealed to 5' 32P-labeled 
primer PRET (5’-CGTAGAATTAAAAATGATATG; 0.2 pmole, ~1.3 x 107 cpm) by 
incubating at 60°C for 3 min in 7 µl of 50 mM Tris-HCl, pH 8.0, 60 mM NaCl, 10 mM 
DTT and then chilling on ice. Reverse transcription reactions were as described above for 
RT-PCR assays, except that 500 µM ddCTP was used instead of dCTP. The reaction was 
terminated by adding an equal volume of gel loading buffer (80% formamide, 10 mM 
EDTA, pH 8.0, 0.025% bromophenol blue, and 0.025% xylene cyanol FF), and the 
products were analyzed in a denaturing 10% polyacrylamide gel, which was dried and 
quantified with a PhosphorImager. 
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6.1.7 Colony-based fluorescence assays 
Cells were plated on LB containing ampicillin at a density of 1200-1500 colonies 
per 150 mm diameter plate and incubated overnight at 37°C. The colonies on each plate 
were then lifted onto five to seven 35-mm diameter nitrocellulose filter circles, and the 
filters were incubated on petripads (Millipore, Billerica, MA) saturated with LB medium 
containing ampicillin and IPTG (0.2 mM) for 4 h at 37°C. For fluorescence assays, the 
filters were scanned with a FluorImager SI (Molecular Dynamics, Sunnyvale, CA), using 
an excitation wavelength of 488 nm and a built-in 515-nm long-pass emission filter. 
Splicing-competent colonies that produce GFP appeared as black dots against a light 
background. 
6.1.8 Colony western assay 
Colonies were plated, transferred to nitrocellulose filters, and induced with IPTG 
as described above for the colony-based fluorescence assay, then lysed by incubating 
filters on drops of protoplast buffer (15 mM Tris-HCl, pH 8.0, 0.45 M sucrose, 8 mM 
EDTA, 0.4 mg.ml lysozyme) for 15 min at 4°C, followed by lysis buffer (10 mM Tris-
HCl, pH 8.0, 10 mM NaCl, 1 mM sodium citrate, 1.5% SDS) for 10 min at room 
temperature.  The filters were then washed twice in the DNase I Buffer (40 mM Tris-
HCl, pH 7.5, 10 mM MgCl2) at room temperature and incubated with drops containing 50 
units/ml DNase I in buffer at 37°C for 15 min.  For immunoblotting, the filters were first 
blocked by incubating in TTBS containing 5% dry milk and 1% BSA at room 
temperature for 1 h. Cell debris was wiped away with a Kimwipe. The filters were 
incubated with primary anti-GFP antibody (Clontech antibody; 1:3000 dilution) for 2 h at 
room temperature, washed four times with TTBS at room temperature for 5 min each 
time, and then incubated with HRP-conjugated secondary antibody for 1 h at room 
temperature. After several washes, the filters were developed using the supersignal West 
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Dura Extended Duration substrate (Pierce) and exposed to X-ray films. Both the primary 
and secondary antibodies had been pre-adsorbed with pET2-transformed cell lysate at 
room temperature for 0.5 h. Splicing-competent colonies were identified by aligning the 
exposed and developed X-ray film and corresponding filters.  Splicing was confirmed by 
RT-PCR. 
6.1.9 Unigenic evolution 
For the unigenic evolution analysis in chapter 2, a library of LtrA proteins with 
random mutations was constructed by error-prone PCR (Fromant et al., 1995) in 100 µl of 
reaction medium containing 0.06 pmol of pLI1 template, 50 pmoles each of primers LtrA 
5’-SpeI and LtrA 3’-ClaI (see above), 0.39 mM dATP, 0.15 mM dCTP, 1.17 mM dGTP, 
3.85 mM dTTP, 11 mM MgCl2, 0.5 mM MnCl2, and 5 units of Taq DNA polymerase 
(Invitrogen). The reaction conditions were initial denaturation at 94°C for 5 min, 
followed by 16 cycles of 91°C for 1 min, 51°C for 1 min, and 72˚C for 10 min, with final 
extension at 72°C for 15 min. The 1.8-kb PCR product containing the mutagenized LtrA 
ORF was then gel-purified, digested with SpeI and ClaI, and cloned between the 
corresponding sites of pELG1-∆ORF. The mutation frequency determined by sequencing 
36 randomly selected clones from the library was 0.78%, corresponding to ~10 amino 
acid substitutions per protein. 
After transforming the library into HMS174(DE3), splicing-competent LtrA 
variants were identified by colony-based fluorescence assay (see below). Individual 
colonies were then grown up in LB medium containing ampicillin, and plasmids 
encoding LtrA variants were isolated and transformed into HMS174(DE3) to retest their 
splicing phenotype by FACS assays. Variants that spliced the Ll.LtrB-∆ORF intron with 
efficiency ≥ 50% that of wild-type LtrA assayed in the same experiment were sequenced 
to identify changes in the LtrA ORF. 
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Mutational data were analyzed as described by Deminoff et al (1995). The 





where fOmis is the observed frequency of missense mutations and fEmis is the expected 
frequency. The latter was calculated for each codon based on the probability of a single 
nucleotide change producing a missense mutation, correcting for the 
transition/transversion ratio of 3.4 for the variants selected from the library. Negative 
mutability values indicate hypomutability, with a maximum value of -1 indicating no 
missense mutations in a given window. Positive values indicate hypermutability and were 




so that all mutability values fall between -1 and +1. Chi square was calculated for each 
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where “abs” indicates the absolute value; Omis and Osil are numbers of missense and silent 
mutations observed in a given region; and Emis and Esil are expected numbers of missense 
and silent mutations in the region. Boundaries were moved inward to improve chi square 
scores when necessary. Hypomutable regions are defined as the longest continuous 
stretch of amino acid residues that has a P-value < 0.01. 
The LtrA library used in chapter 3 was generated in the same way by error-prone 
PCR and cloned into SpeI and ClaI sites of pELG1-∆DIVa. Based on sequencing results 
of 48 randomly picked clones, the mutation rate of the library was 0.6%. The ratio for 
transition to transversion was 3.0. On average, each mutant contained 10 mutations. 
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Positive clones were identified by using the Colony Western assay (see below). 
Mutational data were analyzed as described above except that positive mutability values 
were not normalized. 
6.1.10 Biochemical assays 
Wild-type and mutant LtrA proteins were expressed from the intein-based 
expression plasmid pImp1P or its mutant derivatives in E. coli BL21(DE3) or Rosetta 
(DE3) and purified on a chitin-affinity column, as described (Saldanha et al., 1999). 
Protein concentrations were measured by Bradford assay against a standardized LtrA 
preparation, whose concentration had been determined spectrophotometrically based on 
its calculated extinction coefficient (Saldanha et al., 1999). The wild-type and mutant 
protein preparations were > 99% and 80-99% pure, respectively, as judged by 
Coomassie-blue stained SDS-gels. 
RT assays with poly(rA)/oligo(dT)18 were carried out with 20 nM LtrA protein 
and 1 µg substrate per 10 µl reaction, as described (Matsuura et al., 1997). RT assays 
with Ll.LtrB/E2+10 were carried out in 10 µl of reaction medium containing 20 nM 
protein, 40 nM Ll.LtrB template, 400 nM E2+10 primer, 450 mM NaCl, 5 mM MgCl2, 
40 mM Tris-HCl, pH 7.5 plus 10 µCi [α-32P]dTTP (3,000 Ci/mmol; New England 
Nuclear, Boston, MA) and 0.2 mM each of dATP, dCTP, and dGTP (Wank et al., 1999). 
Reactions were initiated by addition of dNTPs and incubated at 30°C for 30 min, which 
was shown previously to be in the linear range. In both RT assays, incorporation of [α-
32P]dTTP into high molecular weight material was measured by spotting onto DE81 
paper (Whatman, Maidstone, England) and counting Cherenkov radioactivity in a 
scintillation counter (LS6500, Beckman, Fullerton, CA). 
RNA splicing and binding reactions were carried out in reaction medium 
containing 450 mM NaCl and 5 mM MgCl2, the relatively high salt concentration being 
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necessary for specific binding and optimal activity of the LtrA protein (Saldanha et al., 
1999). For RNA splicing assays, 32P-labeled RNA substrates were synthesized by in vitro 
transcription of BamHI-linearized pGM∆ORF with phage T3 RNA polymerase 
(Stratagene) and purified in a denaturing 4% polyacrylamide gel (Wank et al., 1999). In 
vitro splicing reactions were carried out with 32P-labeled gel-purified RNA substrate (20 
nM; 2-4 x 104 cpm) and wild-type or mutant LtrA protein (20 or 200 nM) in 150 µl of 
450 mM NaCl, 5 mM MgCl2, 40 mM Tris-HCl, pH 7.5, 5 mM dithiothreitol (DTT) and 1 
unit/µl RNasin (Wank et al., 1999). Splicing reactions were initiated by adding LtrA 
protein and incubated at 30oC. At different times, 5 to 10 µl portions were removed, and 
the reaction was terminated by extraction with phenol-chloroform-isoamyl alcohol 
(25:24:1). After centrifugation, the aqueous phase was mixed with an equal volume of 
loading dye, and products were analyzed in a denaturing 4% polyacrylamide gel, which 
was dried and quantified with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). 
Data from splicing time courses were best fit to single or double exponential equations 
using KaleidaGraph (Synergy Software, Reading, PA) to obtain kobs. 
For equilibrium binding assays, 32P-labeled RNA (5 pM) was incubated with 
increasing concentrations of LtrA protein in 500 µl of reaction medium containing 450 
mM NaCl, 5 mM MgCl2, and 40 mM Tris-HCl, pH 7.5. After incubation for 1 h at 30°C, 
RNA-protein complexes were isolated by filtration through a nitrocellulose filter 
(PROTRAN BA85, Scheicher & Schuell, Keene, NH). The filters were washed three 
times with 1 ml of reaction medium, dried, and counted for Cerenkov radioactivity. 
Varying the incubation time from 5 to 60 min had no significant effect on the binding 
curves. 
koff values were measured as described (Saldanha et al., 1999). Complexes were 
formed by incubating 20 nM LtrA protein with 20 nM 32P-labeled Ll.LtrB RNA (2-5 x 
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105 cpm) in 100 µl of 450 mM NaCl, 5 mM MgCl2, 40 mM Tris-HCl, pH 7.5, 5 mM 
DTT, 1 unit/µl RNasin, and 100 µg/ml bovine serum albumin. The complexes were then 
diluted 20-fold into the same reaction medium containing a 100-fold excess of unlabeled 
Ll.LtrB RNA, and the dissociation of the complexes as a function of time was followed 
by nitrocellulose filter binding. Unless noted otherwise, the data were best fit to equations 
with two exponentials reflecting rapidly dissociating and stable complexes, with the koff 
values reported in the text being those for the stable complex (Saldanha et al., 1999).  
6.2 MATERIALS AND METHODS FOR STUDYING SPLICING AND TARGETING OF THE 
LL.LTRB INTRON IN MAMMALIAN CELLS 
6.2.1 E. coli strain, cell lines, and medium 
Cell lines HEK 293 and COS-7 were obtained from Dr. Robert Krug.   DMEM 
was from Invitrogen.  Leibovitz’s L-15 modified medium was from ATCC. Medium 
supplements were from Invitrogen. Fetal bovine serum was from Gemini.  Cells were 
grown in a 37°C incubator with 5% CO2 except when grown in Leibovitz’s medium, 
where cells were kept airtight. 
Transfection reagents used were Fugene 6 (Roche Applied Science, Indianapolis, 
IN), Lipofectamine 2000 (Invitrogen Corporation, Carlsbad, CA), and Polyfect (Qiagen 
Inc., Valencia, CA).  
6.2.2 Recombinant plasmids 
pCMV/myc/nuc was purchased from Invitrogen. pIRES was from Clontech. 
pCMV-LtrA was constructed by inserting the PCR amplified LtrA ORF into the NcoI and 
XhoI sites of pCMV/myc/nuc. pCMV-IVS was constructed by inserting the 214-bp AluI 
fragment from pIRES into the PmlI site of pCMV/myc/nuc. pCMV-IVS-LtrA was 
constructed by replacing the NcoI and XbaI fragment of pCMV-IVS with the NcoI and 
XbaI fragment of pCMV-LtrA. pHHWT was constructed by inserting PCR-amplified 
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intron with flanking sequences into the two BsmBI sites of pHH21 plasmid (Neumann et 
al., 1999). pGM∆ORF/NL was constructed by inserting the SalI/XhoI fragment from 
pcDNA3.1/NL to the SalI site of pGM∆ORF. pcDNA3.1/NL-∆ORF was constructed by 
inserting the ApaI/blunted + XbaI fragment of pGM∆ORF/NL into the EcoRV and XbaI 
sites of pcDNA3.1/NL-∆ORF. pTZU6+27-∆ORF was constructed by inserting the 
XhoI/XbaI fragment of pGM∆ORF/NL into the SalI and XbaI sites of pTZU6+27 (kindly 
provided by Engleke, U. of Michigan, Ann Arbor, MI). pBS∆ORF.500 was constructed 
by replacing the fragment between the BseRI and StuI sites on pBSU3hTR500 with 
blunt-ended XhoI/BamHI fragment from pGM∆ORF. pBSU3∆ORFNL was constructed 
by replacing the BseRI/EcoRV fragment with the blunt-ended AflII/PvuII fragment. 
6.2.3 Codon optimization and recombinant plasmids 
All oligonucleotides were synthesized by HHMI/Keck Oligonucleotide Synthesis 









ACCCCCAGCCCGTGCGCCGCATGTACATCGCC3’; Short oligonucleotides are s-













GTACTGCC3’. Short oligonucleotides are s2-HIII: 5’AAAAAAGCTTGGAGTCCATC-
TACGAGCCCGTGTTCGAGGACGTGAGCCACGGCTTCC3’ and s2-XbaI: 5’AAAA-
TCTAGACTCGCGGTCGAACTTCATCTTCAGCTGCAGCACGAACTTGTCCAAC-
TCG3’. 


















oligonucleotides are s4-HIII: 5’AAAAAAGCTTGCCAGTGGATCAAGGAGCAGCT-
GAAGCTGTTCATCC-ACAACAAGC3’ and s4-XbaI: 5’AAAATCTAGAGCGGTGC-
ACGGGGAACCAGCTGCTGTCCTTCTTCTGGATGGCG3’. 



















GCTGGTGCCG-CAC3’. Short oligonucleotides are s6-HIII:  5’AAAAAAGCTTGCCA-
GGCCCCCGTGCTGTACGGCTACGCCCGCAACACCC3’ and s6-XbaI: 5’AAAATC-
TAGAGTCGACCTTGTGC-TTGTGGATCACGTGGCGGTGGC3’. Oligonucleotides 
used for overlapping segments 5 and 6 were hLtrA5/6F: 5’GCCAGGCCCCCGTGCTG3’ 
and hLtrA5/6R: 5’CAGCACGGG-GGCCTGGC3’. 
For each segment, PCR was done with the long oligonucleotides as overlapping 
templates. To reduce mutations, PCR reactions were carried out by using Vent DNA 
polymerase (New England Biolabs, Boston, MA), high annealing temperatures (58-
60°C), and manual hot start (adding Vent DNA polymerase after sample temperature 
reached 94°C). PCR products were gel purified and digested with EcoRI and XbaI or 
HindIII and XbaI, then cloned into pKSBluescript to form pKS-hLtrA1-pKS-hLtrA6. 
After sequencing, a correct clone of pKS-hLtrA1 was digested with EcoRI and XbaI first, 
gel purified and then digested with HinfI.  A correct clone of pKS-hLtrA2 was digested 
with HindIII and XbaI first, gel purified, and then digested with HinfI. Digested segments 
1 and 2 were then ligated to the vector pKSBluescript digested with EcoRI and XbaI to 
construct pKS-hLtrA1/2. Similarly, segments 3 and 4 were ligated at TspRI site to 
pKSBluescript digested with HindIII and XbaI to construct pKS-hLtrA3/4. Segments 5 
and 6 were gel purified and used as overlapping templates to obtain a fragment flanked 
by HindIII and XbaI sites and cloned to the vector accordingly to form pKS-hLtrA5/6. 
pKS-hLtrA1/2 was then digested with EcoRI and XbaI, gel purified, and again digested 
with BsiEI. pKS-hLtrA3/4 was then digested with HindIII and XbaI, gel purified, and 
then digested with BsiEI. pKS-hLtrA(1-4) was constructed by ligating hLtrA1/2 and 
hLtrA3/4 at the BsiEI site and to pKSBluescript at EcoRI and XbaI sites. Finally, pKS-
hLtrA was constructed by ligating hLtrA (1-4) and hLtrA5/6 at the ApaLI site and to 
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pKSBluescript at the EcoRI and NotI sites. phLtrA was constructed by cutting and 
pasting the EcoRI and SalI fragment from pKS-hLtrA and annealed oligonucleotides 
SV40-F and SV40-R, flanked by SalI and NotI sites, to corresponding sites in pIRES. 
pLtrA was constructed by ligating the PCR-amplified bacterial version of LtrA ORF into 
theEcoRI and SalI sites of phLtrA. ∆NLS was constructed by replacing the 1.8-kb 
EcoRI/SalI fragment of phLtrA with a PCR-amplified 1.8-kb fragment from pELG2-
∆ORF, flanked by the same restriction sites.  
6.2.4 Western Analysis 
Cells were collected 48 h after transfection. To achieve even loading, the same 
number of cells was used in each lane. The transferred membrane was stained with 
AuroDye after blotting to confirm even loading. Anti-LtrA antibody was used at 1:1000 
dilution, and the secondary antibody was used at 1:60,000 dilution. 
6.2.5 RT-PCR 
Total RNAs were prepared 48-h post transfection with a QIA RNeasy mini kit 
(Qiagen, Inc.). RT-PCR was done using the first-strand reverse transcription kit from 
Invitrogen following the manufacturer’s instructions. Primer 3’BamHI was used for RT, 
which has the following sequence: 5’-GTGGATCCCCCAGCTTTGCCGC-3’. Primer 
E1-F, with the following sequence: 5’-GAGAAAAATAATGCGGTGCTTGG-3’, was 
used in combination with primer 3’BamHI in PCR. 
6.2.6 Immunofluorescence 
The entire procedure was carried out at room temperature. Cells were first washed 
with PBS twice, and then fixed in 2% paraformaldehyde for 30 min, at room temperature.  
After three washes with PBS, 0.5% Triton X-100 in PBS was used to permeabilize the 
cells for 15 min, followed by three washes with PBS containing 0.2% Tween 20 (PBST).  
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Blocking was achieved by incubating the permeabilized cells with 10% normal goat 
serum and 1% BSA in PBST for 1 h. Primary antibody was first incubated with 
untransfected cell lysate (prepared by sonication) to deplete nonspecific antibody and 
then was used at 1:500 dilution in blocking buffer for a 1 h incubation. After four five-
min washes in PBST containing 0.1 M NaCl, cells were incubated with 1:100 dilution of 
goat anti-rabbit antibody conjugated with fluorescein in blocking buffer for 1 h, washed 
with PBST containing 0.1 M NaCl five times for five min each time, incubated with 2 
µg/ml Hoechst for 10 min, and washed twice with PBS.  After mounting, cells were 
observed under a fluorescence microscope. 
6.2.7 Construction of stable cell lines expressing hLtrA 
To construct stable cell lines expressing LtrA, phLtrA was first linearized with 
BamHI, phenol extracted, and ethanol precipitated. The linearized phLtrA was then 
electroporated into the cells. Forty-eight hours after electroporation, neomycin was used 
to select for cells containing one or more integrated neomycin-resistance genes. 
Neomycin-sensitive cells started to die after two weeks of selection. Finally, neomycin-
resistant colonies were picked up, seeded into 96-well dishes and grown under selection 
conditions. Western analysis was used to detect LtrA expression. 
6.2.8 Purification of Ll.LtrB RNPs from E. coli and RNP reconstitution in vitro 
RNPs were purified as described for LtrA protein synthesized from pImp-1p in 
Saldanha et al. (1999) with following modifications. The intron and LtrA sequences were 
cloned into expression vector, pImp-1p, so that both the intron RNA and the LtrA are 
under the control of T7 promoter.  The C-terminus of LtrA is fused to the N-terminus of a 
chitin binding domain with an intein cleavage site and expressed downstream of the 
intron.  The RNP contruct was transformed to E. coli BL21 (DE3), and a single colony 
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was used to start an overnight culture.  The next day, cells were diluted 1:50 into fresh 
LB medium plus ampicillin and grown until O.D.595 equals 0.6, then induced with 0.5 
mM IPTG for 3 h at 25°C. Cells were collected and lysed in column buffer (500 mM 
NaCl, 25 mM Tris-HCl, pH 8.0, 0.1 mM EDTA) with 10 ug/ml of lysozyme and three 
cycles of freezing and thawing between –80°C and 25°C. The lysate was then loaded 
onto a chitin column for affinity purification.  In order to minimize nuclease exposure, 
the flow rate was set at ≥ 1 mL/min. The loaded column was first washed with 100 mL of 
column buffer containing 750 mM NaCl, then with 500 mM NaCl.  After overnight 
cleavage with 30 mM DTT, RNPs were eluted with two bed-volume of column buffer 
(500 mM NaCl) and ultracentrifuged overnight in the Beckman 50.2 Ti rotor at 50,000 
rpm and 4°C.  The pellet was washed in ice-cold water and resuspended in ice-cold 10 
mM Tris-HCl, pH 8.0, 1 mM DTT. In vitro reconstitution of RNPs was done essentially 
as described in Saldanha et al. (1999) with an additional step of ultracentrifugation step 
as described above. 
6.2.8 Electroporation of RNPs 
Cells were grown to about 80% confluence, trypsinized, diluted with growth 
medium, and washed with ice-cold PBS at least 4 times.  They were then resuspend in an 
appropriate volume of PBS to achieve a density of 5x106/ml. Ten micrograms of RNPs 
were mixed with 400 µl of cells and incubated on ice for less than 2 min.  
Electroporations were carried out at 230 v and various capacitance settings. After 
electroporation, to minimize the degradation of the RNPs by nucleases in the medium, 
cuvettes were left on ice for 10-15 min before 1 ml of growth medium was added to the 
cuvettes and cells were aliquoted into two 60-mm dishes.  Fluorescence microscopy, flow 
cytometry, and immunofluorescence were performed 24 h after electroporation. 
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6.2.9 Cell preparation for FACS analysis 
Transfected cells were trypsinized and neutralized with growth medium.  After 
washing in PBS, cells were resuspended in PBS and run through a FACS. 
6.2.10 In vitro TPRT-PCR  
 Ten micrograms of chromosomal DNA and 1-10 µg RNPs were added to 20 µl 
reaction medium containing 40 mM Tris-HCl, pH 7.5, 10 mM KCl, 10 mM MgCl2, and 
0.2 mM dNTPs. The reaction was incubated at 37°C for 2 h, followed by PCR using one 
tenth of the TPRT reaction as template. For targeting in nuclear lysates, one to two 
microliter RNPs (2-5 µg/µl) and 2 µl 2 mM dNTPs were added to 15 or 17 µl lysates 
with or without 2 µl 10xRT buffer. After TPRT, each reaction was treated with 
proteinase K for > 1 h at 55°C and then heated to 98°C for 30 min to inactivate proteinase 
K prior to PCR.   
For detecting the 3’ integration junction, intron primers ∆DIV-F 
(5’CAGAGCCGTATACTCCGAGAGG3’) and LtrBs1 
(CAGTAATGTGAACAAGGCGGTACCT3’) were used. For detecting the 5’ junction, 
intron primers slx-seq (5’CTTGTTTAGGGTATCCCCAG3’) and 400-R ( 
AACCGAAATTAGAAACTTGCGTTC3’) were used. The PCR program was 94°C, 3 
min, 30 cycles of 94°C, 30s, 58°C, 30s, and 72°C, 1 min 30 s, and an additional extension 
at 72°C for 10 min. I found it helpful to include 2-4% DMSO in PCR reactions involving 
chromosomal DNA. DMSO lowers the melting temperature of nucleic acids with high 
GC content (Escara & Hutton, 1980). 
6.2.11 Preparation of nuclear extract 
HEK 293 cells were grown to full confluence, washed with PBS, and blown off 
the dishes with ice-cold hypotonic buffer (10 mM HEPES, 10 mM KCl, 1 ml/100 mm 
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dish), and incubated on ice for 15 min.  Cells were broken by 15 strokes of Dounce 
homogenizer. Nuclei were collected by centrifugation at 800xg for 5 min at 4°C.  The 
supernatant was then drained. Complete separation of the nucleus from the cytoplasm 
was not critical for my purposes. Nuclei were resuspended in the residual buffer in the 
tube.  Typically, 4 to 5 100-mm dishes of cells made 100 to 150 µl of lysate.  After 3 
cycles of –80°C/25°C freezing and thawing, chromosomal DNA was sheared by repeated 
pipetting.  Eight µl of the solution was used in each in vitro TPRT reaction. 
6.2.12 Purification of chromosomal DNA from cultured cells 
 Most of the time, cells were pelleted and washed with PBS before subjected to 
proteinase K digestion at 55˚C water bath for overnight in a solution containing 50 mM 
Tris, pH 7.5, 0.5% SDS, 0.2 mg/ml proteinase K. The homogeneous solution was then 
phenol extracted, and the top phase was transferred to a new tube with 1/10 vol 5 M 
NH4Cl and 1 vol isopropanol. Chromosomal DNA was then picked out with a tip after a 
few inversion of the tube, washed, dried, and dissolved in TE (10 mM Tris-HCl, pH 8.0, 
1 mM EDTA). However, the quality of DNA was better when cells were first lyzed with 
cold lysis buffer (0.32 M sucrose, 10 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 1% Triton X-
100), and nuclei were collected before proteinase K digestion. 
6.2.13 Staining of lacZ expressing cells 
Cells were fixed as in section 6.2.6 and then washed in washing buffer (2 mM 
MgCl2, 0.02% NP40, 0.1 M sodium phosphate buffer, pH 7.3) for three times at room 
temperature for 15 m each before subjected to overnight staining in washing buffer 
containing 1 mg/ml X-gal, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide). 
Cells were then kept in washing buffer at 4˚C. 
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6.2.14 Mg2+ treatment of the cells 
MgCl2 was either added onto the cells in medium to a final concentration of 80 
mM or cells were fed with fresh medium containing 80 mM MgCl2. The latter may avoid 
local unevenness. It may be more important for HEK 293 cells because they do not 
adhere well. Cells were left in 80 mM MgCl2 for 1-4 h before harvesting for RNA 
preparation. In order to avoid self-splicing during RNA preparation, I washed the cells 
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